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Background: Gene expression profiling of human acute ischemic stroke (AIS) has the potential 
to identify a diagnostic panel for differential diagnosis of AIS early in the treatment phase. 
Purpose: The objective of this dissertation was to identify peripheral blood biomarkers that 
could be further explored for use in differential diagnosis of AIS and the design of stroke 
therapeutics.
Methods: A prospective gene expression profiling study of 39 patients and 25 healthy controls 
was conducted. Peripheral blood samples were collected in Paxgene Blood RNA tubes from 
patients who were ≥18 years of age with MRI diagnosed AIS after differential diagnosis and 
controls who were Non-stroke neurologically healthy. In stroke patients, blood was redrawn 24 
hours following onset of symptoms to determine changes in gene expression profiles over time. 
RNA was hybridized to Illumina humanRef-8v2 bead chips. Validation was performed using 
Taqman Gene expression polymerase chain reaction on significant targets.  
Results: A nine gene profile has been identified for AIS. Five of these nine genes were identified 
in the previously published whole blood gene expression profiling study of stroke and therefore 
play a likely role in the response to AIS in humans. One of these nine genes (s100A12) was 
significantly associated with increasing age and therefore may be non-specific for stroke. Three 
genes were identified as the whole blood expression profile change over time (LY96, IL8, and 
SDPR). Pathway analysis revealed a robust innate immune response, with toll like receptor 
 iv 
(TLR) signaling as a highly significant pathway present in the peripheral whole blood of AIS 
patients. 
Conclusion: The findings of this study support the claim that gene expression profiling of 
peripheral whole blood can be used to identify diagnostic markers of AIS. A plausible case for 
innate immunity through the activation of TLR4 as a mediator of response to AIS has been made 
from the results of this study. This study and those conducted by Moore et al (2005) and Tang et 
al (2006) provide the foundation of data that support the use of peripheral whole blood for future 
blood profiling studies of neurological disease; which significantly opens the door of 
opportunity. 
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1.0  INTRODUCTION 
1.1 ISCHEMIC STROKE 
Stroke is the third leading cause of death in the United States (Thom, Haase et al. 2006) and 
accounts for 10% of deaths worldwide. (McKay, Mensah et al. 2005) Approximately 780,000 
people experience a stroke each year in the US contributing to an overall financial burden of 
$65.5 billion per year. (Rosamond, Flegal et al. 2008) Stroke subtypes include ischemic stroke 
(87%), hemorrhagic stroke (10%) and subarachnoid hemorrhage (3%). (Thom, Haase et al. 2006; 
Rosamond, Flegal et al. 2008)  Of the 88% of ischemic strokes that occur each year, 8-12% 
results in death within 30 days. (Thom, Haase et al. 2006) The risk of ischemic stroke is 
associated with various familial and environmental factors, such as the presence of hypertension, 
obesity, tobacco use, and a positive family history. (Rosamond, Flegal et al. 2008) Determinants 
of outcome include non-modifiable risk factors such as age, race, gender and genetic variation 
along with clinical phenotypes of severity, such as stroke scale score, the presence of fever and 
serologic blood markers. Advances in neuroimaging and acute clinical management have 
resulted in greater numbers of patients surviving the initial insult.(Kim and Liebeskind 2005) 
However, morbidity remains high secondary to complications following the primary event and 
initial misdiagnosis. The only Food and Drug Administration (FDA) approved treatment for 
ischemic stroke is recombinant tissue plasminogen activator (rtPA), alteplase. Multiple attempts 
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to identify other pharmacologic agents have resulted in negative findings; therefore a redirection 
of the science is necessary to understand the human variable response to ischemic stroke to 
provide alternative avenues for therapeutic treatment.  
 Since its commencement into the clinical arena in 1996, rtPA has proven to be a 
promising therapeutic treatment for ischemic stroke and is safe and effective for use in routine 
clinical practice. (1995; Wahlgren, Ahmed et al. 2007)  However, its powerful effects are not 
seen without significant clinical complications. (1995)  In addition, rtPA is only approved for use 
when patients present to the hospital within three hours from onset of symptoms. The downside 
is that the median time from stroke symptom onset to presentation to the emergency department 
is 3-6 hours.(Rosamond, Flegal et al. 2008) A recent study conducted by Hacke et al addressed 
the possibility of extending this limited therapeutic time window and the group was able to show 
that intravenous rtPA given between 3 and 4.5 hours after onset of symptoms significantly 
improves clinical outcomes following ischemic stroke compared to placebo. (Hacke, Kaste et al. 
2008) This is promising given that the time window limit of 3 hours and a large list of 
contraindicating factors for thrombolytic therapy currently results in only 3-8% of stroke patients 
receiving rtPA. (Reeves, Arora et al. 2005) 
 The advancements of rtPA therapy aside, there is still a demand for alternative acute 
stroke therapies in clinical practice. Unfortunately, the results of recent clinical trials have 
demonstrated that there is still a gap in the understanding of the variable human response to 
ischemic stroke. Numerous promising pre-clinical therapeutics display insignificant clinical 
utility in human patients, which speaks to the difficulty of translating what we learn at the bench 
to the patient at the bedside. (Lees, Asplund et al. 2000; Ginsberg, Hill et al. 2006; Warach, 
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Kaufman et al. 2006; Diener, Lees et al. 2008; Montaner, Chacon et al. 2008) These negative 
findings may be due in part to the complexity of the human physiologic response to ischemic 
stroke, limited knowledge about the multiple pathways interacting in response to ischemic stroke 
and the implications of genomic variability on individual recovery from ischemic stroke. The 
difficulty may also be attributable to insufficient classification of ischemic stroke subtype. It is 
possible that gene expression profiling can help to identify subtypes of ischemic stroke, which 
has tremendous utility in designing therapeutic strategies for treatment. Only by studying the 
human genomic response to ischemic brain injury will we begin to understand how to clinically 
and pharmacologically treat the negative outcomes of ischemic stroke. A better understanding of 
stroke pathophysiology in humans and more appropriate stroke subtyping will ultimately provide 
the foundation needed to design patient appropriate clinical trials accounting for human variation 
and potentially unmask therapeutic effects of trial medications. To develop appropriate 
alternative treatments for ischemic stroke, the genomic process behind the events associated with 
cerebral ischemia in humans must be revealed.  
1.1.1 The cerebral ischemic response 
Ischemia and reperfusion related oxidative stress injury plays a critical role in ischemic stroke 
progression and recovery. (Kamada, Yu et al. 2007)  Oxidative stress refers to an imbalance 
between antioxidant and pro-oxidant factors that favors tissue destruction and if left untreated 
ultimately leads to cell death. Reactive oxygen species (ROS) are produced in the healthy human 
body as a by-product of metabolism. However, during episodes of ischemia the number of ROS 
generated dramatically increases. Since the brain does not store glucose and oxygen like other 
parts of the body, ROS are produced very quickly and in large amounts. Low antioxidant 
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capacity and low oxygen reserve in the brain establishes an environment normally on the brink 
of tissue ischemia. Therefore small perturbations of cerebral blood flow can have significant 
negative repercussions.  
1.1.2 The cerebral genomic response 
Animal modeling has allowed the assessment of the cerebral genomic response under various 
conditions of ischemia and reperfusion. (Millan and Arenillas 2006) Cerebral ischemia 
stimulates expression of genes involved in excitotoxity, inflammation, apoptosis and 
neuroprotection and can result in both cell death and cell recovery.(Buttner, Cordes et al. 2009) 
In rat brain following middle cerebral artery occlusion (MCAO) there appears to be a delayed 
peak in differentially expressed genes which supports the previous hypothesis that the majority 
of damage produced by ischemia is the result of delayed damaging processes, rather than the 
primary ischemic insult. (Kim, Piao et al. 2004; Buttner, Cordes et al. 2009) However, there is 
evidence that the genomic response in the rat brain does not entirely reflect the process of stroke 
evolution in humans, secondary to species specific responses and pathophysiologic differences 
between human stroke and induced stroke in animals.(Mitsios, Saka et al. 2007) Even so, the 
animal models and human brain investigations have identified episodes of ischemia result in 
severe reductions in messenger RNA (mRNA) expression and protein synthesis within the 
ischemic core. The penumbra receives some blood flow and therefore this area can maintain 
some fundamental cellular homeostatic functions and is therefore salvageable within a certain 
time frame. Given the results of studies at present, it seems logical that the most fruitful areas of 
investigation will be involved in identification of treatments to augment the delayed secondary 
responses to ischemia and rescue of the ischemic penumbra.  
4 
1.2 HYPERINTENSE ACUTE REPERFUSION INJURY MARKER 
One goal of Healthy People 2010 is to decrease death and disability in stroke patients by 20%, 
from 60 to 48 per 100,000 of the population. To achieve this goal, attention must be made to the 
cause of death and disability following ischemic stroke. In the first month after ischemic stroke, 
51% of deaths can be attributed to secondary complications of the primary ischemic event, such 
as oxidative stress injury followed by cerebral swelling and hemorrhage.(Vernino, Brown et al. 
2003) There are no treatments for the secondary sequela of cerebral ischemia and oxidative 
stress. While reperfusion at times reduces infarct volume and helps to improve clinical 
symptomatology in some patients, in others it has been shown to exacerbate ischemia and 
produce additional cerebral reperfusion injury.(Aronowski, Strong et al. 1997) Ischemia and 
reperfusion injury contribute to free radical production, an increase in proteolysis, and activation 
of the inflammatory/immune response, resulting in impairment of cerebral vessels and disruption 
of tight junction proteins. Disruption of tight junction proteins can lead to cerebral swelling, 
hemorrhagic transformation and blood brain barrier (BBB) disruption.  
Up to 33% of ischemic stroke patients display evidence of reperfusion injury as BBB 
disruption on magnetic resonance imaging (MRI). (Latour, Kang et al. 2004; Warach and Latour 
2004) BBB disruption can be observed as delayed gadolinium (Gd-DTPA) enhancement of the 
cerebrospinal fluid (CSF) space on fluid-attenuated inversion recovery (FLAIR) MRI. The 
presence of this enhancement has been termed Hyperintense Acute Reperfusion injury Marker 
(HARM). Treatment with rtPA is associated with an increased prevalence of BBB disruption 
with subsequent hemorrhagic transformation (HT) and worse clinical outcome.(Kidwell, Latour 
et al. 2008) Therefore, it is of primary importance to determine which patients are more 
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susceptible to BBB disruption and the detrimental effects of thrombolytic therapy. By doing so, 
the therapeutic effects of rtPA can be maximized.  
1.3 WHOLE GENOME EXPRESSION 
A novel approach to the study of cerebral ischemia in humans is gene expression profiling using 
microarray technology.(Baird 2006; Sharp, Xu et al. 2006; Baird 2007; Sharp, Xu et al. 2007) In 
the last 5-10 years there has been an incredible increase in the knowledge of genetic and genomic 
mechanisms that contribute to simple and complex diseases 
(http://www.genome.gov/gwastudies/ ; http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim) 
 Ischemic stroke is a multi-factorial complex neurologic insult that is mediated by a specific 
interplay between genes and gene products and their interactions with other genes and the 
environment. For such a complex disorder it is difficult to use candidate gene approaches and 
directed hypotheses to identify significant biomarkers associated with prognosis and outcome. 
The nature of the disease is such that it requires a platform, such as microarray, that can assess 
various genes and molecular pathways simultaneously and integrate that knowledge into 
information that can be interpreted with clinical relevance.  
Gene expression profiling allows for the simultaneous assessment of the approximately 
25,000 genes of the human genome and is a powerful and effective approach to either identify 
genes correlated with a phenotype or find a classifier for predicting a phenotype. The best tissue 
for gene expression profiling in ischemic stroke is brain; however this is not feasible in most 
clinical situations, being only accessible at post-mortem. Proof of principle gene expression 
profiling studies have been performed on ribonucleic acid (RNA) extracted from whole blood in 
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ischemic stroke.(Moore, Li et al. 2005; Tang, Xu et al. 2006; Grond-Ginsbach, Hummel et al. 
2008) These studies support the potential for genomic profiling of whole blood RNA to 
transform neurologic disease research in the post-genome era.(Moore, Li et al. 2005; Du, Tang et 
al. 2006; Tang, Xu et al. 2006) Identifying patterns of gene expression associated with ischemic 
stroke has the potential to pave the way for advanced diagnostics and therapeutic strategies 
aimed at the complex biological pathways associated with the human response to ischemic 
stroke.  
1.4 PURPOSE 
The purpose of this project was to elucidate the clinical variability of gene expression in acute 
ischemic stroke (AIS) patients through the use of gene expression profiling using microarray to 
identify a panel of markers for the diagnosis of acute ischemic stroke. This data can be used to 
further study the candidate genes identified and inflammatory/immune pathways for their 
relationship with response to ischemic stroke and BBB disruption.  
1.5 SPECIFIC AIMS 
1. Determine which expressed transcripts are under- and over-expressed in acute ischemic stroke 
patients compared to neurologically healthy age-matched control subjects.  
2. Determine the changes in gene expression that occur in the first 24-48 hours following acute 
ischemic stroke. 
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3. Determine whether acute ischemic stroke patients with BBB disruption have a specific blood 
gene expression profile compared to AIS patients without BBB disruption.  
1.6 RESEARCH QUESTIONS/HYPOTHESES 
Question 1: Is there a specific gene expression profile in blood associated with AIS that can be 
used to identify candidates for diagnostic biomarkers of acute ischemic stroke?                                          
Hypothesis 1:  AIS patients will display a specific gene expression profile in blood that will aid 
in identifying candidate biomarkers for ischemic stroke diagnosis and in identifying molecular 
pathways to target treatment.  
 
Question 2: How will blood gene expression profiles in blood change between the acute phase of 
ischemic stroke (0-24 hours) and 24-48 hours following onset of symptoms? 
Hypothesis 2: Gene expression patterns in blood will change over time reflecting individual 
responses to cerebral ischemia and may aid in identifying molecular pathways involved in the 
delayed neuronal response to ischemia. 
 
Question 3: Is there a specific gene expression profile in blood associated with the development 
of BBB disruption as HARM on MRI after AIS?                                                                                               
Hypothesis 3: A specific gene expression profile in blood will be associated with BBB disruption 
in acute ischemic stroke patients that will serve as a readily accessible marker of HARM and 
may help elucidate the mechanisms behind BBB disruption in this population  
.  
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1.7 DEFINITION OF TERMS 
1.7.1 Independent variables 
1.7.1.1 Acute ischemic stroke 
Cases have been classified by acute ischemic cerebrovascular syndrome (AICS) diagnostic 
criteria. (Kidwell and Warach 2003) This classification scheme for ischemic stroke defines four 
categories ranging from “Definite AICS” to “Not AICS”, based on evidenced-based 
neuroimaging diagnostic certainty. Only patients with a diagnosis of Definite AICS were 
recruited for the aims of the study. See Appendix A for AICS diagnostic criteria. 
1.7.1.2 Hyperintense acute reperfusion injury marker 
Baseline (0-20 hours) and follow-up (20-40 hours) MRI images were assessed for presence (e.g., 
sulcal, bilateral, ventricles, vitreous) and level (none, mild, moderate, severe) of HARM. See 
Appendix B for NINDS Stroke Team-HARM Rating Scale.   
1.7.2 Dependent variables  
1.7.2.1 Whole genome expression 
For its ease of use in the clinical setting, and its ability to maintain the specific biological 
signatures (i.e. stabilization of RNA) at the time of the blood draw,  
Paxgene whole blood RNA tubes were used to collect 2.5ml of whole blood from acute ischemic 
stroke patients at baseline (0-20 hours) and follow-up (20-40 hours) time points and control 
subjects at one time point.  
9 
1.7.3 Covariates 
1.7.3.1 Environment  
Previous history of ischemic stroke, history of hypertension, and medication history were 
obtained from the patient or the patient’s medical record during the initial clinical assessment. 
Age and gender were used as covariates in the modified k-prototypes algorithm. There were only 
four African American stroke patients recruited at this study site and given the small number 
they were not included in this analysis.  
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Figure 1. Conceptual Framework 
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2.0  BACKGROUND AND SIGNIFICANCE 
2.1 ISCHEMIC STROKE 
Ischemic stroke occurs when there is a decrease or loss of blood flow to an area of the brain 
resulting in tissue damage or destruction.  It is the largest subtype of stroke pathologies and 
therefore accounts for the majority of the death and disability associated with stroke.  
2.1.1 Pathophysiology of Ischemic Stroke 
There are numerous scenarios that contribute to compromised cerebral perfusion; combine this 
with the multifactorial effects of the environment and individual genomic responses secondary to 
DNA variation and epigenetic DNA modification and the result is variability of patient 
presentation and recovery. This complexity makes ischemic stroke very difficult to treat, both 
medically and pharmacologically. Most cerebral ischemic pathologic conditions involve 
alterations in cerebrovascular reactivity (Cipolla and Curry 2002; Dohmen, Bosche et al. 2007; 
Gur, Gucuyener et al. 2007; Kunz, Park et al. 2007) and clot formation.(Kuge, Yokota et al. 
2001; Smith, Bis et al. 2008) Ischemia is the consequence of one or more of the following 
causes: thrombosis, embolism or decreased systemic circulation. Thrombosis is a localized 
obstruction of blood flow in one or more blood vessels, most commonly caused by 
atherosclerosis.(Badimon and Vilahur 2007) Embolic stroke refers to a blockage of the blood 
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vessel not caused by a localized process, but rather material originating from outside of the 
cerebral circulation, most commonly the heart.(Weir 2008) Decreased systemic perfusion results 
in a decrease in cerebral perfusion pressure, and ultimately cerebral blood flow secondary to 
cardiac pump failure or systemic hypotension.(Murkin 2002) Although each scenario has a 
different origin, the result is either a temporary or permanent decrease or loss of cerebral blood 
flow. Permanent loss of cerebral blood flow to an area of the brain resulting in cell death is 
termed infarction. The penumbra is the area of the brain receiving less than optimal blood flow 
and is damaged but “salvageable”, not yet infarcted. In all cases of ischemic stroke, the intent of 
therapy is to rescue this penumbral tissue and if therapy or reperfusion occurs quickly, this tissue 
can be rescued. (Lo 2008) The extent of tissue damage depends on the location and duration of 
the infarction or lack of blood flow and the extent to which collateral vessels can supply oxygen 
and nutrients to compromised areas. The cerebral ischemic response is complex and involves a 
decrease in oxygen and glucose delivery but also an accumulation of detrimental metabolic 
waste products. Therefore reactive oxygen species (ROS) and inflammatory mediators play a 
critical role in the events following ischemia. 
 Immediately following ischemic brain injury a cascade of events occurs in response to 
loss of blood flow (either trickle flow or complete obstruction of flow). Alterations at the cell 
membrane result in release of glutamate, activation of N-methyl-D-aspartic acid (NMDA) 
receptors and release of calcium (Ca+2) into the extracellular space. This process ultimately 
leads to the activation of Immediate Early Genes (IGE’s), such as c-fos and c-jun. IGE’s 
propagate the physiologic response by participating in transcription of neurotrophic factors 
(endogenous neuroprotection), heat shock proteins (general stress response), cytokines and 
immune mediated complexes (inflammatory and immune activation), and nitric oxide synthase 
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(NOS) activation (neuronal stimulation). Pathway specific responses are mediated by non-
modifiable factors (DNA variation, age, gender, and severity of injury), modifiable factors (diet, 
physical activity, temperature, and environmental stress) and the interaction of signaling 
molecules within the pathways themselves. The collective response, secondary to human genetic 
variation, results in either propagation of injurious mechanisms and cell death or initiation of 
repair mechanisms and neuronal sustainment.  
Ischemic Stroke
”trickle flow”
Or Complete 
Obstruction               
Endogenous 
Neuroprotection
General Stress 
response               
Inflammatory & 
Immune activation
Neuronal 
Stimulation
Pathway specific responses 
are mediated by:
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-Genetics: APOE e4; ANKK1
-Age
-Gender: sex steroids
-Severity of Injury
-Innate and Adaptive immunity
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-Diet
-Physical activity
-Temperature
-Environmental stressors1
Constant 
Interaction
Collective response of pathways and mediation by non-modifiable and 
modifiable factors contributes to degree of tissue injury and initiation of 
repair mechanisms
Good outcome Poor outcome
Figure 2. Multifactorial response to ischemia 
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2.1.1.1 Reactive oxygen species 
Since the brain does not store oxygen or glucose, cellular energy production fails to maintain 
normal metabolism within minutes following compromised cerebral blood flow. Within the 
mitochondria, the electron transport chain removes electrons from an electron donor and passes 
them onto oxygen to form water through a series of redox reactions. These reactions create a 
proton gradient across the mitochondrial membrane that drives production of adenosine 
triphosphate (ATP). ATP then enters the Krebs cycle (citric acid cycle) to become part of a 
metabolic pathway that converts carbohydrates, fats, and proteins into usable forms of energy 
(e.g. carbon dioxide and water). When oxygen is unavailable the electron transport chain can no 
longer accept electrons; a proton gradient is not produced, ATP production ceases, and pyruvate 
becomes the final acceptor of electrons in the chain. This switch from oxygen dependent aerobic 
metabolism to anaerobic energy production results in an accumulation of lactic acid and ionic 
pump failures.(Adam-Vizi 2005) 
Sodium potassium (Na+/K+) pumps are highly dependent upon ATP energy production 
and begin to fail within minutes of anaerobic metabolism. Na+, water and calcium (Ca+2) begin 
to pass from the extracellular space to the intracellular space and cerebral cells begin to swell, 
resulting in cytotoxic edema. Capillary endothelial cells begin to function abnormally and the 
tight junctions between them loose their integrity, leading to BBB disruption. Intravascular fluid 
leaks into the extravascular space and spreads easily throughout the white matter, resulting in 
vasogenic edema. Additionally, excess intracellular Ca+2 triggers free radical production along 
with free radicals produced during anaerobic metabolism contributing to protease and lipase 
activation. Superoxide and peroxynitrite (free radicals) production increases beyond the cells 
capacity to quench them, which in turn activates the production of other detrimental 
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ROS.(Chrissobolis and Faraci 2008) Eventually the swollen cells enter cell death pathways 
through necrotic or apoptotic processes dependent upon the cell type, severity of injury and the 
level of available ATP. Unfortunately, reoxygenation through reperfusion also acts as a substrate 
for enzymatic reactions that produce ROS. Cells attempt to minimize damage caused by 
ischemia by rebalancing energy supply and demand. This early neuroprotective response results 
in an overall suppression of non-essential energy consumption. (Barr and Conley 2007) 
  All of these events together result in BBB permeability, loss of cell ion homeostasis, and 
excitotoxicity, (Wong and Crack 2008) resulting in a modulation of gene and protein expression.  
The molecular imprint of these processes is visible within all cells that migrate and circulate 
throughout the area of cerebral injury. These cells then circulate out of the central nervous 
system and throughout the body making it possible to obtain an indirect measurement of the 
cerebral microenvironment by sampling the peripheral blood.(Emsley, Smith et al. 2003)  
2.1.1.2 Neuro-inflammatory and immune responses 
Inflammation following ischemic stroke is initiated at the blood endothelial interface and is 
propagated over a period of time following the initial infarct. Polymorphonuclear leukocytes 
rapidly enter the brain tissue at the site of ischemia followed by mononuclear cell invasion. 
Vascular and non-vascular cells generate cytokines and chemokines which activate inflammatory 
mediators which may be both detrimental and beneficial.(Hallenbeck 1996)  An inflammatory 
response begins in the microcirculation of the cerebral vessels following microglia release of the 
pro-inflammatory cytokines, interleukin-1beta (IL1B) and tumor necrosis factor-alpha (TNFα). 
Microglial activation parallels the induction of cellular apoptosis and correlates with severity of 
ischemia.(Rupalla, Allegrini et al. 1998) This activation is early and contributes to a secondary 
response mediated by IL6 and IL8. (Rodriguez-Yanez and Castillo 2008) These cytokines trigger 
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the release of cell adhesion molecules (e.g. selectins, immunoglobulins, and integrins). 
Leukocytes begin to adhere to the endothelial cell wall and aggregate contributing to a pro-
coagulant environment within the luminal endothelium, resulting in microvascular occlusion. 
Leukocytes activate matrix metalloproteinases (MMPs) through the release of nuclear factor-κB 
(NF-κB) which degrades the extracellular matrix, basil lamina, and tight junction proteins 
allowing leukocyte entry past the endothelium. (Rosenberg, Estrada et al. 1998; Rosenberg 2002; 
Castellanos, Leira et al. 2003; Montaner, Molina et al. 2003; Rosenberg 2009)  MMP activity, 
specifically MMP9 (e.g. gelatinase B) increases the permeability of the BBB contributing to 
edema and subsequent hemorrhagic transformation.  
 Evidence suggests that mediators of post-ischemic inflammation have both deleterious 
and beneficial effects on outcome following stroke.(Tuttolomondo, Di Raimondo et al. 2008) 
There is an unclear period in which these processes turn from deleterious to mediating 
neuroprotection, tissue repair, and angiogenesis. The function of TNFα and IL1B signaling has 
not yet been fully elucidated; although the data support a potentially detrimental role of these 
cytokines in ischemia. Inhibition of IL1 converting enzyme decreases infarct volumes in both 
mice and rats (Relton and Rothwell 1992; Hara, Friedlander et al. 1997) and injection of TNFα 
24 hours prior to MCAO exacerbates the size of infarction. (Wang, Yue et al. 1994) Following 
cerebral ischemia there is an initial upregulation of pro-inflammatory cytokines that results in the 
recruitment of other inflammatory mediators and a subsequent secondary cytokine signaling 
response.  
Animal studies have been helpful in guiding human stroke trials; however inflammatory 
events in humans are not identical to that of animal models. In addition, the nature of cytokine 
modulation is extremely complex and is dependent upon severity of injury, duration of ischemia, 
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and innate mediators of immunity. Therefore the molecular mechanisms that lead to activation 
and regulation of inflammatory genes in the post-ischemic human brain are even less understood.  
The development of cDNA microarrays provides a convenient method for identifying therapeutic 
targets in this neuro-inflammatory cascade since many genes with complex responses are 
differentially expressed in human cerebral ischemia, and one cannot possibly conduct candidate 
studies on all of them. (Wong and Crack 2008) 
2.1.2 Clinical Diagnosis 
Clinical diagnosis of ischemic stroke is often difficult, complicated by its multiple etiologies and 
variable clinical presentation. In most hospitals, diagnosis is made when the patient presents with 
symptoms suggestive of acute cerebral ischemia in conjunction with  pathologic findings on 
cerebral imaging that are most likely associated with the presenting symptoms. When possible, 
history is obtained via inquisition of the following: personal and family history; discussion of 
history of stroke or symptoms suggestive of stroke; time and activity at the onset of symptoms; 
temporal progression of symptoms; and whether or not they are accompanied by other factors, 
such as headache or nausea.(Caplan 2000) Unfortunately more often than not, this information is 
unobtainable secondary to severity of the stroke and whether or not the patient has family 
available that can provide the history. At this point the physical examination and brain imaging 
findings are used to make the definitive diagnosis. Identifying the physical location of the stroke 
is made by assessment of neurologic status via the neurologic examination, which may include 
National Institutes of Health Stroke scale (NIHSS) score and the presence of pathologic findings 
on computed tomography (CT) or magnetic resonance imaging (MRI).  
19 
 The majority of hospitals in the United States use CT to rule out stroke; however it has 
been found that CT is less than optimal for identifying acute ischemia.(Chalela, Kidwell et al. 
2007) A recent study of emergency room (ER) neurology consults found that the initial diagnosis 
of the ER physician agrees with the final diagnosis ~60% of the time.(Moeller, Kurniawan et al. 
2008) There was a significant pattern of mis-diagnosis for stroke and seizure; other benign 
medical conditions (e.g. migraine) and psychiatric disorders were originally diagnosed and 
medically treated as stroke. Although over-diagnosis of stroke early may appear to err on the side 
of patient safety, it puts a percentage of patients into a category where they are being treated for 
an acute stroke that they do not have. Given the complications associated with bleeding 
following rtPA administration, this practice is quite risky.  For this reason, a lot of ER physicians 
are reluctant to treat a patient with rtPA unless they are completely sure of a stroke diagnosis.  
 Where possible, hospitals are moving toward using MRI for acute diagnosis of stroke; 
however this is facilitated best by the presence of a dedicated stroke clinical team and only 
possible in facilities with 24 hour MRI availability.  Additionally, even though rtPA is FDA 
approved, only a small number of stroke patients actually receive the drug. The Brain Attack 
Coalition has recommended a movement toward the creation of widespread primary stroke 
centers to increase the utilization of rtPA and creation of standards of care for ischemic stroke 
patients.(Alberts, Hademenos et al. 2000) In a small community hospital located in Bethesda, 
MD the establishment of a primary stroke team resulted in a 7-fold increase in the proportion of 
stroke patients treated with rtPA within 24 months after the onset of the program.(Lattimore, 
Chalela et al. 2003) This paradigm can be applied to other small community hospitals and has 
the potential to increase the numbers of stroke patients treated with rtPA by an additional 30,000 
patients per year. More and more hospitals are moving towards the establishment of primary 
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stroke teams; however there are still quite a few hospitals that rely solely on the ER physician’s 
expertise in diagnosing ischemic stroke.  
  Quick and definitive diagnosis in the acute care setting is essential to separate stroke from 
non-stroke, distinguish hemorrhage from ischemia, and identify the potential cause of the 
infarction, but most importantly to determine eligibility for thrombolytic therapy to begin 
treatment within the three hour window of opportunity. An additional diagnostic measure, such 
as a serologic blood test or a screen of a panel of markers, would be extremely beneficial in 
obtaining a definitive diagnosis of acute stroke and increasing the utilization of rtPA, especially 
in hospitals where primary stroke centers are non-existent.  
2.1.2.1 Imaging Biomarkers 
Until recently a CT scan was the only radiologic examination routinely performed during the 
acute clinical assessment of stroke patients. There is growing evidence that MRI is now more 
sensitive in identifying acute ischemic changes and is the imaging mode of choice when 
determining eligibility for rtPA or stratifying patients for clinical trials.(Chalela, Kidwell et al. 
2007) CT has low sensitivity for ischemic changes in the hyperacute stage; it is difficult to 
determine the age of the infarct, and cannot identify hypoperfused but viable penumbral tissue.  
However, CT is more widely available and less expensive than MRI; it can be performed in 
patients with pacemakers or other metallic foreign bodies, and is less sensitive to patient motion. 
MRI on the other hand is very sensitive to acute ischemic changes and the age of the infarct, and 
it can be optimized to identify the penumbral area. However, it is much more expensive than CT, 
cannot be performed in patients with pacemakers or metal within the body, is quite sensitive to 
artifact from motion of the patient and requires a trained eye to identify small but significant 
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lesions. There are pros and cons to both modalities and often the imaging platform of choice will 
depend on the training of the physicians involved during the acute stroke assessment.  
 MRI has the ability to image the ischemic penumbra through perfusion/ diffusion 
mismatch identification, which can be used in clinical trials or even decisions to treat with rtPA 
to increase the time window for ischemic stroke treatment. Diffusion weighted imaging can 
detect a reduction in cerebral blood flow within minutes from onset of ischemia and therefore 
presents a picture of the ischemic core. Perfusion weighted imaging reveals the ischemic core 
and tissue at risk, so at times the area of compromised perfusion may be larger then that of the 
ischemic core, indicating penumbral tissue. The diffusion weighted imaging evaluation for 
understanding stroke evolution (DEFUSE) and echoplanar imaging thrombolytic evaluation trial 
(EPITHET) randomized clinical studies have identified the use of perfusion-diffusion mismatch 
for penumbral identification. (Albers, Thijs et al. 2006; Davis, Donnan et al. 2008) The benefits 
of using perfusion/diffusion mismatch in selecting patients for clinical trials was recently shown 
in a clinical trial in patients treated with rtPA within 3-6 hours from onset (Albers, Thijs et al. 
2006) and an additional trial of Desmoteplase treatment with in 3-9 hours from symptom 
onset.(Hacke, Albers et al. 2005) 
 In addition to mismatch identification, contrast enhanced imaging using gadolinium 
derivatives allows for the assessment of blood brain barrier integrity and cerebral blood vessel 
patency. Gadolinium enhancement of parenchymal tissue has been used as reference for BBB 
disruption in multiple sclerosis (Bonzano, Roccatagliata et al. 2008)  and only recently identified 
as an imaging biomarker in acute ischemic stroke. (Latour, Kang et al. 2004)  
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2.1.2.2 Blood Biomarkers 
A rapid blood test to confirm the diagnosis of ischemic stroke would transform stroke care in the 
US and across the world. Most patients with acute stroke are not assessed by stroke-certified 
neurologists; especially in hospitals that are not primary stroke centers.  Interpretation of CT 
scan and MRI images by non-neurologists is difficult and often leads to misdiagnosis, 
inappropriate use or non-use of rtPA, and clinical mismanagement. There has been a substantial 
attempt to identify blood biomarkers for ischemic stroke; however the task has proven difficult. 
Many potential blood markers of ischemia and inflammation are also found in other conditions 
that may mimic stroke, which aggravates the ability to identify a specific biomarker of stroke. A 
recent meta-analysis of published blood biomarker studies for stroke revealed significant 
weaknesses associated with methodological designs, such as small sample size, poor references, 
poor choice of control subjects and lack of validation. All of which lead to a recommendation of 
a redesign of blood biomarker studies. (Whiteley, Tseng et al. 2008) 
A recent study published by Laskowitz et al has identified a “biomarker panel” for stroke 
that may help in definitive diagnosis and the implementation of rapid treatment.(Laskowitz, 
Kasner et al. 2009) The concept of a biomarker panel for stroke is identical to the use of serum 
troponin and CK-MB (creatinine kinase, muscle and brain) values for the evaluation of 
myocardial infarction and congestive heart failure. Unfortunately the brain poses huge obstacles 
to the identification of biomarkers specific for brain injury and no single blood biomarker study 
for stroke has proven clinically useful. The authors explored the feasibility of using a four panel 
blood biomarker approach to provide adjunctive information for definitive diagnosis of acute 
ischemic stroke. The four biomarkers, matrix metalloproteinase-9 (MMP9), D-dimer, S100β, and 
B-type natriuretic peptide (BNP) were evaluated as a point-of-care test and a separate validation 
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study was performed on 343 patients using a logistic regression model for interpretation. The 
model demonstrated modest discriminating power that resulted in a sensitivity of 86% for 
detecting stroke. However the model performed better for discriminating between hemorrhagic 
stroke and ischemic stroke than stroke mimic and stroke. This has huge clinical implications, 
since hemorrhage on MRI or CT is most times obvious to detect, therefore this blood test may 
not provide any additional information for those patients without a clear picture. In addition, the 
model performed poorly beyond 3 hours from onset; which makes the test only applicable to the 
small percentage of patients who make it to the ER within 3 hours from onset. Even given these 
limitations, the study demonstrates the feasibility of using a “biomarker panel” to aid in stroke 
diagnosis and suggests that a biomarker-based assay when used in conjunction with imaging 
parameters has tremendous clinical utility.  
 Most likely, a panel of serum biomarkers will be identified as definitive for ischemic 
stroke. (Montaner, Perea-Gainza et al. 2008) An ideal biomarker panel should distinguish 
ischemic stroke from stroke mimic and hemorrhage, be available in small centers without the 
need for interpretation outside of the facility, and easily accessible. A diagnostic assay, similar to 
what was used in the BRAIN Study, has been trialed by Biosite Diagnostics. However, the 
company has withdrawn its premarket approval application with the FDA secondary to ongoing 
issues regarding the results of their clinical trials and methodological issues in trial design.  
2.1.3 Treatment 
In spite of the large amount of knowledge acquired over the last 25 years in stroke research, there 
are still very few therapies available for the treatment of acute ischemic stroke. (Segura, Calleja 
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et al. 2008) The only FDA approved treatments for ischemic stroke are rtPA and the MERCI 
retrieval device.  
2.1.3.1 Thrombolysis 
Thrombolysis in ischemic stroke is aimed at reperfusion to restore cerebral blood flow. 
Thrombolytic agents, rtPA-alteplase, enhance the formation of fibrinolysin which disrupts fibrin 
and lysis blood clots. In 1996, the FDA granted approval for the use of intravenous rtPA in the 
treatment of ischemic stroke within three hours from onset of symptoms based on the findings of 
the NINDS rtPA study. (1995) In Europe, approval of rtPA was not until 2002, secondary to 
unsuccessful results of rtPA in the European Cooperative Acute Stroke Studies (ECASS and 
ECASS II). (1995; Steiner, Bluhmki et al. 1998) Intra-arterial thrombolysis has been shown 
effective in middle cerebral artery (MCA) occlusions up to 6 hours following stroke onset. 
(Furlan, Higashida et al. 1999) 
 There are recommended evidence-based clinical practice guidelines put forth by the 
American College of Chest Physicians for the administration of rtPA.(Albers, Amarenco et al. 
2008) For eligible patients, IV rtPA is administered in a dose of 0.9mg/kg with a maximum dose 
of 90mg, with 10% of the total dose given as an initial bolus, then the remainder administered 
over one hour. Patients are treated with rtPA based on the following inclusion and exclusion 
criteria on the following page:  
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Table 1. Inclusion and exclusion criteria for administration of rtPA 
Inclusion criteria for rtPA administration: 
• Age ≥18 
• diagnosis of stroke with a clinically meaningful neurologic deficit 
• clearly defined time of onset < 3hours before treatment 
• baseline CT or MRI scan negative for intracranial hemorrhage 
 
Exclusion criteria for rtPA administration: 
• minor or rapidly improving symptoms 
• CT or MRI is positive for intracranial hemorrhage 
• history of intracranial hemorrhage 
• seizure at stroke onset 
• stroke or serious head injury in the past 3 months 
• major surgery or trauma in the past 2 weeks 
• GI or urinary tract hemorrhage within 3 weeks 
• systolic BP>185 mmHg 
• diastolic BP>110 mmHg 
• aggressive treatment required to lower BP 
• glucose <50mg/dL or >400 mg/dL 
• symptoms of subarchnoid hemorrhage 
• arterial puncture at a noncompressible site  
• lumber puncture within 1 week 
• platelet count <100,000/mm3 
• heparin therapy within 48 hour associated with ↑ PTT 
• post-myocardial infarction pericarditis 
• pregnant women 
• international normalized ratio (INR) >1.7 
 
The recent results of the ECASS III study support the use of rtPA beyond 3 hours from onset of 
injury.(Hacke, Kaste et al. 2008) A total of 821 patients were randomly assigned to receive either 
alteplase (rtPA) or placebo. Treatment was initiated between 3-4.5 hours from symptom onset. 
When compared to placebo, alteplase treatment significantly improved outcomes following 
ischemic stroke; the incidence of symptomatic hemorrhage was higher in the alteplase group. 
Patients in each treatment group were similar by age, gender and presence of comorbidities. 
However, the placebo group presented with higher baseline NIHSS scores and was more likely 
to have a history of stroke, which has significant implications for the interpretation of the 
26 
primary end-point of the study (good outcome as determined by the modified rankin score). 
There are skeptics to using rtPA beyond 3 hours and raise the argument that ECASS III is only 
one of two studies that have shown efficacy of rtPA beyond 3 hours.(Clark and Madden 2009) 
The ATLANTIS (Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic 
Stroke) study was conducted in the US to determine the efficacy of rtPA administration between 
3-5 hours from symptom onset.(Clark, Wissman et al. 1999) There was no benefit of rtPA 
therapy post 3 hours from onset, which completely contradicts the findings of the ECASS III 
study. In addition, post-hoc analyses of the NINDS rtPA trial also suggest no additional benefit 
of rtPA beyond 3 hours. (Marler, Tilley et al. 2000) Throughout medicine there have been many 
conflicting results between US and European studies. Even though the ECASS III results are 
promising, investigators urge clinicians to use caution when interpreting the results, and continue 
to push for treatment as early as feasibly possible. Even the ECASS III investigators 
acknowledge, “Having more time does not mean we should be allowed to take more 
time.”(Hacke, Kaste et al. 2008) 
2.1.3.2 Other treatments 
Endovascular mechanical thromboectomy provides an alternative to rtPA therapy for patients 
with large vessel occlusion.  Endovascular clot retrievers restore cerebral blood flow between 
41% and 54% of the time.(Berlis, Lutsep et al. 2004; Smith, Sung et al. 2005; Smith 2006)  The 
MERCI retriever consists of a flexible nickel titanium wire that once passed through a guide 
catheter conforms to a helical shape. The catheter/wire is advanced through the groin to the brain 
distally to the site of the thrombus. The clot becomes trapped in the helical shape of the wire and 
is then withdrawn from the cerebral vessels. The MERCI retrieval device received FDA approval 
in 2004, yet its clinical utility has yet to be established and is still up for debate. (Becker and 
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Brott 2005; Smith, Sung et al. 2005) TEven so, this option is particularly promising for patients 
who do not respond to conventional intravenous rtPA therapy or those who are ineligible for 
rtPA therapy.  
 There are multiple other clinically relevant treatments and models of care in use by 
Stroke Neurologists. Body positioning with head of bed flat to promote cerebral blood flow has 
been shown to increase CBF by 20% and is implemented for most stroke patients; however it is 
unclear in which time frame this should be implemented, and for how long. (Wojner-Alexander, 
Garami et al. 2005) Additionally, anticoagulants and antiplatelets, statin therapy, 
antihypertensive therapy, and glucose management are all areas of active clinical management of 
acute stroke patients. Take together; the basic advances in acute care medicine over the last 
decade have resulted in better outcomes for patients with ischemic stroke.  
2.1.3.3 Neuroprotection 
There has been an emphasis in the last few years to identify agents that could mitigate the effects 
of cerebral ischemia and possibly offset the negative effects of reperfusion after rtPA 
administration. The most extensively explored are a variety of neuroprotective agents targeting 
calcium antagonists, N-methyl-D-aspartate (NMDA) antagonists, free radical scavengers, agents 
that stabilize the neuronal membrane and various others. (Chacon, Jensen et al. 2008) 
Disappointingly, almost all human trials have failed to produce clinically significant results. 
(Kidwell, Liebeskind et al. 2001) Various reasons have been proposed for these unsuccessful 
attempts at translational science including inappropriate subject selection, wrong stroke subtype 
and absence of viable penumbra, outcome measures, and medication dosage and duration. 
(Gladstone, Black et al. 2002) There are a number of ongoing clinical trials evaluating the effects 
of hypothermia and therapeutic agents (e.g. Caffeinol, Albumin) in the setting of ischemic 
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stroke.  Recently, the free radical scavenging agent NXY-059 was reported to show a significant 
effect for acute ischemic stroke patients; which is being accepted as possibly the first 
neuroprotective trial to show clinical benefit. 
 The SAINT I study was a randomized trial comparing intravenous administration of 
NXY-059, a nitrone free radical spin trap agent that serves as a free radical scavenger, with 
placebo. SAINT II was a replication/confirmation of the first trial. NXY-059 was infused within 
6 hours from stroke for a total of 72 hours and the results showed an improved distribution of 
scores on the modified rankin scale (MRS) and a significantly lower risk of symptomatic 
intracerebral hemorrhage (ICH) after rrtPA. (Lees, Zivin et al. 2006) This trial has been 
criticized because the improvement in outcome was only ~5% indicating limited clinical utility. 
Unfortunately the results of the larger SAINT II study failed on all study end-points, failing to 
confirm the positive findings of SAINT I.(Shuaib, Lees et al. 2007) Possible reasons given for 
this include errors in clinical trial design and preclinical drug study problems.(Savitz and 
Schabitz 2008) Given the disappointment with NXY-059 future neuroprotective studies should 
emphasize the importance of more rigorous study methods. Savitz and Schabitz (Savitz and 
Schabitz 2008) offer the following suggestions:  
1. Animal studies should adhere to more rigorous quality controls for blinding, 
randomization, and cerebral blood flow monitoring along with reproducibility of 
efficacy across different laboratories.   
2. Determination of which behavioral tests and at what time points should these tests be 
performed in rodents and higher order species to determine clinical utility in humans.  
3. Use MRI in future studies to separate cortical gray matter stroke from white matter 
stroke.  
4. Study neuroprotection and reperfusion separately. 
5. Consider the use of drugs with both neuroprotective and regenerative properties to 
achieve long lasting effects on functional outcome.  
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The Stroke Therapy Academic Industry Round table (STAIR) forum developed out of 
need for a venue in which academia and industry could come together to deal with the issues in 
stroke drug development.(1999; 2001; Fisher 2003; Fisher, Albers et al. 2005) The guidelines put 
forth by the forum have been influential in guiding stroke drug research, but given the recent 
failures of many neuroprotective agents, including the SAINT trials that followed the STAIR 
recommendations, it appears a different approach may be necessary. It is suggested that a 
consortium between academia, government and the pharmaceutical industries be created and the 
parties involved began focusing more on translation medicine to achieve much needed success in 
the design of stroke therapeutics.(Feuerstein, Zaleska et al. 2008) 
2.2 BLOOD BRAIN BARRIER DISRUPTION 
The blood brain barrier (BBB) refers to a specialized system of brain endothelial cells (BEC) and 
accessory cells (astrocytes, microglia, pericytes, etc.) that work in concert to separate the brain 
from the circulating blood. Homeostasis of the brain environment is maintained by controlling 
the entry and exit of blood-borne substances into the central nervous system. This is required for 
proper synaptic transmission, remodeling, angiogenesis and other necessary networks within the 
brain.  
Normal blood brain barrier permeability is limited to molecules smaller than ~400 
Daltons (DA). (Pardridge 2007) For perspective, albumin is about 65,000-66,000 DA. Therefore 
most molecules are not allowed easy access into the cerebral environment and must do so by way 
of active or facilitated transport mechanisms. Glucose, amino acids, and other metabolites must 
be ushered into the brain via transport by specific proteins such as insulin, transferrin and other 
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plasma proteins that aid in endocytosis. (Pardridge 1998) Lipophilic compounds enter the brain 
more readily than hydrophilic compounds. Such tight regulation is particularly troublesome for 
drug delivery across the BBB, but necessary to maintain cerebral homeostasis.  
The BBB consists of a monolayer of endothelial cells that line the entire cerebral 
vasculature. These BEC’s are connected to one another through tight junctions (TJ’s), adherens 
junctions, and gap junctions. The composition of the TJ’s consists of integral membrane proteins, 
such as occludin, claudin, and junctional adhesion molecules. These proteins inhibit even small 
molecules from diffusing through the endothelial cells of the vessels into the brain parenchyma. 
In addition cerebral vascular cells lack fenestrations, in contrast with other vascular cells of the 
body. TJ’s anchor the BEC’s to the surrounding cytoskeleton through use of scaffold proteins 
(ZO-1, -2, -3). Adheren junctions are found together with TJ’s and are dependent on signals from 
the cadherin’s and catenin’s (e.g. VE-cadherin and β-catenin). The structure of these juctions are 
reinforced by astrocytes and maintained possibly by signals from BBB cells including 
endothelial cells of the vasculature, and possibly neurons and microglia. The stability of the 
microvessels is maintained by the basement membrane (which anchors the BEC’s), extracellular 
matrix proteins, pericytes, microglia, and astrocytes.(Zlokovic 2008)  (Persidsky, Ramirez et al. 
2006) 
The BBB, neurons, and non-neuronal cells (e.g. pericytes, astrocytes, etc) together form 
what is referred to as the Neurovascular Unit. During ischemia the viability of this unit is 
compromised, either through direct injury by free radicals or other proteolytic processes or 
diminished protein synthesis and those molecules once prevented access to the brain, easily cross 
through loosened tight junction gaps which further contributes to BBB impairment.  
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2.2.1 Pathophysiology following ischemic stroke 
The human brain receives approximately 20% of cardiac output. Small reductions of cerebral 
blood flow (CBF) by 20% result in decreased protein synthesis of most cells in the brain 
(Hossmann 1994); however more severe reductions in CBF lead to decreased delivery of oxygen 
and ultimately a switch to anaerobic metabolism and accumulation of waste by-products.(Drake 
and Iadecola 2007) Reductions in CBF >80% result in ischemic neuronal cell death ad 
degeneration of the neurovascular unit.  
 The integrity of the BBB following ischemic stroke is dependent upon the patient’s 
medical history and subsequent comorbidities along with the mechanism, severity, and duration 
of ischemia. (Rosenberg 1999; Brott and Bogousslavsky 2000) The cerebral ischemic response 
results in white blood cell invasion and the release of proteases, particularly matrix 
metalloproteinases that degrade the basement membrane of BBB vessels and loosen the tight 
junction proteins. This results in cytotoxic and vasogenic edema. Transient ischemia can be 
worse than permanent occlusion for BBB cells, attributable to proteolytic properties of molecules 
released by reperfusion related oxidative stress. (Rosenberg 1999)  
 BBB opening following stroke is biphasic, particularly following reperfusion. (Kuroiwa, 
Ting et al. 1985) The first opening is minutes to hours following the onset of ischemia followed 
by a second opening between 22 and 46 hours post-reperfusion. (Huang, Xue et al. 1999) A 
proposed complication of BBB opening is cerebral swelling; however there is room for debate 
regarding the direct role of BBB permeability of the presence of cerebral edema. Some studies 
suggest that cerebral swelling following ischemia/reperfusion can occur in the presence or 
absence of BBB disruption and attribute the cerebral edema to disruptions in ion homeostasis, 
increased tissue osmolality, and increased hydrostatic pressure. (Gartshore, Patterson et al. 1997) 
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Blood brain barrier (BBB) disruption following ischemic brain injury propagates a series 
of detrimental events, escalating secondary injury and the likelihood of poor outcome (Latour, 
Kang et al. 2004; Warach and Latour 2004; Dinapoli, Huber et al. 2007). The identification of 
factors contributing to impaired BBB integrity following ischemia and reperfusion is crucial to 
developing effective stroke therapies. There is a vast amount of empirical evidence, both human 
and animal, implying that activation of matrix metalloproteinase’s (MMP’s), specifically MMP9, 
contributes to proteolysis of the BBB basal lamina (Pfefferkorn and Rosenberg 2003; Rosenberg 
and Yang 2007).  Proteolytic breakdown of the BBB vasculature increases the permeability of 
the barrier resulting in vasogenic edema, leukocyte infiltration, and hemorrhagic transformation 
(HT). 
MMP’s are zinc and calcium dependent endopeptidases responsible for regulation of the 
extracellular matrix (ECM). ECM homeostasis is maintained by a balance between pro- and anti-
proteolytic factors including MMP9 and its natural inhibitor tissue inhibitor of matrix 
metalloproteinase -1 (TIMP1). The MMP9/TIMP1 ratio provides an in vivo assessment of the 
proteolytic potential of MMP9 to degrade the ECM. The balance between MMP9 and TIMP1 
likely plays a role in reperfusion injury. (Rosenberg, Estrada et al. 1998)  
Ischemia and reperfusion injury results in oxidative stress that mediates BBB disruption 
through metalloproteinase activation. (Gasche, Fujimura et al. 1999; Gasche, Copin et al. 2001) 
The tight junction protein, occludin, is a specific target in oxidative stress induced microvascular 
injury. (Maier, Hsieh et al. 2006) Occludin is integral to the maintenance of the BBB and once it 
is damaged, permeability of the barrier increases, allowing substances free movement between 
blood and brain parenchyma. A recent publication from Kelly et al identified a significant 
association between F2-isoprostane (F2IP) levels, which is a valid biomarker of oxidative stress, 
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and plasma MMP9 in rtPA-treated stroke patients (Kelly, Morrow et al. 2008) which implies a 
relationship between oxidative stress and proteolytic activity. MMP9 expression is the result of 
activated leukocytes (particularly neutrophils), (Gidday, Gasche et al. 2005) and results in 
IL1beta activation (Russo, Siviglia et al. 2007) and initiation of the inflammatory cascade 
(Kolev, Skopal et al. 2003), further contributing to BBB impairment. Matrix metalloproteinases 
are closely related to endogenous rtPA concentrations (Sumii and Lo 2002; Kahles, Foerch et al. 
2005; Wang, Lee et al. 2006; Lee, Guo et al. 2007) in that endogenous rtPA enhances MMP9 
expression and plays a role in MMP9/heparin induced hemorrhagic transformation (HT). (Zhao, 
Ikeda et al. 2004)  Early inhibition of MMP9 or MMP9 gene knockout mice models consistently 
show decreased infarct volumes and attenuation of BBB disruption and inflammation. (Amantea, 
Russo et al. 2007; Svedin, Hagberg et al. 2007) However, late inhibition of MMP9 can be 
detrimental, suggesting a role for MMP9 in neurovascular remodeling and recovery following 
ischemic brain injury. (Zhao, Wang et al. 2006) Taken together, the data suggest that early 
MMP9 inhibition in stroke may be beneficial, especially when used in combination with 
thrombolytic therapy to attenuate inflammation and BBB disruption. 
2.2.1.1 Age and the BBB 
Age-related changes in the BBB can be attributed to alterations in ion and nutrient transport, 
hemodynamic changes in the microcirculation, and changes in neurotransmitter 
activity.(Mooradian 1994) The number of brain capillary endothelial cells decreases with age in 
conjunction with capillary wall thinning.(Mooradian 1988) There is also a decreased amount of 
occludin (one of the essential accessory proteins of tight junctions) in cerebral tissue of aged rats. 
(Mooradian, Haas et al. 2003) It is well known that aging is associated with morphological 
changes in the BBB that increases susceptibility to brain injury during ischemia. However the 
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mechanisms by which aging mediates the response of the BBB to ischemia are not well 
understood. In addition, most animal models of stroke fail to incorporate aged animals for 
comparison to young. The disparity found between laboratory animal models and clinical studies 
of stroke may be associated with age related changes in the BBB. Dinopali et al demonstrated 
that aged rats (17-18 months) have more severe infarcts and greater disruption of the BBB 
following embolic MCAO compared to younger rats (3-4 months).(DiNapoli, Huber et al. 2008) 
The group identified that BBB disruption occurs prior to neuronal damage and age has an 
influence on this response.   
2.2.2 Hyperintense acute reperfusion injury marker 
The integrity of the BBB can be assessed by specific MRI sequences following the 
administration of the contrast agent gadolinium-diethylene triamine penta-acetic acid (Gd-
DTPA). Gd-DTPA does not cross an intact BBB and the visualization of contrast enhancement 
within the sulcal spaces of cerebral tissue is therefore indicative of a compromised BBB. 
Extravasation of GD-DTPA into the cerebrospinal fluid (CSF) results in hyperintensity within 
the CSF space on fluid-attenuated inversion recovery (FLAIR) MRI. (Mathews, Caldemeyer et 
al. 1999) (Henning, Latour et al. 2008) 
 Warach and Latour first aimed to describe the phenomena of post-contrast FLAIR 
enhancement of the CSF space in acute stroke patients in 2004 and have since termed this 
observation Hyperintense Acute Reperfusion injury Marker (HARM). (Warach, Latour et al. 
2003; Latour, Kang et al. 2004; Warach and Latour 2004) An analysis of 213 ischemic stroke 
patients, over a 22-month period, imaged using 1.5 Tesla MRI within 24 hours of symptom onset 
revealed that 33% of stroke patients develop BBB disruption as HARM on MRI. (Latour, Kang 
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et al. 2004) Reperfusion was the strongest predictor of HARM, suggesting that HARM may be 
an indicative sign of reperfusion related injury to the BBB. Additionally, HARM was more 
common in patients with HT. This relationship was stronger when the patients were treated with 
rtPA. The presence of HARM was also associated with poor clinical outcome defined by 
Modified Rankin Score >2. This association was maintained after baseline risk factors, such as 
NIHSS and HT, were adjusted for in a logistic regression model. A second study provided the 
first evidence of the toxic effect of thrombolytic therapy in humans, reporting that the rate of 
HARM was greatest in patients treated with intra-arterial rtPA, following by the intravenous 
rtPA group, and was lowest in the MERCI retrieval and no thrombolytic therapy groups. 
(Kidwell, Latour et al. 2008)  Findings from these studies suggest that early BBB disruption 
following ischemic stroke is related to significant adverse effects, and treatment with rtPA may 
exacerbate these complications. (Kidwell, Latour et al. 2008) 
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Figure 3. HARM Examples 
 
HT following ischemic stroke has tremendous implications for treatment and outcome, however 
the molecular underpinnings of the process are not completely understood, nor are there 
undisputable predictors of HT. Stroke severity, age, and thrombolytic administration have been 
associated with the development of HT. More recently elevated plasma MMP9 has emerged as a 
predictor of HT (Castellanos, Leira et al. 2003; Castellanos, Sobrino et al. 2007), especially in 
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the presence of rtPA administration (Montaner, Fernandez-Cadenas et al. 2003). If an association 
between plasma MMP9 and HARM can be found, it may be possible to select patients who will 
benefit from thrombolytic therapy, without the risk of HT. The use of an MMP9 inhibitor to 
augment rtPA therapy and attenuate HT may serve as an additional option for the treatment of 
acute ischemic stroke.  Validation of preclinical animal models and human studies concerning 
the association between MMP9 and BBB disruption provides justification for the use of MMP9 
inhibition in humans.  
BBB disruption is a primary event initiating HT, and given associations between plasma 
MMP9 and the occurrence of HT have already been made, it is hypothesized that plasma MMP9 
will be associated with HARM on MRI. At this time MRI cannot allow for the identification of 
the mechanism of injury behind BBB disruption; however peripheral biomarker analysis can. 
Combining an imaging marker (HARM) with peripheral biomarker protein analysis (MMP9 and 
TIMP1) allows for the identification of feasibly observable clinical indicators of BBB disruption.  
Gd-DTPA has a relatively short half life of about 1 ½ hours in the plasma. Therefore 
patients who present with HARM on follow up imaging must have BBB disruption around the 
time of the acute contrast injection. The occurrence of BBB disruption and the time window for 
thrombolytic therapy make HARM a relevant clinical indicator of the therapeutic response to 
tPA. By examining the factors that predispose patients to HARM, it may be possible to allocate 
treatment to those who will have the greatest benefit.  
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2.3 WHOLE GENOME EXPRESSION 
The utilization of microarray gene expression analysis in the study of ischemic stroke has the 
potential to reveal the mechanisms of disease and pathways associated with ischemic stroke 
progression and recovery and contribute to the detection of therapeutic targets and novel drug 
discoveries. However, as in the purpose of this study, the technique can also be used to aid in the 
identification of diagnostic biomarkers irrespective of etiology. 
 
2.3.1 Ischemic Stroke and Genetics 
Twin and family studies have shown that there is a significant familial component involved in 
the occurrence of stroke. (Brass, Isaacsohn et al. 1992; Liao, Myers et al. 1997; Bak, Gaist et al. 
2002) An even larger number of well known studies have identified environmental factors such 
as hypertension, smoking, and diabetes as potential culprits. There is no doubt that ischemic 
stroke has both environmental and genetic components involved in its pathogenesis and course 
of recovery. Therefore the complexity involved in determining associated genetic factors is 
tremendous. However, there have been some advances in identifying purely genetic elements 
responsible for stroke onset and recovery. Joutel et al (1996) characterized human Notch3 gene 
mutations affecting the Notch signaling pathway as an associated factor in the development of 
Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy 
(CADASIL). (Joutel, Corpechot et al. 1996) CADASIL is characterized by relapsing strokes 
with neuropsychiatric symptoms clearly distinct from arteriopathy and amyloid angiopathy that 
affects relatively young adults of equal numbers in both sexes. (Tournier-Lasserve, Joutel et al. 
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1993) In addition to the findings associated with CADASIL, others have attempted to establish a 
relationship between the angiotensin converting enzyme (ACE) insertion/deletion (I/D) 
polymorphism and the occurrence of stroke with mixed results.  Markus et al (1995) identified 
the deletion polymorphism in the ACE gene as an independent risk factor for lacunar stroke. 
(Markus, Barley et al. 1995) However, Ueda et al (1995) only found evidence of an association 
between ACE genotype and presence of ischemic stroke in a subgroup of hypertensive patients. 
(Ueda, Weir et al. 1995) An even larger prospective study found no association between the 
ACE genotype and subsequent stroke risk, further complicating the interpretation of the results. 
(Zee, Ridker et al. 1999) Others have attempted to correlate the presence of APOE 
polymorphisms and genotype with ischemic stroke with both success (Luo, Chen et al. 2003) and 
failure (Sturgeon, Folsom et al. 2005). Clearly these inconsistencies demonstrate that the answers 
to genetic stroke risk and recovery may not be associated with one specific gene mutation, but 
rather a collection of mutations that subsequently interact with environmental factors to produce 
ischemic stroke and varying degrees of BBB disruption. It is also these same mutations that may 
play a significant role in the recovery from an ischemic event. The ability to assess multiple sets 
of genes at one time, such as what is proposed in this project using whole genome wide 
expression, associated with BBB disruption may provide more information on the 
pathophysiologic processes of ischemic stroke rather than studying candidate genes alone.  
The first whole genome association study of ischemic stroke was performed by Matarin 
and colleagues in 2007. (Matarin, Brown et al. 2007) Over 400,000 unique SNPs from the 
Illumina Infinium Human-1 and HumanHap300 were genotyped in a cohort of 278 patients with 
ischemic stroke and 275 neurologically normal control subjects. The analysis revealed hundreds 
of statistically significant markers with the challenge now to distinguish the true associations 
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from the false positives. Some of these SNPs are within or near interesting candidate loci. Three 
significant SNPs were found within the KCNK17 gene; a member of the acid-sensitive subfamily 
of tandem pore K+ channels contributing to cellular resting membrane potential. In the heart, 
background K+ currents are thought to modulate the cardiac action potential. 
2.3.2 Ischemic stroke and whole genome expression 
The success of the human genome project and the ability of gene expression microarrays to 
assess the 25,000 or so genes in the human genome have rapidly advanced the science of 
genomics. Whereas genetics is the study of single genes and their effects, genomics is the study 
of the functions and interactions of all the genes in the genome. The study of genomics will most 
likely make its greatest contribution to health by revealing mechanisms of common diseases. 
(Guttmacher and Collins 2002) 
 The future of genomic profiling in ischemic stroke is quite promising. (Sharp, Xu et al. 
2006) Recent studies have demonstrated that different patterns of gene expression are associated 
with different diseases, and these patterns can be used for diagnostic verification and treatment 
decision making. Progress in genomic approaches to neurological diseases has been slow 
secondary to the inability of obtaining brain tissue. However, findings from recent studies 
proving that genomic profiling of blood may serve as a surrogate marker of brain disease offers 
promise for the application of genomics to the study of ischemic stroke.  
Gene expression profiling simultaneously assesses the approximately 25,000 genes of the 
human genome. It has proven to be a powerful and effective approach to identify genes, 
pathways and interactions correlated with a phenotype (e.g. leukemia disease 
classification(Andersson, Ritz et al. 2007; Basso, Case et al. 2007)); the technology has also been 
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used to identify genes and gene interactions for the prediction of a phenotype (e.g. positive 
versus negative response to chemotherapeutics (Cardoso, Van't-Verr et al. 2008)). Given these 
advancements it is possible that gene expression profiling can be used to diagnosis stroke from 
stroke mimic or predict the occurrence of good versus bad outcome. The tissue with the most 
specificity for identifying the genomic response to ischemic stroke or neurological disease is 
brain; however access to human brain tissue is unfeasible in most clinical situations, being 
accessible only post-mortem. The use of post-mortem tissue complicates the interpretation of 
findings and the relevancy of the candidate genes/proteins identified in this manner to the acute 
response to ischemic brain injury.  
DNA microarrays are most commonly used to examine gene expression profiles between 
two different cell populations. Recently the technique of constructing the arrays has been slightly 
modified to detect single nucleotide polymorphisms (SNPs) or copy number variations across 
different samples for use in genome wide association studies (GWA) to identify SNPs with 
variability. In addition, the microarray can be custom designed to target specific molecular 
pathways (e.g. targeted analysis of cancer related genes or genes in an inflammatory pathway). 
Microarray is a high-throughput technology necessary in the post-genome era. Since the 
completion of the Human Genome project in 2003, attention has been turned to assessing DNA 
variation, the function of the 20-25,000 genes present in the human genome and identifying 
mediators of gene expression (Guttmacher and Collins 2002). The field of functional genomics is 
rapidly expanding and the microarray is a valuable tool for use in understanding the complex 
interactions between the genes of our genome. 
Gene expression microarrays today generally fall into one of two categories: either two-
color cDNA or oligonucleotide. cDNA arrays contain long sequences of cDNA (~50 bases) 
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generated from gene libraries and amplified using polymerase chain reaction (PCR), which are 
then printed into spotted matrices onto glass slides. Each spot corresponds to a specific gene or 
transcript (probe). RNA is extracted from the cells of interest and amplified using PCR in which 
two types of fluorescent base pairs (Cy3 and Cy5) are inserted into the generated cDNA. These 
fluorescently labeled cDNA’s from both cell lines are then allowed to hybridize to the glass chip 
with the cDNA transcripts generated from the gene libraries. The amount of hybridization to the 
cDNA transcripts on the glass chip is proportional to the amount of mRNA expression in the cell 
and can be quantified as a fold change in expression between the two fluorescent tags.  
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Figure 4. Two color cDNA microarray 
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Oligonucleotide arrays consist of shorter nucleotide sequences and have been pioneered by the 
commercial companies Affymetrix© and Illumina© (Lipshutz, Fodor et al. 1999). Since the 
lengths of the oligonucleotides are generally 25-50 bases, the density of these chips is much 
greater than that of cDNA arrays, allowing the user to assess greater numbers of gene products at 
the same time. Oligonucleotide arrays can be manufactured as traditional cDNA arrays where the 
probes are spotted or synthesized on a 2-dimensional substrate or by using BeadArray 
technology. Beadchips are constructed by introducing oligonucleotide bearing 3-micron beads 
into microwells etched into the surface of a slide-sized silicon substrate. Using the Illumina© 
platform, the beads self assemble onto the beadchips resulting in an average of 30-fold 
redundancy of every full-length oligonucleotide. After random bead assembly, 29-mer address 
sequences present on each bead are used to map the array, identifying the location of each bead. 
Oligonucleotide sequences are selected based on their uniqueness to the target genes and may 
require the use of several matched sequences for high specificity to a single target. Similar to 
cDNA arrays, RNA is extracted from target cells and allowed to hybridize to the oligonucleotide 
array. However, with oligo arrays, only a single fluorescent channel is used, thus only a single 
sample can be measured on one array.   
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 There are a number of other microarray platforms available, however the use of commercially 
developed products are encouraged to ensure robust and reproducible results. Before this method 
can be applied in routine clinical practice and research consensus on the validity of data 
generated across platforms must be reached. Efforts to examine the inter-platform variability 
have been undertaken by the Microarray Quality Control (MAQC) project as part of the FDA’s 
Critical Path Initiative. http://www.fda.gov/nctr/science/centers/toxicoinformatics/maqc/  The 
data reveal promising results regarding the consistency of findings across different platforms and 
laboratories (Guo, Lobenhofer et al. 2006; Patterson, Lobenhofer et al. 2006; Shi, Reid et al. 
2006).  Even so, some still claim there is a significant divergence of conclusions (2006).  Those 
who support the findings of the MAQC project suggest that reliable estimates of gene expression 
can be obtained equally across platforms (Woo, Affourtit et al. 2004; Barnes, Freudenberg et al. 
2005; Maouche, Poirier et al. 2008). Inconsistencies across platforms can be attributed to 
different background correction methods and normalization techniques, cross-hybridization 
problems, technical noise and ultimately investigator interpretation. All of which can lead to over 
or under estimates of expression levels (Shi, Reid et al. 2006). The important point to remember 
is that dependable results will be produced with either commercial platform as long as the user 
identifies clear project goals and designs the study appropriately, follows experimental 
procedures correctly and minimizes procedural variation, and employs appropriate statistical 
modeling to analyze the differential expression. 
2.3.2.1 Animal proof of principle studies 
A series of four animal studies were conducted by Sharp and colleagues to examine the 
relationships between brain and blood genomic profiles in brain injury and whether or not blood 
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genomic responses could serve as fingerprints of medical or neurological diseases. (Tang, Lu et 
al. 2001; Tang, Lu et al. 2002; Lu, Tang et al. 2003; Tang, Nee et al. 2003) 
 The first study examined whether the gene expression profile of systemic white blood 
cells (WBC) could serve as a fingerprint of different types of neurological insults. (Tang, Lu et 
al. 2001) Adult male rats were grouped and subjected to one of the following: ischemic stroke; 
hemorrhagic stroke; kainite induced seizure; insulin-glucose deprivation; hypoxia; untouched 
controls; and sham. Each condition demonstrated a unique gene expression pattern in the WBCs 
and it was suggested that the differences found in the WBC profiles could relate to the unique 
immune responses to the different induced injuries. This was the first study to show the potential 
for genomic profiling of the blood response as a marker of end-organ disease.  
 A similar study design was employed with the aim of examining the role of neurologic 
insults on the gene expression profile of brain tissue. (Tang, Lu et al. 2002) In comparison to the 
6 other groups studied (ischemic stroke; hemorrhagic stroke; kainite induced seizure; insulin-
glucose deprivation; hypoxia; untouched controls; and sham.), brain ischemia altered the 
transcription of the most genes in general and induced the greatest number of immune mediated 
molecules along with a family of hypoxia-responsive genes. This could possibly be due to the 
fact that ischemia damages all cellular components of the cerebrum including neurons, glia, 
axons, white matter, and the cerebral vasculature. A surprising finding here was a failure to 
detect common genes that were down regulated in all conditions, suggesting that transcriptional 
down regulation may not be a major part of the brain injury genomic response.  
 The first whole blood expression profiling study of ischemic stroke in animals was 
performed in 2003. (Tang, Nee et al. 2003) Rats were grouped as before and RNA was isolated 
from mononuclear and polymorphonuclear cells, including RNA from red blood cells and 
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platelets. This study verified that gene expression profiling of whole blood demonstrates unique 
gene signatures for each group studied, suggesting that expression profiling of peripheral whole 
blood could be used to assess the occurrence of neuronal injury associated with various 
neurological insults, including ischemic stroke. An important finding of this study was that many 
regulated genes identified via expression profiling were not shared between isolated 
mononuclear cells and the whole blood experiments.  
 A subsequent study of the genomic expression profile of brain tissue identified a series of 
molecular pathways associated with cerebral ischemia in the rat. (Lu, Tang et al. 2003) The 
multiple numbers of genes induced after ischemia suggests that future pharmacological 
approaches should be designed to target multiple pathways simultaneously, instead of targeting 
single genes or single gene pathways.  
 These studies were crucial to identifying the utility of genomic expression profiling of 
peripheral blood in ischemic stroke. The next steps were to replicate the findings in humans, 
offering a promise to transform stroke research.  
2.3.2.2 Human proof of principle studies 
Several mechanisms have been proposed to explain the genomic response of peripheral blood 
cells to cerebral injury. The most supported is that of the interaction between peripheral cells and 
their ability to migrate and infiltrate ischemic brain tissue.(Kochanek and Hallenbeck 1992) In 
the clonal selection theory, each lymphocyte is genetically committed to express a unique 
antibody or receptor that when encountered by external antigens, responds by clonal expansion 
and differentiation.(Jerne 1985; Neuberger 2008) Therefore various clones of lymphocytes will 
be selected and expanded in response to external stimuli, and the cumulative changes in the 
transcriptional pattern of blood could reflect those lymphocytes that have been selected to 
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respond to cerebral ischemia.(Sharp, Xu et al. 2007) Additionally, various signaling molecules 
and neurotransmitters are released into the serum in response to neuronal injury. Peripheral white 
cells contain neurotransmitter receptors and transporters which may play a role in signal 
transduction pathways and the immune response of the CNS. Therefore surveying the genomic 
fingerprint of peripheral whole blood can serve as a surrogate for the genomic response of 
ischemia within the cerebral environment.  
 The first blood gene expression profiling study of human ischemic stroke was published 
by Dr. Allison Baird and colleagues at the National institute of Neurologic disorders and stroke 
(NINDS) in 2005. (Moore, Li et al. 2005) The objective of the study was to evaluate whether it 
was possible to use whole blood expression profiling in human acute ischemic stroke with the 
following aims to determine: which genes were expressed in peripheral blood mononuclear cells 
(PBMC); whether there was a specific genomic profile for stroke; whether the genes found had 
clinical significance for stroke; and whether a larger study was justifiable. A total of 20 ischemic 
stroke patients were compared to a referent group of 20 mainly elderly volunteers. An additional 
group of patients with active multiple sclerosis (MS) (n=12) and control subjects (n=10) was 
used to represent a positive disease control to address whether the results could be due to a 
nonspecific stress response. For the ischemic stroke patients, blood was drawn as soon after 
hospitalization as possible: <24 hours (n=7), 24-48 hours (n=10), and >48 hours (n=3). Whole 
blood was obtained in EDTA blood tubes and RNA was isolated from PBMCs and hybridized to 
Affymetrix Human genome U133A microarrays.  
 Of the 5,060 genes found to be different between stroke patients and control subjects, 
after Bonferroni correction and prediction analysis for microarray (PAM) classification, 22 genes 
predominantly involved in activation and differentiation of WBCs were found to be statistically 
50 
significant. Refer to Appendix C for the gene list. Validation of the gene list resulted in a 
sensitivity and specificity of 89% and 95% respectively, indicating that expression profiles 
strongly differentiated stroke patient from control subject. Even after adjusting for stroke risk 
factors, there was still a substantial difference in gene expression between the groups. There was 
also a lack of concordance of the gene expression between stroke patients and MS patients, 
demonstrating that the expression profile found may indeed be specific for stroke.  
 Soon after the publication of Dr. Baird’s study, Dr. Frank Sharp and colleagues followed 
up their animal gene expression profiling studies with a human ischemic stroke 
population.(Tang, Xu et al. 2006) The aim of the study was to examine the genomic changes 
present in whole blood before 3 hours, at 5 hours, and at 24 hours after ischemic stroke. A total 
of 15 stroke patients enrolled in a clinical trial (combination approach to lysis utilizing 
eptifibatide and recombinant tissue-type plasminogen activator (rtPA) (CLEAR)), and 8 healthy 
control subjects were recruited to address the aims of the study.  For stroke patients, whole blood 
was obtained in Paxgene RNA tubes and for control subjects whole blood was obtained in EDTA 
blood tubes. RNA was isolated and hybridized to Affymetrix Human U133 Plus2 arrays. 
 The results identified 18, 22 and 24 genes significantly regulated at 3, 5, and 24 hours 
respectively compared to healthy control subjects. Nearly all of the genes regulated at 3 hours 
were also regulated at 5 and 24 hours. PAM classification identified 18 genes specific for 
ischemic stroke (Appendix D) and revealed that neutrophils and monocytes are the major blood 
cell types involved in the human blood genomic response to acute ischemic stroke. These 
findings suggest that the rapid changes of whole blood gene expression may be useful for 
making early diagnosis of ischemic stroke in humans. Post hoc analyses of this data set revealed 
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a unique pattern of gene expression for patients with cardioembolic versus large-vessel 
atherosclerotic disease. (Xu, Tang et al. 2008)  
 There are significant limitations and differences worth discussing between Dr. Baird’s 
and Dr. Sharp’s human studies. Only two genes found to accurately predict stroke were 
identified by both groups (v-ets Erythroblastosis virus E26 oncogene homolog 2 (avian); and N-
acetylneuraminate pyruvate lyase (dihydrodipicolinate synthase)  This is likely due in part to the 
fact that different cell populations were studied. The other major difference is that all of the 
patients in Dr. Sharp’s study were treated with rtPA alone or rtPA plus eptifibatide as part of the 
CLEAR trial. It cannot be determined whether the changes in gene expression found in Dr. 
Sharp’s study were the result of the ischemic stroke or the treatment of these medications.  The 
groups used different microarray chips, with Dr. Baird’s microarray chip containing significantly 
less probes. Additionally, the time of onset of symptoms was significantly different between the 
patient groups in each study. 
A recent publication by Grond-Ginsbach et al (2008)(Grond-Ginsbach, Hummel et al. 
2008) suggests that gene expression profiling of whole blood, compared to peripheral blood 
mononuclear cell (PBMC) isolation is the most promising for characterizing the blood genomic 
response to ischemic stroke (Grond-Ginsbach, Hummel et al. 2008). The group sampled acute 
ischemic stroke patients (n=15) within 22 to 26 hours from symptom onset and compared the 
expression profiles of PBMC’s to an acute TBI cohort (n=15; 14 hours to 4 days from injury), 
healthy subjects without vascular risk factors (n=15), and stroke survivors (n=15). RNA samples 
for the groups were pooled into final samples of 4 pools for ischemic stroke, 3 pools for TBI, 3 
pools for control subjects, and 3 pools of stroke survivors. Therefore a total of 13 array 
experiments were conducted. Only a single probe and single gene group yielded a significant 
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gene expression difference for stroke. Phosphodiesterase 4D (PDE4D) was found to be 50% 
down-regulated for stroke, whereas genes involved in the inflammatory response were found to 
be up-regulated. They were not able to replicate the findings of the first two studies performed 
by Dr. Baird and Dr. Sharp. Possible reasons for this include the use of PBMC’s for RNA 
isolation, blood sampling after 24 hours from onset of stroke symptoms, pooling of RNA 
samples into 4 stroke groups, small sample size, and the use of different statistical analysis 
techniques.  
2.4 SIGNIFICANCE AND INNOVATION 
Despite promising preclinical therapeutics, rtPA is the only FDA approved treatment for acute 
ischemic stroke. There is an urgent need to reassess the best approach to study the human 
response to brain injury moving forward (Maas, Marmarou et al. 2007). Most of what we have 
discovered of the physiologic response to ischemic brain injury has been identified in preclinical 
animal and cell modeling and treatments based on these findings have been largely unsuccessful, 
therefore a redirection of the science is necessary.  A novel approach to the study of ischemic 
stroke is the use of gene expression profiling to identify biomarkers associated with ischemic 
stroke diagnosis. A secondary advantage of gene expression profiling is its ability to unveil the 
molecular pathways involved in brain recovery and health and elucidate complex genomic 
interactions that may play a role in outcome. Since brain tissue is neither easily accessible nor 
practical to obtain in live subjects and post mortem analysis can introduce bias, we need to rely 
on other mechanisms as the means by which we analyze gene expression in most patients 
affected by stroke and neurological disease. Peripheral blood is easily accessible in all clinical 
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situations and therefore provides greater clinical utility. There is the hope that this approach 
could aid in earlier diagnosis of neurological disease, identify therapeutic targets for brain injury, 
and help in treatment decision making and predictions regarding prognosis (Baird 2006; Sharp, 
Xu et al. 2006). 
The advantages of this proposed thesis study are the following: peripheral blood samples 
of stroke patients will be gathered within 24 hours from onset of symptoms; the follow up blood 
draw will provide an unbiased expression profile; diagnosis of ischemic stroke will be made by 
MRI; patients will be matched to healthy control subjects in an attempt to control for 
environmental variation; and molecular pathways will be assessed for their relevance in ischemic 
stroke.  
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3.0  PILOT STUDIES 
3.1 PILOT STUDY I, MANUSCRIPT I: MMP9 AND HARM 
Barr T, Latour LL, Lee KY, Schaewe T, Luby M, Chang G, El-Zammar Z, Alam S, Kidwell C, 
Warach S. 
Early blood brain barrier disruption is associated with plasma matrix metalloproteinase-9 
concentration in acute stroke patients. 
Targeted Journal: Stroke. 
*Podium Presentation International Stroke Conference 2008 
 
Abstract 
 
Objective: Matrix metalloproteinases (MMP’s) may play a role in blood brain barrier (BBB) 
disruption following ischemic stroke. BBB disruption is characterized by gadolinium 
enhancement of cerebrospinal fluid (CSF) on fluid attenuated inversion recovery (FLAIR) 
magnetic resonance imaging (MRI) and is termed Hyperintense Acute Reperfusion injury Marker 
(HARM). We hypothesized that acute MMP9 is associated with a marker of BBB disruption on 
MRI.  
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Methods:  Patients evaluated for acute stroke underwent MRI on presentation and 24 hours later. 
The presence of HARM on post-contrast FLAIR images was assessed by blinded readers.  
MMP9 and tissue inhibitor of matrix metalloproteinase -1 (TIMP1) was measured by ELISA.  
Logistic regression models tested for predictors of HARM on 24 hour follow-up scans separately 
for MMP9 and MMP9/TIMP1 ratio. 
Results: Forty-one patients were enrolled. Diagnoses were acute ischemic cerebrovascular 
syndrome 34 (82.9%), intracerebral hemorrhage 6 (14.7%) and stroke mimic 1 (2.4%).  HARM 
was present on 24 hour follow-up in 17 (41.5%) patients. In model 1, HARM was associated 
with acute plasma MMP9 concentration: odds ratio (OR) = 1.01 (95% confidence interval (CI) 
=1.001-1.019), p=0.033. In model 2 HARM was associated with MMP9/TIMP1 ratio: OR=4.94 
(95% CI=1.27-19.14), p=0.021. 
Interpretation: Acute MMP9 was a significant predictor of HARM at 24 hour follow-up, 
supporting the hypotheses that HARM reflects early BBB disruption and MMP9 is associated 
with BBB disruption. If the association between MMP9 and HARM is confirmed in future 
studies, HARM may be a useful imaging marker to evaluate MMP9 inhibition in ischemic stroke 
and other populations with BBB disruption.  
 
*Barr, T. performed all ELISA’s necessary for the completion of this study.  
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3.2 PILOT STUDY II: KCNK17 AND ISCHEMIC STROKE 
Barr, Taura; Nalls, Mike; Arepalli, Sampath; Singleton, Andrew; Meschia, James; Hardy, John; 
Matarin, Mar 
Polymorphisms in KCNK17 are not associated with ischemic stroke 
*Poster Presentation Eastern Nursing Research Society Conference 2009 
 
Abstract 
 
Objectives: The recent genome wide association (GWA) study of ischemic stroke (IS) identified 
hundreds of statistically significant single nucleotide polymorphisms (SNPs) associated with IS. 
The objective of this study was to attempt to replicate the significant association found between 
these SNPs in the KCNK17 gene and ischemic stroke (IS) in a separate cohort of Caucasian 
stroke patients and control subjects of North American descent.  
Methods: A total of 548 stroke patients and 376 control subjects were included in this replication 
study. All samples were selected from the Ischaemic Stroke Genetics Study (ISGS), a 
prospective five-centre case-control study in the USA; unrelated IS affected probands from the 
SWISS study; a sibpair linkage study; and IS cases from the National Institute of Neurological 
Disorders and Stroke neurogenetics repository. All individuals underwent a detailed medical 
history and diagnosis of ischemic stroke by trained neurologists. For the 3 SNPs (rs2395721, 
rs10807204, rs10947803) single-tube reagent-based genotyping assays (TaqMan) were used. 
Results were validated by direct DNA genotyping in a subset of samples (n=96). From our GWA 
study in IS, 100 samples were genotyped with the same probes used in this study to test the 
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concordance between assays. All five exons of KNCK17 were genotyped in 288 stroke patients 
and 288 control subjects to examine the variability of the gene. 
Results: No significant association was found between genotype of either SNP and IS in 924 
individuals after adjusting for stroke risk factors (age, gender, hypertension, diabetes, atria 
fibrillation, and myocardial infarction). Sequencing of 576 stroke patients and control subejcts 
across exons 1-5 did not reveal obvious candidates for IS with the exception of one stop codon in 
exon 5, which was found in only one stroke patient.  
Interpretation: The genetic variants examined in the KCNK17 gene did not reveal a reproducible 
association with ischemic stroke. The association found in our recent GWA study of ischemic 
stroke may have been a false positive.  
3.3 PILOT STUDY III, MANUSCRIPT II: AGE AND HARM 
Barr, T.; Latour, L.; Kidwell, C.; Lee, K.; Merino, J.; Warach, S. 
Age is the major risk factor of early blood brain barrier disruption  in acute ischemic stroke 
Targeted Journal: Stroke. 
 
*Poster Presentation International Stroke Conference 2009 
 
Abstract 
 
Objective: Advanced age is a known predictor of ischemic stroke (IS) and is associated with the 
presence of Hyperintense Acute Reperfusion injury Marker (HARM) in IS patients. It is proposed 
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that the integrity of the blood brain barrier (BBB) is compromised with age. The objective of this 
study was to further examine the relationship between age and HARM in IS patients and 
determine whether age remains a significant predictor of HARM after controlling for 
comorbidities and known risk factors associated with advanced age.  
Methods: This is a pooled analysis of 235 patients from studies conducted between June 2000 
and June 2007. Clinical demographic data and risk factor history was obtained by the patient or 
family members during the acute clinical workup. The time of onset was determined as the time 
the patients were last known to be normal or free of acute symptoms, if exact time of onset was 
unknown. Patient evaluations and management were standardized. Patients were included if they 
received a diagnosis of ischemic stroke, had a baseline MRI within 24 hours from time of stroke 
onset and received a follow up MRI with contrast-enhanced fluid attenuated inversion recovery 
(FLAIR) imaging.  HARM was determined as hyperintensity present in sulci across greater than 
10 MRI slices and dichotomized as present or absent. A forward conditional logistic regression 
with an entry criterion of 0.15 was performed in an attempt to develop a predictive model of 
HARM based on the following covariates: age, National Institutes of Health Stroke Scale Score 
(NIHSS), administration of tissue plasminogen activator (tPA), and history of hypertension, 
diabetes, hyperlipidemia, or ischemic stroke.  
Results: Age (OR=1.03; p=0.002), NIHSS (OR=1.08; p<0.000), hypertension (OR=2.18; 
p=0.033), previous ischemic stroke (OR=2.73; p=0.004), and tPA administration (OR=2.24; 
p=0.009) were associated with presence of HARM in univariate analysis. In a binary logistic 
regression model, age >75 years (OR=3.46; p=0.000), NIHSS category (OR=1.46; p=0.018), 
previous ischemic stroke (OR=2.27; p=0.036), history of diabetes (OR=2.04; p=0.073), and 
thrombolysis (OR=1.86; p=0.083) were predictors of HARM. The odds of developing HARM in 
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patients with age greater than 75 years was 3.4 times higher than for younger patients (p<0.00). 
In addition, patients with age greater than 75 years of age who received tPA had a higher risk of 
developing HARM (OR=3.2; p=0.012) when compared to those younger in age who received 
tPA (OR=1.7; p=0.26).  
Conclusions: After adjusting for risk factors known to be associated with advanced age and 
presence of HARM, age remained the strongest predictor of BBB disruption. We have confirmed 
other factors that independently contribute to the risk of BBB disruption. BBB changes 
associated with age may be the most clinically relevant for stroke and should be accounted for in 
future studies of BBB biology. It will be important to determine what factors associated with age 
contribute to HARM in this population.  
3.4 REVIEW, MANUSCRIPT III: GENE EXPRESSION PROFILING IN BRAIN 
INJURY 
Barr, Taura; Alexander, Sheila; Conley, Yvette. 
Gene expression profiling for discovery of novel targets in human traumatic brain injury 
Submitted to Journal of Neurotrauma April 13, 2009 
 
Abstract 
 
Several clinical trials have failed to demonstrate a significant effect on outcome 
following human traumatic brain injury (TBI) despite promising results obtained in pre-clinical 
animal studies. This may be due in part to a misinterpretation of the findings obtained in pre-
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clinical animal models of TBI; a misunderstanding of the complexity of the human response to 
TBI; limited knowledge about the biological pathways that interact to contribute to good and bad 
outcomes after brain injury; and the implications of genomic variability and environment on 
individual recovery. Recent publications suggest data obtained from gene expression profiling 
studies of complex neurological diseases, such as Stroke, multiple sclerosis, Alzheimer’s and 
Parkinson’s may contribute to a more informed understanding of what contributes to outcome 
following TBI. This may help to bridge the gap between successful preclinical studies and 
negative clinical trials in humans to reveal novel targets for therapy. Gene expression profiling 
has the capability to identify biomarkers associated with response to TBI, elucidate complex 
genetic interactions that may play a role in outcome following TBI and reveal biological 
pathways related to brain health. The following review highlights the current state of the 
literature on gene expression profiling, discuss its ability to aid in unraveling the variable human 
response to TBI and the potential for it to offer treatment strategies in an area where we currently 
have limited therapeutic options primarily based on supportive care.  
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4.0  METHODS 
4.1 DESIGN 
A whole genome expression analysis with a case control design is proposed to assess whole 
blood gene expression in acute ischemic stroke patients (cases) compared to neurologically 
healthy control subjects. The primary aim of the study is to determine which genes are under- 
and over-expressed in acute ischemic stroke patients compared to neurologically healthy control 
subjects. The secondary aim of the study is to determine the changes in gene expression that 
occur in the first 24-48 hours following acute ischemic stroke. The tertiary aim of the study is to 
determine whether acute ischemic stroke patients with BBB disruption have a specific blood 
genomic profile compared to AIS patients without BBB disruption.  
Gene expression profiles for acute ischemic stroke patients will be assessed at acute and 
twenty four hour time points to evaluate changes in gene expression over time using a within 
patient control approach. For the last aim of the study, stroke patients with BBB disruption will 
be matched to stroke patients without BBB disruption.  Whole genome expression microarrays 
will provide a specific gene expression profile in whole blood for acute ischemic stroke patients, 
neurologically healthy control subjects, and patients with BBB disruption.  
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4.2 SAMPLE 
A total of 39 acute ischemic stroke patients and 25 neurologically healthy matched control 
subjects were recruited to address the aims of the study. The NIH Stroke Team is consulted on 
about 500 cases per year at Suburban Hospital Bethesda, MD. Of those 500 cases, about 60% 
(n=300) receive a diagnosis of probable or definite acute ischemic cerebrovascular syndrome 
(AICS) (Kidwell and Warach 2003). All patients consulted were eligible for the study. Those 
enrolled included patients with diagnosis of definite acute cerebrovascular syndrome (ischemic 
stroke) and non-stroke patients without neurologic deficits that could be used as control subjects.  
Recruitment took place weekdays Monday-Friday during regular working hours. To achieve the 
original goal of 22 acute ischemic stroke patients, over sampling of acute ischemic stroke 
patients occurred for a goal of 40.  
To increase the success of healthy volunteer enrollment in future studies, a Healthy 
Volunteer Protocol has been written and submitted to the Institutional review board (IRB) to 
allow for the enrollment of patient family members or significant others. Once this is approved, 
family members or significant others of patients enrolled in the NIH Natural History study will 
be approached for enrollment into subsequent gene expression profiling studies. This approach 
has the advantage of attempting to control for some environmental factors associated with 
differences in gene expression profiles. Non-hospital admission volunteers will be recruited and 
evaluated at Suburban Hospital. Subjects will be considered for enrollment if they contact the 
research team and would like to volunteer to participate in the study or are a family 
member/significant other of a patient enrolled in the Natural History Disease Pathogenesis of 
Stroke study.   Following enrollment, volunteers will be assigned a date and time in which to 
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return to the magnetic resonance imaging (MRI) suite. Healthy subjects will not be followed 
over time. 
For the present study, a healthy volunteer cohort of 25 subjects has been recruited under a 
separate IRB approved protocol of Dr. Andrew Singleton’s. The population consists of friends or 
family members of patients affected with amyotrophic lateral sclerosis (ALS). Medical history, 
family history and medication history was obtained on all control subejcts. None of these 
volunteers underwent MRI testing nor were they followed over time.  
Peripheral blood samples were collected from patients who met the following inclusion 
criteria: age ≥18 years with diagnosis of definite acute ischemic cerebrovascular syndrome (acute 
ischemic stroke) or those who were non-stroke neurologically healthy control subjects who 
presented to Suburban Hospital, Bethesda Maryland. Exclusion criteria included pre-existing 
neurological disease, patients presenting past 24 hours following onset of symptoms and those 
patients with contraindications to MRI scanning. All patients received an MRI of the brain on 
admission and follow-up on day two. Non-hospital admission healthy control subjects were 
recruited on a volunteer basis. Upon enrollment the subjects had an MRI performed and the 
subject’s blood was drawn. For those patients with acute ischemic stroke blood was redrawn 24 
hours following onset of symptoms to determine changes in gene expression profiles over time. 
Acute ischemic stroke patients were frequency matched to healthy control subjects on a 1:2 basis 
by gender, age within +/- 10 years and race. There were only three African American (AA) 
patients recruited at Suburban hospital and no AA control subjects were recruited; therefore the 
AA patients were left out of this study to avoid potential problems with population stratification.  
A subsequent sample collected at Washington Hospital Center, Washington DC will be analyzed 
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to determine the validity of the gene expression profile identified in this study for an AA 
population.  
4.3 RATIONAL FOR SAMPLE SIZE 
Sample size calculations for microarray analysis are based on the number of genes available on 
the chip, probability of Type 1 error, probability of Type 2 error, random error, and effect size. 
Sample size calculations have been conducted using PASS: Power analysis and sample size 
system and JMP software. A 2.0 fold change is generally expected in genes of significance; 
however a smaller fold change of 1.5 may be used to identify genes with similar but slight 
differences in expression between the two groups.  For Aim 1, a total of 22 patients and 22 
healthy control subjects achieves 90.68% power for each gene to detect a true difference in 
expression with at least a 1.5 fold change and an estimated standard deviation of 1.5 with a false 
discovery rate of 0.05 using a two-sided one-sample t-test. Of the 50 genes with anticipated true 
mean difference in expression >1.5, 45 are expected to be detected. For Aim two, a total of 22 
patients with two time points will achieve the same: 90.68% power for each gene to detect a true 
difference in expression with at least a 1.5 fold change and an estimated standard deviation of 1.5 
with a false discovery rate of 0.05 using a two-sided one-sample t-test. For Aim three, eight 
patients with BBB disruption and eight patients without BBB disruption achieves 90% power for 
each gene to detect a true difference in expression with a 2.0 fold change and estimated standard 
deviation of 1.1 with a false discovery rate of 0.05 using a two-sided one-sample t-test. See 
Appendix E for sample size calculations.  
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4.4 SETTING 
Patients were recruited from the Suburban Hospital Stroke Team Center. All patients were 
initially evaluated in the hospital Emergency Department or an inpatient unit and followed for 24 
hours. Suburban hospital is a community owned, not-for-profit 228 bed hospital located in 
Bethesda Maryland. In 1999 the NIH stroke program at Suburban hospital was established and 
became the first acute stroke program in Montgomery County Maryland. The acute stroke team 
is available 24 hours a day seven days a week and patients evaluated have direct access to the 
NIH MRI center with a 1.5T MRI.  
4.5 RECRUITMENT 
Subjects were chosen for this study from patients enrolled in a larger prospective NIH Natural 
History of Stroke study conducted by the NIH/NINDS Stroke Program at Suburban Hospital. 
Patients were consented either by T. Barr or an associate investigator of the larger NIH study. 
Each patient received an oral and written explanation of the purposes, procedures, and potential 
risks of the study. Copies of the signed informed consent were obtained and placed in the 
patient’s medical chart, research chart, and one copy given to the patient.  Due to the need to 
include all patients who presented to the emergency department with suspected acute stroke there 
were patients who were cognitively impaired as a result of their medical condition. Surrogate 
consent was obtained for these individuals. Exclusion criteria included: patient’s less than 18 
years of age; patients presenting >24 hours following onset of symptoms; and patients with 
contraindication to MRI scanning including patients with the following devices or conditions: a. 
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Central nervous system aneurysm clips b. Implanted neural stimulator c. Implanted cardiac 
pacemaker or defibrillator d. Cochlear implant e. Ocular foreign body (e.g. metal shavings) f. 
Insulin pump g. Metal shrapnel or bullet h. Any implanted device that is incompatible with MRI; 
patients with a condition precluding entry into the scanner (e.g. morbid obesity, claustrophobia, 
etc.). 
4.6 STANDARD MEDICAL CARE 
All patients recieved standardized medical care based on management decisions established by 
Class 1 evidence and recommendations of professional societies. All members of the clinical 
stroke team follow the “Standard Non-Investigational Inpatient Stroke Care Protocol for Acute 
Ischemic Cerebrovascular Syndromes of the NINDS Stroke Diagnostics and Therapeutics 
Section”. Acute management includes stabilization of the patient to maximize cerebral perfusion 
(HOB flat, IV normal saline); no treatment of blood pressure except as required for thrombolytic 
therapy or SBP>220 or DBP>120; stroke labs; stroke MRI stat (or CT if MRI contraindicated); 
and accurate determination of last known to be free of symptoms to determine eligibility for rtPA 
therapy. National Institutes of Health Stroke scale (NIHSS) is performed during the initial 
clinical workup and at subsequent neurologic examinations. The NIHSS is a 15-item assessment 
tool that provides a quantitative measure of neurologic deficit. Patients were admitted to the 
Stroke Unit or the Intensive care unit (ICU) and received care to maximize cerebral perfusion 
pressure; started on deep vein thrombosis (DVT) therapy; strict glucose monitoring and control; 
and received a complete work up for stroke etiologies and risk factors. Secondary stroke 
prevention was started as early as possible.  
67 
4.7 DATA COLLECTION 
Demographic and medical data was collected as part of the clinical work up and recorded on the 
clinical data sheets by a member of the stroke team. Case report forms (CRFs) were developed 
for this study (Appendix F) and were filled out by T. Barr using the clinical data sheets, 
discussion with the patient and a clinical member of the stroke team who was present during the 
patient’s acute work up. Laboratory data and in-hospital medication administration data was 
gathered from Suburban hospitals Meditech system for the patients hospital stay and placed with 
the CRFs and clinical data sheets in the research chart. Patient research charts are stored in a 
locked office. All data was entered and verified into an SPSS database, which has been designed 
specifically for this project.  
Acute peripheral blood samples were obtained via standard phlebotomy procedures by T. 
Barr following consent. Follow up blood draws were performed by T. Barr as close to 24 hours 
following onset of symptoms. All blood draws were performed via venipuncture for a total of 5 
ml of blood at each time point. Specimens were immediately taken to the Suburban hospital 
laboratory and placed in a -80°C freezer until RNA isolation. All data and specimen collection, 
processing, and laboratory analysis was conducted by T. Barr under the supervision of Dr. 
Steven Warach and Dr. Andrew Singleton. 
4.8 DATA MANAGEMENT 
Subjects were assigned a unique identification code upon admission to the study that was used to 
link all clinical and medical data to the appropriate laboratory specimens. Data was entered into 
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an SPSS database and verified at a separate time by the T. Barr. All hard copy data sheets are 
kept in a locked office and the SPSS database is kept on a password protected computer.  
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5.0  VARIABLES, MEASURES, AND LEVEL OF MEASUREMENT 
5.1 GENE EXPRESSION 
5.1.1 Paxgene Blood RNA system 
The best tissue for gene expression studies of stroke would be human brain tissue, however this 
is clearly not feasible given the fact that most ischemic strokes are relatively mild and therefore 
do not provide an opportunity to collect brain tissue samples (either through decompressive 
craniotomy or autopsy after death). The alternative is gene expression profiling of peripheral 
blood. Peripheral blood analysis is a powerful tool for biomarker discovery in the clinical setting. 
Although peripheral blood samples are collected routinely in practice, it is relatively difficult to 
maintain the integrity and biological signature of RNA because mRNA since it is constantly 
being degraded in the cytoplasm and therefore the half life is short lived. A widely used method 
for RNA isolation requires the isolation of peripheral blood mononuclear cells (PBMC). This 
additional step adds to both the time and instrumentation requirements for RNA isolation, and 
may potentially cause a change in the biological signature of the RNA (Debey, Schoenbeck et al. 
2004).  
A new technology that has recently gained entrance into the clinical arena, especially 
clinical trials research is the Paxgene Blood RNA isolation system. Paxgene blood RNA tubes 
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contain a reagent that protects RNA from degradation, preserving the RNA expression profile 
during and after phlebotomy. Using Paxgene RNA tubes eliminates the isolation of PBMC by 
integrating and consolidating nucleic acid stabilization and RNA purification thereby reducing 
the unpredictability associated with RNA processing of PBMC isolation and therefore enhances 
the accuracy of RNA expression analysis.  Paxgene RNA tubes are a reliable source of RNA 
isolation and have been shown to be a valid approach to RNA extraction from human whole 
blood (Rainen, Oelmueller et al. 2002). Proof of principle studies have been performed in our 
laboratory verifying the Paxgene RNA isolation method (Barr, Unpublished data). For its ease of 
use in the clinical setting, and its ability to maintain the specific biological signatures at the time 
of the blood draw, Paxgene blood RNA tubes were used to collect 2.5ml of peripheral blood 
from subjects using standard phlebotomy procedures then immediately inverted 8-10 times to 
ensure adequate red blood cell lysis.  
5.1.2 RNA extraction 
Paxgene blood RNA tubes were immediately placed in a -80°C freezer at Suburban Hospital 
until RNA isolation and analysis. All frozen whole blood specimens were allowed to thaw at 
room temperature for 24 hours on a rotating bed prior to RNA isolation procedures to ensure 
complete red blood cell lysis, per manufacturer recommendations. Once thawed, purification 
began with centrifugation to pellet the nucleic acids. The pellet was washed and resuspended in 
buffer with proteinase K to optimize protein digestion. The lysate was then centrifuged through a 
Paxgene shredder spin column for homogeneity and to remove cell debris. Then through a 
process of washes and centrifugation, RNA was eluted in the buffer. Total RNA purified using 
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the Paxgene system is highly pure, with A260/A280 values between 1.8 and 2.2 and ≤1.0% (w/w) 
genomic DNA. RNA yields are ≥3 μg from 2.5ml of whole blood. Appendix G 
RNA isolated from whole blood typically consists of a high proportion of mRNA 
encoding globin polypeptides. Some have been concerned that this high proportion of globin 
mRNA results in reduced sensitivity of hybridization on some microarray platforms. A recent 
study demonstrated that globin reduction does not increase the number of differentially 
expressed transcripts when hybridizing to HumanRef-8 v2 beadchips and therefore has little 
impact on probe detection when using the Illumina platform. (2007)   Therefore, globin reduction 
was not conducted on any sample in this study. 
5.1.3 RNA amplification 
The Illumina TotalPrep RNA amplification kit was employed to generate biotinylated, amplified 
RNA for hybridization to the arrays. The procedure consisted of reverse transcription with an 
oligo (dT) primer and a reverse transcriptase designed to produce higher yields of first strand 
cDNA. The cDNA underwent a second strand synthesis and clean up to become a template for in 
vitro transcription. The in vitro transcription resulted in biotin labeled antisense cRNA copies of 
each mRNA in a sample which will be hybridized to the arrays. Appendix H 
5.1.4 Human Ref-8 v2 expression bead chips 
Illumina humanRef-8 v2 expression bead chips were used for gene expression analysis and have 
the capability to analyze 18,631 unique curated genes at once. The beadchips contain up to date 
content derived from the National Center for Biotechnology Information reference sequence 
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(NCBI RefSeq) database. The multi-sample format allows for up to eight samples to be arrayed 
in parallel, increasing throughput and decreasing experimental variability. Reproducibility has 
been demonstrated by high concordance and precision between hybridization replicates. The 
expression beadchips are constructed by introducing oligonucleotide bearing 3-micron beads into 
microwells etched into the surface of a slide-sized silicon substrate. The beads self assemble onto 
the beadchips resulting in an average of 30-fold redundancy of every full-length oligonucleotide. 
After random bead assembly, 29-mer address sequences present on each bead are used to map 
the array, identifying the location of each bead. cRNA will be fragmented prior to hybridization 
to the gene chip. Sample labeling, hybridization, and scanning were conducted using standard 
Illumina protocols. Appendix I 
5.1.5 Quantitative real time PCR validation 
Taqman gene expression probes exploit the 5’ nuclease activity of Taq DNA polymerase to 
detect the accumulation of target PCR product by using a cleaved fluorescent probe. Most are 
available as “off-the-shelf” assays and all have been designed to have high amplification 
efficiency and specificity for the target gene, eliminating non-specific amplification.  A 
housekeeping gene (Beta-actin) was chosen from the microarray data for normalization of target 
genes because the expression between stroke patients and control subjects was relatively the 
same for Beta-actin.  cDNA was generated from total RNA per standard laboratory technique 
and RT-PCR was performed on 5 of the significant genes determined by array analysis 
normalized by Beta-actin on all 39 stroke patients and 24 control subjects in triplicate for each 
gene. These 5 genes were chosen because four were also found to be significant in the first gene 
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expression profiling study for stroke and one was the only down-regulated gene in stroke. See 
Appendix J for cDNA synthesis and RT-PCR protocol.  
 A key attribute to PCR is that there is a doubling of PCR product with every PCR cycle. 
Identification of the PCR cycle when the exponential growth phase is first detectable (cycle 
threshold=CT) is an accurate measurement of quantitative gene expression. (2006)When using 
Taqman gene expression assays the comparative CT (??CT) method for determining relative 
fold change correlates well with expected fold change values.(2006) The ??CT method 
assumes the amplification efficiency is the same across all probes. CT values greater then 35 
approach the sensitivity limits of the detection system and were therefore eliminated from 
analysis. The average CT value for each sample was identified across the triplicate wells. Then an 
overall CT average for stroke subjects and control subjects was determined. The difference 
between the Beta-actin and the target gene average was determined for stroke subjects and 
control subjects separately and then the ??CT values between the target and Beta-actin were 
converted to relative expression (RQ) values using the following equation: 2 -??CT. Validation 
was determined positive if the relative fold change in expression was similar to what was 
identified with the microarray results; t-test analysis revealed significance and there was a 
positive correlation between PCR and microarray results.  
5.2 HYPERINTENSE ACUTE REPERFUSION INJURY MARKER 
MRI was performed using a 1.5-Tesla clinical MR system on patients upon admission or onset of 
symptoms and follow up at 24 hours. MR imaging of healthy control subjects was not performed 
in this study. The scanning protocol for patients was standardized for sequence parameters and 
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order of acquisition to include: diffusion weighted imaging (DWI), T2*-weighted gradient 
recalled echo (GRE), FLAIR, and perfusion-weighted imaging (PWI). Perfusion weighted 
imaging was obtained using the bolus passage of contrast method by injecting Gd-DTPA at a 
dose of 0.1 mmol/kg via power injector. Image analyses were performed independently and blind 
to clinical information. MRI was assessed for location of HARM (e.g., sulcal, bilateral, 
ventricles, vitreous) and level (none, mild, moderate, or severe). HARM was identified positive 
when the intensity in the cerebrospinal fluid (CSF) in the sulci or ventricles appeared 
hyperintense in comparison with the previous examination.  Level of HARM was identified as a 
categorical variable: 1. No HARM: Black CSF or 1-2 point like hyperintense regions; 2. Mild: 
Numerous point-like hyperintense regions; 3. Moderate HARM: Linear hyperintense regions 
confined to less than 10 MRI slices; 4. Severe HARM: Linear and continuous hyperintense 
regions present in at least 10 MRI slices. For the purpose of analysis, previous work conducted 
by investigators in the Section on Stroke Diagnostics and Therapeutics, NINDS/NIH have found 
that Severe HARM is the only clinically relevant presentation of HARM, therefore HARM was 
further categorized as a binary variable: Severe HARM yes/no. Differential gene expression was 
assessed across all groups then by HARM Severe yes/no. See Appendix B for NINDS Stroke 
Team-HARM Rating Scale developed by investigators in the Section on Stroke Diagnostics and 
Therapeutics, NINDS/NIH.(Latour, Kang et al. 2004)   
5.3 TIME 
 Time of onset was identified as the time the patient was last known to be normal or free of 
symptoms. At times this was hard to determine, especially if the patient lived alone or had 
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neglect and was unaware of their symptoms. In this case, the time of onset was determined as 
when the patient was last seen normal. If a patient fell asleep normal and woke up in the morning 
with symptoms, the time of onset was noted as the time the patient fell asleep. All attempts to 
determine an accurate time of onset were made by the stroke neurologist, especially when the 
patient was eligible for rtPA therapy.  
The acute blood draw was performed as early after time of onset, but not greater than 24 
hours from time of onset. The follow up blood draw was drawn as close to 24 hours from time of 
onset, or last known normal as possible. In times where the acute blood drawn was performed 
near 24 hours from time of onset, the follow up blood draw was timed as 24 hours from acute 
blood draw.  
5.4 STROKE PATIENTS AND CONTROL SUBJECTS 
Cases were classified by AICS diagnostic criteria (Kidwell and Warach 2003) during the stroke 
neurologists assessment at the acute work up.  This classification scheme for ischemic stroke 
defines four categories ranging from “Definite AICS” to “Not AICS”, based on evidenced-based 
neuroimaging diagnostic certainty. Transient ischemic attack (TIA) generally refers to an episode 
in which symptoms resolve completely and has been considered a different clinical entity than 
ischemic stroke. However, MRI and MR spectroscopy have identified that the majority of TIA 
patients have imaging evidence of permanent ischemia. For this reason, a redefinition of TIA 
based on tissue pathophysiology rather than an arbitrary time cutoff was warranted. This type of 
diagnostic certainty provides universally applicable and standardized definitions important for 
clinical therapeutic decision making and rigorous research studies and clinical trials. All patients 
76 
with imaging positive ischemia are categorized as Definite AICS, regardless if the symptoms 
resolve. For the purposes of this study, only patients with a diagnosis of “definite” AICS were 
included. Patients with a diagnosis of “probable” or “possible” AICS were excluded from this 
study. Refer to appendix A for the classification categories of AICS.  
 For stroke patients, ischemic stroke was classified using the TOAST (Trial of ORG 
10172 in Acute Stroke Treatment) subtype criterion which classifies stroke into 5 core 
pathologic groups: large-artery atherosclerosis (LAA), including large-artery thrombosis and 
artery-to-artery embolism; cardioembolism (CE); small artery occlusion (SAO); stroke of other 
determined cause (OC); and stroke of undetermined cause (UND).  
 Three month outcome was determined using the Modified Rankin Scale score (MRS). 
The MRS measures degree of disability following stroke on a 0-6 scale, from no symptoms to 
death: 0- No symptoms at all; 1- No significant disability despite symptoms; able to carry out all 
usual duties and activities; 2-Slight disability; unable to carry out all previous activities, but able 
to look after own affairs without assistance; 3- Moderate disability; requiring some help, but able 
to walk without assistance; 4- Moderately severe disability; unable to walk without assistance 
and unable to attend to own bodily needs without assistance; 5-Severe disability; bedridden, 
incontinent and requiring constant nursing care and attention; 6- Dead. 
Volunteers recruited under Dr. Singleton’s protocol completed a neurologic Clinical Data 
Elements (CDE) form which included information about medical and family history and an 
additional form for medication history. Refer to Appendix K for a copy of the CDE’s used to 
obtain medical histories.  
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6.0  DATA ANALYSIS 
6.1 DESCRIPTIVE STATISTICS 
Data analysis for gene expression was conducted using Illumina BeadStudio Gene Expression 
(GX) Module (version 1, Illumina ®, San Diego CA) and GeneSpring GX v10 ® (Agilent 
technologies). Ingenuity pathways analysis was used to evaluate potential biomarkers associated 
with ischemic stroke and to elucidate the biological pathway associated with ischemic stroke and 
BBB disruption. Baseline descriptive statistics for the sample were computed using SPSS 
(version 15, SPSS, Inc., Chicago, IL). Descriptive and frequency analysis was conducted for all 
demographic and clinical data. Baseline demographic and clinical characteristics were compared 
between acute ischemic stroke patients and healthy control subjects using chi-square analysis for 
the following categorical variables: gender, race, presence of comorbidities (HTN, DM, etc.), 
and medication history. Differences between patients with and without HARM were also 
compared using chi-square analysis for severity and rtPA administration. In addition Student’s t-
test (or Mann-Whitney) was used to analyze the difference between ischemic stroke and control 
subjects by age. To determine the change in medication usage from baseline to follow up in 
stroke patients McNemar’s χ2 test for matched pairs was used.  For patients with and without 
HARM, Student’s t-test (or Mann-Whitney) was used to analyze the difference on the following 
continuous variables: age, admission National Institutes of Health Stroke Scare score (NIHSS), 
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Modified Rankin scale score (MRS), onset time to blood draw and onset time to imaging. The 
level of significance for these descriptive comparisons was established at a p value of 0.05 for 
two-sided hypothesis testing. 
6.2 DATA SCREENING PROCEDURES 
Univariate descriptive statistics were used to examine continuous baseline variables to ensure the 
values were within the appropriate ranges, and means and standard deviations are plausible. 
Categorical variables were examined to determine if they were within the appropriate categorical 
ranges and the coded values were appropriately programmed. Outliers were detected by 
graphical methods (histograms, box plots, and normality probability plots) and statistical 
procedures (Z-score).  The Shapiro-Wilks test and graphical methods (histogram) was employed 
to assess for normality of the variables. Missing data was analyzed for the degree to which the 
data were missing and the patterns associated with the missing data.  
6.3 GENE EXPRESSION QUALITY ASSURANCE 
6.3.1 Quality Checks 
The ratio of absorbance at 260 nm and 280 nm was used to assess purity of RNA using a 
Nanodrop. A ratio of ~2.0 is generally accepted as “pure” for RNA.  Further more, RNA quality 
was examined by assessing RNA degradation. Twenty five percent of the RNA samples were run 
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on agarose gels prepared with tris/acetate/EDTA (TAE). The presence of 18S and 28S ribosomal 
RNA without smearing using gel electrophoresis was evidence that the RNA is intact. Each 
microarray chip contained a set of positive and negative control probes. The signal of both 
probes was assessed and the array was of good quality when the negative controls reported low 
signals and the positive controls showed uniform intensities across the microarray chip.  
6.3.2 Unsupervised and Supervised Clustering 
First, the raw microarray data was clustered based on how the samples grouped, without 
knowledge of diagnosis (stroke patients vs. control subjects and stroke patients with BBB 
disruption vs. stroke patients without BBB disruption) to determine the phylogenetic distances 
between the samples. When the phylogenetic distances were larger than 0.1 the sample was 
considered an outlier and removed prior to analysis. Once outliers were removed, the raw 
microarray data were clustered again based on the true sample groups (supervised) (stroke 
patients vs. control subjects and stroke patients with BBB disruption vs. stroke patients without 
BBB disruption) to determine the phylogenetic distances between the samples. An un-
normalized correlation matrix was calculated between subjects using the Pearson product-
moment correlation coefficient to determine if arrays had an average inter-subject correlation <2 
or 3 SDs below the mean; if so they would have been excluded, however no arrays were 
excluded from this analysis. 2D heat maps were generated to represent the relative level of 
expression of the genes across the samples. There are several data visualization functions 
available in the BeadStudio gene expression module and the GeneSpring GX v10 software 
including: scatter plots, bar plots, line plots, box plots, heat maps, cluster analysis dendograms, 
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principal components analysis, control summary reports, histograms and images. Additional 
visualization methods were chosen based on sample grouping.  
6.3.3 Normalization of Array Data 
 After scanning the array, primary image data were analyzed with the aims of background 
elimination, filtration, and normalization to enable group comparisons. Normalization algorithms 
adjust sample signals in an attempt to minimize variation from non-biological factors.  For all 
algorithms, normalization is computed with respect to a mathematically calculated sample that 
represents average probe intensities across all samples in the experiment. Two different 
normalization approaches were employed within BeadStudio to ensure that the data was of good 
quality: Quantile and Rank invariant. Quantile normalization is used to make the distribution, 
median and mean of probe intensities the same for every sample. The normalization distribution 
is chosen by averaging each quantile across the samples and is not that much affected by outliers 
and works best with non-linear data. Rank invariant normalization uses a set of probes that is 
rank invariant between a given sample and a virtual sample. The algorithm operates under the 
assumption that probes with similar ranking between samples have similar expression levels. 
When the data is of high quality, different normalization techniques will likely not lead to large 
differences in results. The raw intensity values of all genes on a scatter plot will be inspected in 
linear and logarithmic transformation to determine the best method based on the absence of 
curvatures in the data.  
Robust multi-array analysis (RMA) normalization was conducted in GeneSpring on the 
un-normalized, un-background corrected raw signal intensities from BeadStudio occurring in the 
following order: 1. Background correction (using perfect match probe information and correct 
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values on each array separately); 2. Quantile normalization (probe level normalization performed 
across all arrays which causes all distributions to be the same); 3. Summarization (expression 
measure summary performed in log base scale 2 which uses the median to fit a linear model). 
Probesets are then filtered in GeneSpring via signal values based on the percentile of expression 
to determine whether genes are of low or high expression. This procedure tends to over-
normalize at low signal intensities making it difficult to detect differential expression for genes 
with low expression. 
6.3.4 Differential gene expression 
After normalization, expression levels for each gene were calculated based on the absolute value 
of the intensity of the spot per gene on the array and saved into the Illumina BeadStudio GX 
Module software. All differential expression algorithms compare a group of samples to a 
reference group (cases vs. controls). The Illumina custom algorithm was used in BeadStudio and 
t-test analysis was employed in GeneSpring to determine the similarity of the results using two 
different programs. The Illumina custom model assumes that target signal intensity is normally 
distributed among replicates corresponding to a biological condition. To attempt to compensate 
for technical differences between microarray chips, 100 housekeeping genes included on all 
chips were re-scaled so the average values were equal across the chips. Array outlier’s were also 
identified at this point by both visual inspection and normalization values.  
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6.4 DATA ANALYSIS PROCEDURES 
6.4.1 Analysis of Aims 1, 2 and 3 
Specific Aim 1: Determine which genes are under- and over-expressed in acute ischemic 
stroke patients compared to neurologically healthy age- matched control subjects. 
RQ1. Is there a specific blood genomic profile associated with AIS that can be used to 
identify candidates for diagnostic biomarkers of acute ischemic stroke? 
 
Specific Aim 2: Determine the changes in gene expression that occur in the first 24-48 
hours following acute ischemic stroke. 
RG2. How will blood gene expression profiles change between the acute phase of 
ischemic stroke (0-24 hours) and 24-48 hours following onset of symptoms? 
 
Specific Aim 3: Determine whether acute ischemic stroke patients with BBB disruption 
have a specific blood genomic profile compared to AIS patients without BBB disruption.  
RQ3. Is there a specific blood genomic profile associated with the development of BBB 
disruption as HARM on MRI after AIS? 
 
Stroke patients were matched to healthy control subjects by age +/- 10 years and race. 
Stroke patients with BBB disruption were frequency matched to stroke patients without BBB 
disruption by age +/- 10 years and race.  Since fold change comparisons do not address 
reproducibility and cannot be used to determine statistical significance, the gene expression sets 
were compared in a univariate manner between stroke patients and control subjects through the 
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use of Illumina’s custom algorithm (Appendix L) in BeadStudio and with t-test comparisons in 
GeneSpring (Appendix M). The uncorrected probability values were assigned a cutoff threshold 
value of significance of <0.05. Inflation of type one error from multiple hypothesis testing was 
corrected by Benjamini-Hochberg false discovery rate (FDR) technique in BeadStudio and with 
Bonferroni Family wise error (FWER) in GeneSpring and a false detection rate of <.05 after 
correction was considered statistically significant. Benjamini-Hochberg technique uses only the 
genes that pass through the first filter of 0.05 for the correction; therefore it is lest stringent and 
thus results in larger gene lists, but more false positives. On the other hand, the Bonferroni 
technique uses all of the genes available on the array for the correction and is thus more stringent 
and dramatically reduces the number of statistically significant genes but does not tolerate false 
positives. Therefore the gene set identified in BeadStudio was compared to the gene set 
identified in GeneSpring to determine the most likely significant genes.  Hierarchical cluster 
analysis was then performed on the gene subsets found to be significantly different between 
patients and control subjects by using pairwise correlations calculated for each gene along with 
subsequent calculations of a distance matrix forming the basis of the clustering. The distance 
matrix was calculated by the dissimilarity measure (Djk) between two observations, one from 
group one and one from group two. (Djk=|| xj-xk|| for j and k observations) Ingenuity Systems 
Pathway analysis module was used to identify relevant biological pathways in the whole blood 
following acute ischemic stroke.  Appendix N.  
6.4.1.1 Identification of RNA profile associated with HARM 
A logistic regression with stepwise model selection was performed in SAS to identify an RNA 
profile associated with HARM based on the genes significant between stroke patients and control 
subjects. Four models were tested. Two models of HARM (a. none, mild, moderate or severe; b. 
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severe HARM yes/no) with either one of the following covariate groups: 1.intensity data of the 
16 genes specific for stroke,  age, gender, rtPA treatment, hypertension, diabetes, 
hyperlipidemia, and smoking; and 2. intensity data of the 16 genes specific for stroke, age, 
gender, and rtPA treatment.  
6.4.2 Ingenuity systems pathway analysis 
Samples were phenotypically anchored into one of two groups, either stroke patient or control 
subject, or patients with or without BBB disruption. This approach allows for a systems level 
biological interpretation of gene expression profiles. Since it takes into consideration the 
biological system as a whole, a systems biology approach has significant potential in 
prioritization of biomarker candidates. This system wide data analysis is derived by a knowledge 
base that contains materials from well annotated databases and scientific literature gathered by 
the Gene Ontology consortium.(Ganter, Zidek et al. 2008) The ingenuity systems pathway filter 
determines what biological processes and molecular functions are most significantly associated 
with the phenotype of interest.  
 Genes with a 1.5 fold difference in expression between stroke patients and control 
subjects were identified. The data set that contained gene identifiers and their corresponding 
expression signal intensities was uploaded into the ingenuity systems program. Each probe set 
was mapped to its corresponding data base gene object to designate focus genes, which were 
genes that fall into the <0.05 significance threshold and they directly interact with other genes in 
the global molecular network. The ingenuity systems software queried the knowledge base and 
generated a set of networks with a network size of 35 genes/gene products. A score, which was 
derived from a p-value, was generated for each network according to the fit of the set of 
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significant genes.  Scores of 2 or higher were considered to have at least a 99% confidence of not 
being generated by chance alone. Biological functions were then calculated and assigned to each 
network. Networks were displayed graphically as nodes (genes/gene products) and edges (the 
biological relationships between the nodes). The intensity of the node indicates the degree of up 
regulation (red) or down regulation (green).(Schoch, Dugas et al. 2004)  
The significance value associated with the identified biological pathways is a measure of 
how likely it is that genes from the dataset file participate in that function. The significance is 
expressed as a p-value, which is calculated using the right-tailed Fisher's Exact Test. In this 
method, the p-value is calculated by comparing the number of user-specified genes of interest 
that participate in a given function or pathway, relative to the total number of occurrences of 
these genes in all functional/pathway annotations stored in the Pathways Knowledge Base.  
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7.0  RESULTS 
Data collection was conducted from October 2007 to August 2008. During that time a total of 92 
subjects (67 stroke patients and 25 healthy control subjects) were recruited by T. Barr. For this 
study to occur under the larger NINDS/NIH Natural History of Stroke study T. Barr was 
responsible for IRB amendments to the original protocol and consent, establishing and 
maintaining collaboration with Suburban hospital’s laboratory department for space in the 
laboratory and freezer, maintaining supplies necessary for the project, performing all phlebotomy 
blood draws, processing of all specimens, and maintaining the research database. In addition, T. 
Barr was also responsible for recruiting and submitting samples to the Specialized Program of 
Translational Research in Acute Stroke (SPOTRIAS) and Coriell repositories. During the period 
of recruitment, plasma samples from 30 patients and DNA from 20 patients was submitted to the 
repositories. All patients recruited for this thesis, also had blood drawn and processed by T. Barr 
for plasma and serum at both acute and follow up time points. 
7.1 SAMPLE CHARACTERISTICS 
Of the 67 stroke patients enrolled: 39 stroke patients were Definite AICS patients with acute 
blood drawn within 24 hours. Of the 25 control subjects recruited, only one sample was an 
outlier based on unsupervised dendogram analysis and supervised PCA and appropriately 
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removed, for a total of 24 for analysis. Therefore for the analysis of Aim 1—we compared 39 
stroke patients to 24 healthy control subjects. Of the 39 definite AICS patients, 33 have a follow 
up blood draw. Therefore for the analysis of Aim 2---we compared the acute and follow up gene 
expression profiles in 33 definite AICS patients. Finally, of the 39 definite AICS patients with 
acute blood draw, 30 have a follow up MRI for the analysis of HARM. A total of 4 patients, 8 
have mild HARM, 9 have moderate HARM and 9 have severe HARM. When HARM is 
categorized as a binary variable (Severe HARM yes/no) for the analysis of Aim 3---we can 
compare 21 patients without BBB disruption with 9 patients with BBB disruption.  
7.1.1 Sample characteristics for Aim 1 
 
 
 
 
 
 
 
 
 
 
Figure 6. Aim 1 Sample 
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A total of 39 stroke patients and 24 control subjects were analyzed to address Aim 1. Of the 39 
stroke patients 100% were Caucasian and 43.6% were male. Cardioembolic stroke accounted for 
43.6% of stroke etiologies. Over 59% of the patients were discharged to home. The presence of 
comorbidities was prevalent with the stroke population, with 64% having a history of 
hypertension, 28% with a history of diabetes, 15% with a history of atrial fibrillation, 15% with a 
history of myocardial infarction, 46% with a history of dyslipidemia, 15.4% with a history of 
prior stroke, and 38% with a smoking history (previous or current). Over half of the patients 
were on anticoagulants or antiplatelets and 74% were being treated for their hypertension. Nine 
(23.1%) of the patients received rtPA, of which only one patient had their blood drawn before 
rtPA administration. The mean age of the patients is 73.05±14. The mean time from symptom 
onset to acute blood draw is 10:06 hours ±6:31. The patients have a pre stroke MRS median 
score of zero with an SD of 1.2. The severity of injury for the patient group was mild with a 
median baseline NIHSS of 3 with a range from 0-23 and a discharge NIHSS median of 0 with a 
range from 0-10. Results below are presented as mean ± standard deviation.   
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Table 2. Patient Clinical Characteristics 
 
                          
    Stroke  
 
rtPA administration  9 (231%) 
 
rtPA given before   8 (88.9%) 
 baseline blood draw 
  
Onset time to    10:06±6:31   
  Acute blood draw 
 
Onset time to   29:24±7:10 
  Follow up blood draw 
 
Median Pre-Stroke   0 (range 0-4) 
  MRS   
 
Median Baseline   3 (range 0-23) 
  NIHSS 
 
30 day MRS   1 (range 0-6) 
 
30 day NIHSS   0 (range 0-8) 
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Table 3. TOAST Classification of Patients 
 
                                           
    TOAST 
 
Large Artery   5 (12.8%) 
  Embolus/thrombus  
 
Cardioembolic  17 (43.6%) 
 
Small vessel   3 (7.7%) 
  (lacune) 
 
Other etiology   3 (7.7%) 
 
Undetermined   2 (5.1%) 
  Two or more causes 
 
Undetermined   8 (20.5%) 
  Negative evaluation 
 
Undetermined   1 (2.6%) 
  Incomplete evaluation 
 
 
Table 4.Discharge Disposition 
 
            Discharge 
           Disposition 
 
    Home       24 (61.5%) 
 
    Rehabilitation      11 (28.3%) 
    Nursing Home      2 (5.1%) 
    Expired      2 (5.1%) 
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Of the 24 healthy control subjects 100% were Caucasian and 41.7% were male. The presence of 
comorbidities was not as prevalent in the control group. Approximately 30% of the control 
subjects had a history of hypertension of which only 4% were receiving treatment; 8% had a 
history of diabetes, 62.5% had a smoking history (previous or current), 8.3% had a history of 
stroke and none of the control subjects claimed a history of atrial fibrillation, myocardial 
infarction, or dyslipidemia. The mean age of the control subjects was slightly less than the 
patient group with a mean of 59.9±9.73.  
 Differences in baseline clinical demographic data between stroke patients and control 
subjects was determined by t-test for age and by Pearson χ2 tests using 2x2 contingency table 
analysis for gender, risk factor history, and medication history. Risk estimates as odds ratios 
were obtained with the F test for categorical variables. There was no difference by race or gender 
between the groups. However, stroke patients were significantly older than control subjects (t=-
4.03; p=0.000) and stroke patients were more likely to have the presence of comorbidities for 
which they were receiving medication.  
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Table 5. Stroke patients and control subjects characteristics 
 
             Total Sample            Stroke            Control             Statistic/df       p value 
                            N=63      n=39 (61.9%)       n=24 (38.1%)                     
 
Gender             36 (57.1%)             22 (61.1%)        14 (38.9%)            χ2  0.02/1     0.883 
 (% female) 
  
Mean age,                   68.1±14.02        73.1±14.0          59.9±9.73              t -4.1/61           0.000 
 years 
  
Hypertension              32 (50.8%)             25 (78.1%)         7 (21.9%)      χ2  6.6/1             0.010  
 
Diabetes                     13 (20.6%)             11 (84.6%)         2 (15.4%)              χ2  3.3/1            0.068   
 
Dyslipidemia              18 (28.6%)             18 (100%)          0                           χ2  14.9/1           0.000   
 
Atrial Fibrillation        6 (9.5%)                 6 (100%)           0                           χ2  3.9/1             0.048   
 
Myocardial                  6 (9.5%)                 6 (100%)           0                           χ2  3.9/1             0.048   
  Infarction   
 
Previous              8 (12.7%)               6 (75%)             2 (25%)                 χ2  0.7/1            0.414   
Ischemic Stroke  
 
Previous or 
 Current Smoker         30 (47.6%)             15 (50%)           15 (50%)               χ2  7.8/2             0.020     
 
Hypertension              37 (47.6%)             29 (78.4%)         8 (21.6%)             χ2  10.3/1           0.001   
  Medication 
 
Diabetes   8 (12.7%)        7 (87.5%)          1 (12.5%)              χ2  2.66/1           0.103 
  Medication 
 
Cholesterol  22 (34.9%)        17 (77.3%)        5 (22.7%)              χ2  3.39/1          0.066 
  Medication 
 
Anticoagulant             21 (33.3%)             20 (95.2%)        1 (4.8%)                 χ2  14.8/1           0.000   
 or Antiplatelet 
 
Family history            19 (30.2%)             15 (78.9%)         4 (21.1%)              χ2  3.6/2             0.169   
  of Stroke  
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7.1.2 Sample Characteristics for Aim 2 
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Figure 7. Aim 2 Sample 
 
Of the 34 Definite AICS patients with acute and follow up blood draws, the mean age of the 
sample is 71.94±14.6.  Mean time from symptom onset to acute blood draw is 9:29±6:19 (range 
2:35-23:02); to follow up blood draw is 29:24±7:10 (range 18:45-43:30). Mean time between 
acute and follow up blood draw is 19:55±3:26 (range 13:30-27:32). Median pre stroke MRS is 0; 
median baseline NIHSS is 3 with a range of 0-24. 
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Table 6. Aim 2 Sample Characteristics 
 
 
    Total N=34 
 
Gender       20 (58.8%) 
   (% female) 
 
Age, years       71.94±14.6 (range 43-96) 
 
Baseline MRS       0 (range 0-4) 
 
Baseline NIHSS    2 (range 0-23) 
 
  
Received       6 (17.6%) 
  rtPA 
 
Onset to  
  Acute blood        9:29±6:19 (range 2:35-23:02) 
 
Onset to        29:24±7:10 (range 18:45-43:30) 
  Follow-up 
  Blood 
 
Acute to        19:55±3:26 (range 13:30-27:32) 
  Follow-up 
  Blood 
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Table 7.Aim Two In-hospital medication change 
 
 
       Baseline  24 hour  p-value 
                                              Follow-up 
 
Hypertension      24 (70.6%)  7 (20.6%) 0.000 
 Medication 
 
Cholesterol      13 (38.2%)  27 (79.4%) 0.003 
 Medication  
 
Diabetes      7 (20.6%)  13 (38.2%) 0.031 
 Medication 
 
Antiplatelet/      17 (50%)  27 (79.4%) 0.021 
 Anticoagulant 
 
*p-values generated from the McNemar χ2 test for matched-pairs  
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Of the 39 Definite AICS patients with acute blood draw, 30 have a follow up MRI Therefore a 
total of 30 patients can be appropriately matched; the mean age of the sample is 72.8±14.1.  
Mean time from symptom onset to acute blood draw is 10:26±6:24. Median pre stroke MRS is 0; 
median baseline NIHSS is 3 with a range of 0-19. The mean time from onset to the Acute MRI 
(where the patient would have received the first dose of GD-DTPA contrast) is 4.41 h ± 5.03 
with a range from 0-19 hours. There are 4 (13.3%) in the no HARM group; 8 (26.7%) in the mild 
HARM group; 9 (30%) in the moderate HARM group and 9 (30%) in the severe HARM group.  
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7.1.3 Sample Characteristics for Aim 3 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Aim 3 Sample 
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Table 8.  Aim 3 Sample Characteristics 
 
   Total      None    Mild  Moderate Severe  Statistic/df p-value 
    N=30  4 (13.3%) 8 (26.7%) 9 (30%) 9 (30%) 
 
Gender  16 (53.3%) 3 (18.8%) 4 (25%) 4 (25%) 5 (31.2%)  χ2 1.1/3 0.779  
 (%female) 
 
Age, years  72.1±14.5 53.5±11.5 74.1±9.6 72.9±1.5 77.7±0.7 F 3.4/3  0.034 
 
Baseline MRS  0 (0-4)  0  0  0 (0-4)  0 (0-2)  F 1.6/3  0.214 
 
Baseline NIHSS 3 (0-18) 3 (0-4)  1 (0-7)  3 (0-16) 5 (0-18) F 1.7/3  0.186 
 
Received rtPA  9 (30%) 0   1 (11.1%) 3 (33.3%) 5 (55.6%) χ2 5.73/3 0.126 
 
Hypertension  19 (63.3%) 2 (10.5%) 4 (21.1%) 6 (31.6%) 7 (36.8%) χ2 1.77/3 0.621 
 
Diabetes  2 (6.7%) 0  1 (50%) 0  1 (50%) χ2 1.6/3 0.659 
  
Dyslipidemia  16 (53.3%) 0  5 (31.3%) 4 (25%) 7 (43.7%) χ2 7.29/3 0.063 
 
Atrial   2 (6.7%) 0  1 (50%) 0  1 (50%) χ2 1.65/3 0.648 
 Fibrillation 
 
Myocardial  4 (13.3%) 0  2 (50%) 1 (25%) 1 (25%) χ2 1.64/3 0.652 
 Infarction 
 
Previous  4 (13.3%) 0  0  3 (75%) 1 (25%) χ2 5/3  0.172 
 Ischemic Stroke 
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Table 9. Aim Three Medications 
 
   Total      None    Mild  Moderate Severe  Statistic/df p-value 
    N=30  4 (13.3%) 8 (26.7%) 9 (30%) 9 (30%) 
 
Hypertension  20 (66.7%) 1 (5%)  4 (20%) 8 (40%) 7 (35%) χ2 6.6/3 0.085 
 Medication 
 
Cholesterol  14 (46.7%) 0  5 (35.7%) 4 (28.6%) 5 (35.7%) χ2 4.6/3 0.203 
 Medication 
 
Diabetes  2 (6.7%) 0  2 (100%) 0  0  χ2 5.9/3 0.117 
 Medication 
 
Antiplatet/  15 (50%) 0  5 (33.3%) 5 (33.3%) 5 (33.3%) χ2 4.7/3 0.193 
 Anticoagulant 
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Total      None    Mild  Moderate Severe  Statistic/df p-value 
   N=30  4 (13.3%) 8 (26.7%) 9 (30%) 9 (30%) 
nset to Baseline 4.2±5  4.25±4  5.25±6.3 4.33±5.4 3.11±4.5 F 0.23/3 0.870 
I 
nset to Follow-up 27.13±5.4 26.50±7.8 29.50±5 25.67±4.9 26.78±5.8  F 074/3 0.536 
I 
aseline MRI to  22.5±4.6 21.75±3.3 23.88±2.2 21±7.9  23.22±1.6 F 0.63/3 0.602 
ollow-up MRI 
nset to Baseline 10:11±625 9:58±6:18 12:18±8:08 8:15±4:39 10:20±6:49 F 0.54/3 0.660 
lood draw 
aseline Blood 2253±4.6 16:50±8:43 17:25±8:28 17:67±7:07 16:56±7:73 F 0.04/3 0.989 
raw to Follow-up  
I 
Table 10. Aim Three: Time Variables 
7.2 RNA EXTRACTION AND QUALITY 
RNA extraction was performed according to the Paxgene blood RNA handbook. All samples 
were allowed to thaw at room temperature for at least 24 hours prior to beginning the extraction. 
Due to low initial yield, a portion of the samples (n=34) were placed in the vacuum dryer for 15 
minutes at a temperature of 45°C. Following vacuum dry the samples went from a final volume 
of 80μl to ~40μl. Total mean sample RNA concentration is 82.6ng/μl with a range between 49.1-
282.2ng/μl in a total volume between 40-80μl. Mean 260/280 ratio is 2.14±0.1 with a range from 
1.96-2.8. Total RNA concentration following amplification for the patient group was 938.7ng/ul 
±296.5 and the mean 260/280 ratio was 2.15±0.03. Total RNA concentration following 
amplification for the control group was 854.2ng/ul±265.7 and the mean 260/280 ratio was 
2.14±0.06. A portion of the samples (n=45) were also ran on agarose gels to assess quality and 
presence of degradation. All samples showed clear 28s and 18s bands without smearing, 
indicative of good quality, intact RNA. There were no significant differences between patients 
and control subjects for RNA concentration (t=-1.14; p=0.258) or quality by 260/280 ratio (t=-
0.524; p=0.602).  
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 Figure 9. RNA concentration ng/ul following amplification 
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Figure 10. RNA quality 260/280 ratios following amplification 
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Figure 11.  RNA Gel 
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7.3 ILLUMINA QUALITY CONTROL ASSESSMENTS 
7.3.1 Quality control for arrays 
BeadArrays were visually inspected in BeadStudio for marks or cracks etc, which could interfere 
with hybridization or scanning. All arrays were found to be clear of imperfections.  
 
        
Figure 12.  BeadArray Image 
 
The BeadStudio Gene Expression module displays a graphic summary for quality control 
assessment of arrays based on built-in controls.  All control plots look comparable to what is 
available for review in the BeadStudio handbook, except the High Stringency plot. A 
representative from Illumina stated that the high stringency probes are no longer on the v3 
beadchips, so there should not be signal there; the rest of the plots are consistent with high 
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quality data. Hybridization controls were appropriate for low, medium and high. Negative 
control, background, and noise signals were low (<200) across all arrays and housekeeping and 
biotin signals were high (>20,000). The average signal for internal controls across the arrays was 
similar. 
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Figure 13. Hybridization Controls 
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Figure 14. Negative Controls 
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Figure 15. Labeling and Background 
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Figure 16. Low Stringency 
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Figure 17. Housekeeping Gene Intensity 
biotin high stringency
Biotin  &  High Stringency
10000
20000
30000
S
ig
n
a
l
 
Figure 18. Biotin 
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Figure 19. Average signal for internal controls across arrays 
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Unsupervised clustering of samples using all methods in BeadStudio (correlation; absolute 
correlation; manhattan; Euclidean) revealed two outliers in the data (one stroke patient and one 
control subject) with distances on the dendogram greater than 0.1. Round table discussions 
amongst investigators resulted in the elimination of only the control subject from analysis. It was 
decided that it is impossible to determine if the patient sample was an outlier because of 
technical or biological variability and to keep credibility of the dataset, the patient outlier was 
kept in the analysis.   
7.3.2.1 Unsupervised Clustering 
7.3.2 Quality control for samples 
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Figure 22. CY3 Hybridization signal per array 
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Figure 23. Unsupervised sample cluster 
 
7.3.3 Probe level analysis 
Probes were filtered in GeneSpring based on signal intensity values. The raw data was filtered by 
percentile with a lower cut-off of 20 and an upper cut-off of 100. The stringency of the filter was 
set at 1 out of 63 minimum number of samples in which the probe must pass the filter. 60 probes 
did not pass the first filter. The probes were then filtered based on present and marginal flags 
with at least 1 of 63 with acceptable values. An additional 42 probes did not pass this second 
filter.  This resulted in a final probe set of 24,424 to be used in analysis.  
 
 
Figure 24. Probes filtered based on expression and flags 
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7.3.4 Normalization 
Normalization was conducted under two methods (quantile and rank invariant) to determine the 
most appropriate technique for this dataset. Rank invariant normalization resulted in a larger 
gene set specific for stroke (100 genes with 2 fold difference, p<0.05), but contained all of the 
transcripts identified with quantile normalization (16 genes with 2 fold difference, p<0.05). 
Quantile normalization reduced variability of expression between stroke patients and control 
subjects, but was chosen as the most appropriate method because the patient outlier was left in 
the analysis and quantile normalization is resistant to outliers. In addition quantile normalization 
is based on transforming each of the array specific distributions of intensities so that they all 
have the same values at specific quantiles. In order to take care of array to array bias and 
variation this is the method more strongly advocated. 
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 Figure 25. Normalized intensity by sample 
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A logarithmic transformation (log base 2 scale, baseline transformation to the median) was 
applied to the normalized signal intensities to summarize the data. Log2 transformation provided 
a greater number of normally distributed data points than linear scale. 
 
               
Figure 26. Normalized intensity by group 
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Figure 27. Logarithmic transformation 
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7.3.5 Supervised clustering 
In GeneSpring, supervised clustering with principal components analysis (PCA) was also 
performed to identify sample outliers after the removal of the control subject outlier. PCA 
assumes that samples within a group should be more similar to one another than with those from 
different conditions (case vs. control). It is a variable reduction method that performs eigenvalue-
eignevector decomposition on the covariance matrix of gene expression for all samples. One 
would expect that cases and controls group separately. Similar to the unsupervised clustering 
performed in Bead Studio, the PCA analysis demonstrated a homogenous group of stroke 
patients and control subjects with the same stroke patient outlier.  
 
 Figure 28.  PCA on samples 
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7.4 PRIMARY ANALYSIS RESULTS 
7.4.1 Analysis of Specific Aim One 
Specific Aim 1: Determine which genes are under- and over-expressed in acute ischemic stroke 
patients compared to neurologically healthy age- matched control subjects. 
RQ1. Is there a specific blood genomic profile associated with AIS that can be used to 
identify candidates for diagnostic biomarkers of acute ischemic stroke? 
7.4.1.1 Peripheral blood gene profile for Stroke  
All analyses were conducted first in Illumina Bead Studio and then in GeneSpring to verify the 
findings. In Bead Studio, there were 344 genes with a 1.5 fold difference in expression with a 
diff score > 13 (corrected p<0.05) between stroke patients and control subjects, Appendix 0. 
There were 19 genes with a 2 fold difference in expression with a diff score >13 (corrected 
p<0.05), Appendix P.  Results were comparable in GeneSpring with 355 genes with 1.5 fold 
difference in expression (bonferroni corrected p<0.05) (Appendix Q) and 16 genes with 2 fold 
difference in expression between stroke patients and control subjects (Appendix R), bonferroni 
corrected p<0.05. After comparison there were 9 genes identified by both packages with 2 fold 
difference in expression, corrected p<0.05 significantly different between stroke patients and 
control subjects.
 Figure 29. HeatMap for 9 gene list 
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 Table 11.  Gene List for Ischemic Stroke 
Gene  p-value Fold      Regulation      Description 
             Change  
 
 
ARG1  2.84E-07 3.175  up        Arginase-1 
 
CA4  2.0E-04 2.122  up        Carbonic anhydrase-4 
 
CCR7  4.37E-05 2.094  down        Chemokine CC Motif Receptor 7 
 
CSPG2 3.45E-05 2.087  up        Chondroitin sufate proteoglycan 2 
 
IQGAP1 7.97E-07 2.031  up        IQ motif-containing GTPase-activating protein 1 
 
LY96  0.001  2.159  up        Lymphocyte antigen 96; MD2 protein 
 
MMP9  1.11E-05 2.644  up        Matrix metalloproteinase 9; gelatinase B 
 
ORM1  0.006  2.246  up        Orosomucoid 1; alpha 1 acid glycoprotein 
 
S100A12 3.87E-04 2.354  up        s100 calcium binding protein A12; calgranulin C  
 
Class prediction models are generally used to identify prognostics for classification of disease. 
This model identifies expression signatures of groups under study and uses these expression 
signatures to predict whether an unknown is case or control. A class prediction decision tree 
algorithm was built from these nine genes using the following criteria: pessimistic error pruning 
method; information gain goodness function; local 1.0 leaf impurity; leave one out validation; 3 
folds; 10 repeats; and the attribute fraction of nodes set at 1.0. The accuracy of these genes to 
predict stroke was 94.9% with an overall prediction of 95.2%.  
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Table 12. Prediction model 
     Control    Stroke          Accuracy 
             (Predicted)           (Predicted) 
 
Control      23         1   95.8% 
 (True) 
 
 Stroke       2                                 37    94.9% 
 (True) 
 
Overall Accuracy      95.2%  
 
Five of the 9 genes identified in this study were also found to be significant in the first whole 
blood gene expression profiling study of stroke (ARG1; CA4; LY96; MMP9; S100A12).(Tang, 
Xu et al. 2006). 
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Table 13. Comparison of Gene List to Previous Study 
 
 
Gene  p-value Fold              p-value           Fold 
            Change                Change 
         In this study                  Tang et al 2006 
 
 
ARG1  2.84E-07 3.2  5.03E-04 3.8 
 
CA4  2.0E-04 2.1  3.54E-05 2.2 
 
LY96  0.001  2.2  3.67E-03 2.1 
 
MMP9  1.11E-05 2.6  3.54E-05 3.2 
 
S100A12 3.87E-04 2.4  2.59E-04 2.2 
 
  
Since there were significant differences between stroke patients and control subjects by age, an 
analysis was conducted to determine which genes were significantly regulated by age. To ensure 
there was a relatively equal distribution of control subjects in each group, age was divided into 
two groups at 60 years. This resulted in four groups: Control <60 years (n=13); Stroke <60 years 
(n=9); Control >60 years (n=11); Stroke >60 years (n=30). T-test analysis revealed there were 31 
genes significantly different by age for stroke patients (fold change >2 and corrected p<0.05) 
(Appendix S) and 77 genes significantly different by age for control subjects (fold change >2 and 
corrected p<0.05) (Appendix T). An analysis of variance (ANOVA) was performed to determine 
the changes in gene expression by age between all four groups, which revealed two genes with 
fold change >2 and corrected p<0.05: IFI27 and s100A12. 
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Figure 30. Genes associated with age 
 
Baseline s100A12 signal intensity was significantly correlated with age (r=0.61; p=0.00). 
S100A12 signal intensity was significantly higher in those with age > 60 years (t=-3.9; p=0.00).  
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 Figure 31. Correlation between s100A12 and Age 
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 Figure 32.  S100A12 by Age Group 
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In addition, to the correlation with age, baseline s100A12 signal intensity was significantly 
higher in males versus females for both control subjects and stroke patients (t=3.45; p=0.002 and 
t=3.52; p=0.001 respectively). Males and females were not significantly different by presence of 
hypertension (χ2=0.43; p=0.51) or dyslipidemia (χ2=3.4; p=0.06).  
Figure 33.  S100A12 by Gender 
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7.4.1.2 Quantitative real-time PCR analysis 
Quantitative rt-PCR was used to confirm the results obtained with the Illumina Human ref-8 
beadchip. PCR reactions were performed using Taqman probes for the following genes (ARG1; 
CCR7: LY96; MMP9; and s100A12) by the 7900HT rt-PCR system (Applied Biosystems).These 
5 genes were chosen because four of them were also found to be significant in the first gene 
expression profiling study for stroke and one of them (CCR7) was the only down-regulated gene 
for stroke found in this study. Rt-PCR validated significant changes in mRNA levels in 4 of the 5 
genes. The mRNA level of ARG1 was 3.5 times higher in stroke patients (t=3.7; p=0.00); CCR7 
was 2.3 times lower in stroke patients (t=-4.3; p=0.00); LY96 was 1.2 times higher in stroke 
patients (t=1.94; p=0.06); MMP9 was 1.8 times higher in stroke patients (t=2.24; p=0.03); and 
s100A12 was not validated with rt-PCR (t=1.1; p=0.28). RT-PCR results correlated with 
microarray signal intensity values for all genes: ARG1 (r=0.801; p=0.00); CCR7 (r=0.96; 
p=0.00); LY96 (r=0.96; p=0.00); MMP9 (r=0.59; p=0.00); and s100A12 (r=-0.47; p=0.000). 
Figure 34.  QRT-PCR Results 
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7.4.1.3 Ingenuity Pathway Analysis 
Data were analyzed through the use of Ingenuity Pathway analysis (IPA) (Ingenuity® Systems, 
www.ingenuity.com). The 1.5 fold gene list (containing gene identifiers and corresponding 
expression values) obtained in GeneSpring prior to significance analysis of 500 genes was 
uploaded into the program. Of the 500 genes with 1.5 fold difference between stroke patients and 
control subjects, 484 genes were mapped to its corresponding gene object in the knowledge 
database, and 356 genes were eligible for pathway analysis. Canonical pathways analysis 
identified the pathways from the IPA library that were most significant to the data set. The 
significance of the association between the data set and the canonical pathway was measured in 
two ways: 1) a ratio of the number of genes that mapped to the canonical pathway (the number of 
molecules in a given pathway that meet the 1.5 fold cut off, divided by the total number of 
molecules that make up that pathway). 2) A right tailed Fisher’s exact test to calculate a p-value 
determining the probability that the association between the genes in the dataset and the 
canonical pathway is explained by chance alone.  
IPA analysis showed that the top-5 most significant canonical pathways in the peripheral 
blood of AIS patients were associated with CD28 signaling in T-helper cells (p=4.03E00), 
nuclear factor of activated T cells (NFAT) in regulation of the immune response (p=4.03E00) 
dendritic cell maturation (p=3.4E00), toll-like receptor signaling (p=3.33E00), and calcium-
induced T-lymphocyte apoptosis (p=2.92E00).  
There were 12 genes in the dataset involved in CD28 signaling in T-helper cells: CD247, 
FOS, ACTR3, CD3E, CDC42, PPP3R1, ITPR3, ARPC5, ZAP70, CD3D, HLA-DRB5, and ITK 
(p=4.03E00). 
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However, there were more genes involved in Toll-like receptor signaling within the 
dataset compared to the total number of genes in the Toll-like receptor pathway with a ratio >2 
and  p=3.33E00 (TLR2, TLR1, FOS, LY96, TLR8 (includes EG:51311), IF2AK2, IRAK3).  
The two other most significant pathways associated with stroke in the whole blood are 
NFAT in the regulation of the immune system ((p=4.03E00) and Dendritic cell maturation 
(p=3.4E00). There are 15 genes in the dataset involved in NFAT regulation: FCGR3B, CD247, 
CD3E, FCGR2A, FCGR1A, CD3D, FOS, PPP3R1, ITPR3, ZAP70, GNA13, FCGR1B, FCGR3A, 
HLA-DRB5, and ITK). There are 13 genes in the dataset involved in dendritic cell maturation: 
FCGR3B, FCGR2A, LTB, CD58, HLA-DRB1, CREB5, FCGR1A, HLA-DQB1, TLR2, CCR7, 
FCGR3A, HLA-DRB5, and FCGR1B.  
 Figure 35. Top 10 Associated Pathways in Peripheral blood of AIS patients
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Figure 36. CD28 Signaling in T-Helper cells 
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.  
Figure 37. Toll-like Receptor Signaling 
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Figure 38. NFAT in Regulation of Immune Response 
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 Figure 39. Dendritic cell maturation 
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7.4.2 Analysis of Secondary Aim 
Specific Aim 2: Determine the changes in gene expression that occur in the first 24-48 hours 
following acute ischemic stroke. 
RG2. How will blood gene expression profiles change between the acute phase of 
ischemic stroke (0-24 hours) and 24-48 hours following onset of symptoms? 
7.4.2.1 Change in blood expression profile following stroke 
 
There were only 21 genes with 1.5 fold difference in expression (Bonferroni corrected p<0.05) 
between baseline and 24-48 hour follow up time points in AIS patients (Appendix U). All of 
these genes were down-regulated at the follow up time point.  
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Figure 40. Genes with 1.5 fold difference between baseline and follow up 
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Figure 41. Signal intensity for 21 genes between baseline and follow up 
 
Additionally, only 3 of these genes had a 2 fold difference in expression (Bonferroni corrected 
p<0.05) between baseline and follow up (Appendix V); interleukin-8 (IL8), lymphocyte antigen 
96 (LY96; MD2 protein) and serum deprivation response phosphatidylserine-binding protein 
(SDPR). 
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LY96 (MD2 protein) is necessary for the activation of toll like receptor 4 (TLR4) as part of the 
innate immune system. TLRs are pathogen recognition receptors and respond to both pathogen 
associated molecular patterns (PAMPs) and damage associated molecular patterns (DAMPs) to 
release inflammatory cytokines. LY96 modulates IL8 expression through the activation of NF-
kappaB (nuclear factor of kappa light polypeptide gene enhancer in B-cells). 
 
                                
Figure 42..Genes with 2 fold difference between baseline and follow-up 
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Figure 43. LY96 and IL8 in Toll-like receptor pathway 
 Even though NF-kappaB signal intensity was not differentially expressed between baseline and 
follow up in BeadStudio, the baseline and follow-up signal intensities were significantly 
different (paired t=-4.4; p=0.000) with the follow up being slightly higher than baseline (average 
baseline intensity=5482; average follow-up intensity=6560).  LY96 and NF-kappaB signal 
intensity were significantly correlated at baseline (Pearson R -0.44; p=0.009); and follow up 
(Pearson R -0.563; p=0.001). IL8 and NF-kappaB were also significantly correlated at both 
eline (Pearson R -0.39; p=0.022) and follow-up (Pearson R -0.917; p=0.000). 
There was not a significant association between LY96 at baseline (p=0.5) or follow up 
0.9) with good outcome (MRS 0-1) at 30 days; but there appears to be a trend for a non-linear 
onential correlation where higher levels of baseline LY96 correspond to better outcome at 30 
s (r=0.15; p=0.5); with the exception of the two patients who died. Additionally, there was 
 a significant association between IL8 at baseline (p=0.9) or follow up (p=0.5) with good 
come (MRS 0-1) at 30 days. 
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 Figure 44. LY96 and 30 day MRS 
 
Interestingly however, there is a significant correlation between follow up NF-kappaB signal 
intensity and MRS at 30 days post ischemic stroke (Pearson R -0.531; p=0.009), with higher 
follow-up levels corresponding to better outcome (F=6.05; p=0.003). There is also a correlation 
between follow-up s100A12 signal intensity and 30 day MRS; with higher levels being 
correlated with worse outcome (r=0.59; p0.003). There is no correlation between follow-up NF-
kappaB and follow up s100A12 (r=-0.23; p=0.196). 
144 
 Figure 45. NF-kappaB and 30 day MRS 
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Figure 46. Follow-up s100A12 and 30 day MRS 
 
In addition, baseline  (r=-0.37; p=0.03) and follow-up 
age (r=-0.419; p=0.014) with patients who are less than 60 years having significantly higher 
follow-up NF-kappaB signal intensity compared to patients older than 60 years (t=2.49; 
p=0.018). s100A12 signal intensity was significantly higher in older patients at both baseline  
(t=-2.7; p=0.012) and follow up (t=-1.3; p=0.04). 
NF-kappaB was found to correlate with 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 47.  NF-kappaB by Age 
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Figure 48.  s100A12 by Age 
7.4.3 Analysis of Tertiary Aim 
 
Specific Aim 3. Determine whether acute ischemic stroke patients with BBB disruption have a 
specific blood genomic profile compared to AIS patients without BBB disruption.  
RQ3. Is there a specific blood genomic profile associated with the development of BBB 
disruption as HARM on MRI after AIS? 
7.4.3.1 Genomic profile for BBB Disruption 
Blood brain barrier disruption was characterized as the presence of HARM under two criteria: 1. 
HARM category-none, mild, moderate, or severe; and 2. Severe HARM-yes or no (binary). Each 
of these descriptions was then tested independently against two separate models: 1. signal 
intensities for the 16 genes specific for stroke, using age, gender, rtPA treatment, hypertension, 
diabetes, hyperlipidemia, and smoking history (previou urrent or non-smoker) as covariates; 
and 2. Signal intensities for the 16 genes specific for stroke, age, gender, and rtPA treatment. 
This resulted in the testing of four separate models.  
For the full model one predicting HARM categories the following covariates were 
significant predictors of HARM category: LY96 (p=0.005); ORM1 (p=0.04); age (p=0.01); and 
rtPA administration (p=0.01). For the partial model two predicting HARM categories, only LY96 
(p=0.019), age (p=0.018) and rtPA treatment (p=0.013) were significant. For both the full model 
three and partial model four predicting Severe HARM (yes or no) only AKAP7 was a significant 
predictor of Severe HARM (p=0.042 and p=0.034 respectively). (Appendix T) 
 
s, c
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Patients with any presentation of HARM were significantly older (F=3.36; p=0.034) and 
over 50% of patients who received rtPA displayed HARM. 
 
Figure 49.  Age and HARM Category 
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 Figure 50. HARM Category and rtPA 
 
Similarly, with the exception of one patient, patients with Severe HARM were significantly older 
(t=-2.34; p=0.027) and more likely to have received rtPA ( 2χ =3.99; p=0.046). 
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Figure 51.  Severe HARM and Age 
 
153 
 
ure 52. Severe HARM and rtPA Fig
The mean log transformed signal intensity of LY96 for no Harm (-0.31±1.6), mild Harm (-
0.34±1.03), moderate HARM (0.85±0.73), and severe HARM (0.94±0.36) was significantly 
higher in the moderate and severe HARM groups (F=4.52; p=0.011). LY96 was not correlated 
with age (r=0.2; p=0.29), severity of injury (r=0.28; p=0.14), or MMP9 (r=0.21; p=0.28). 
However there was a trend for a correlation between LY96 and ORM1 (r=0.34; p=0.07). 
 
Figure 53. LY96 and HARM Category 
 
Mean signal intensity of ORM1 was not significantly different between the categories of HARM 
(F=0.249; p=0.861); neither was the mean signal intensity for MMP9 (F=0.49; p=0.69). There 
was no correlation between ORM1 with age (r=0.12; p=0.55) or between MMP9 with age 
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(r=0.15; p=0.43). Interestingly both ORM1 (r=0.44; p=0.01) and MMP9 (r=0.51; p=0.004) were 
correlated with baseline NIHSS and ORM1 was significantly correlated with MMP9 (r=0.72; 
p=0.000).  
 
Figure 54. ORM1 and MMP9 
 
The mean log transformed signal intensity of AKAP7 for Severe HARM (1.53±0.79) was 
significantly higher then the mean r No HARM (0.35±1.29), 
t=-2.5; p=0.017. AKAP7 was not correlated with age (r=0.22; p=0.24), severity of injury (r=0.07; 
 log transformed signal intensity fo
p=0.72), MMP9 (r=0.1; p=0.79), or ORM1 (r=0.2; p=0.28); but it was correlated with LY96 
(r=0.56; p=0.001). There was also a trend for a significance of LY96 with severe HARM (t=-1.9; 
p=0.07). 
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Figure 55. AKAP7 and LY96 
 
 Figure 56. AKAP7 by HARM 
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8.0  SUMMARY OF FINDINGS 
8.1 SUMMARY OF AIM ONE FINDINGS 
 
A nine gene profile has been identified for acute ischemic stroke. Five of these nine genes were 
identified in the first gene expression profiling study. One of the nine genes identified (s100A12) 
was found to be up-regulated with increasing age and is possibly not specific for acute ischemic 
stroke. However RT-PCR validated 4 of the 5 genes tested from this profile; with the exception 
of s100A12. So the analysis by age for s100A12 should be interpreted with caution. Pathway 
analysis revealed a robust inflammator ith CD28 signaling in T-helper 
cells and toll like receptor signaling identified as highly significant canonical pathways present 
in the peripheral whole blood of acute ischemic stroke patients.  
8.2 SUMMARY OF AIM TWO FINDINGS 
Only three genes with 2 fold change in expression (down-regulated) and statistically significant 
at p<0.05 were identified as the whole blood expression profile change over time (LY96, IL8, and 
SDPR). Both LY96 and IL8 are part of the toll like receptor pathway, and LY96 modulates IL8 
expression through NF-kappaB. There was a significant difference between baseline NF-kappaB 
y and immune response, w
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signal intensity and follow-up. NF-kappaB was significantly correlated with both LY96 and IL8 
at both baseline and follow-up. LY96 (baseline or follow-up) was not correlated with 30 day 
MRS; however there was a significant association between follow-up NF-kappaB and 30-day 
MRS with higher levels of NF-kappaB corresponding to better outcome. This relationship may 
be mediated by age, as higher follow-up NF-kappaB was associated with younger age.  
8.3 SUMMARY OF AIM THREE FINDINGS 
Acute ischemic stroke patients who presented with HARM were significantly older and more 
likely to have received rtPA. The mean signal intensity for  was significantly higher in the 
moderate and severe HARM groups. LY96 was not correlated with either age, severity of injury 
or MMP9 but there was a trend for a correlation between ORM1. ORM1 was not significantly 
different between the HARM groups, but it was correlated with baseline NIHSS and MMP9. 
AKAP7 was significantly predictive of severe HARM, as higher mean signal intensity of AKAP7 
was correlated with the presence of Severe HARM. Logistic regression analysis revealed that 
LY96, ORM1, age, and rtPA were significant predictors of HARM category and only AKAP7 was 
a significant predictor of severe HARM after controlling for covariates. 
LY96
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9.0 DISCUSSION 
The findings of this study support the claim that gene expression profiling of peripheral whole 
blood can be used to identify diagnostic m
promise for the use of whole blood gene expression profiling for scientific advancement in other 
9.1 QUALITY ASSESSMENT 
conducted first in Bead Studio and then verified using a different analysis package, Gene Spring.  
Therefore the results of this study are credible and can be used to design trials to test the 
identified genes as diagnostic markers for acute ischemic stroke and to further understand the 
relationship between inflammatory and immune pathways and the response to acute ischemic 
stroke to design novel therapeutics. 
 
arkers of acute ischemic stroke. This leaves great 
neurological and psychiatric diseases. 
All stroke patient and control subject samples were collected under similar situations; all samples 
were treated the same; and RNA extraction, hybridization, and washing were performed in 
parallel. With the exception of one patient outlier, all samples group appropriately and all 
microarrays show uniform intensities across housekeeping probes. Quality control analysis 
reveals high quality RNA and high quality microarray data. In addition, all analyses were 
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 In addition to the high quality of the data, this is the largest gene expression profiling 
study of acute ischemic stroke in humans and the only to interpret the results through pathway 
analysis. It is also one of the first to use clinical demographic data as covariates for the 
identification of genes associated with a phenotype of clinical severity (blood brain barrier 
disruption) and clinical outcome (modified rankin scale). This model should be used in future 
9.2 A GENE PANEL FOR DIAGNOSIS OF ACUTE ISCHEMIC STROKE  
A rapid blood test for the diagnosis of acute ischemic stroke would transform stroke care in the 
US and throughout the world. Most hospitals across the US are not large academic centers where 
ent ischemic attack (TIA) or stroke of 
undetermined cause pays testament to the need to identify additional means of stroke diagnosis.  
gene expression profiling studies to identify clinically useful gene sets for populations of interest 
taking into consideration clinical phenotypes.  
Stroke neurologists are available 24/7 and where an MRI can be used for acute assessment of 
cerebral ischemic changes prior to the administration of rtPA. The norm however is something 
quite different. More often than not, an ER physician is assessing, diagnosing and treating acute 
ischemic stroke through clinical history assessment and CT without the assistance of a stroke-
trained neurologist. Recent studies have reinforced that although ER physicians are more than 
capable of treating stroke patients, they are often reluctant to give rtPA unless the diagnosis is 
definitive. In addition, there is a shortage of trained emergency personnel and ER nursing staff 
capable of identifying stroke symptoms or conducting an appropriate stroke assessment.  The 
small percentage of patients who actually receive rtPA (3-5%) and the large numbers of patients 
who leave the hospital with either a diagnosis of transi
161 
 The field of cardiology is quite familiar with the use of peripheral blood markers as 
diagnostic biomarkers of acute ischemia. Class One A recommendations from the American 
College of Cardiology and the American Heart Association identify the use of cardiac troponin 
as the preferred blood biomarker for acute myocardial infarction (MI) diagnosis and CK-MB as 
the alternative when troponin is unavailable.(Alpert, Thygesen et al. 2000)  More than 30 years 
of research has led to the acceptance of CK-MB and only recently troponin as specific markers 
of acute MI. (Jaffe 2008) The identification of these markers as specific and sensitive for MI 
have withstood the test of time, and have therefore become part of the standard of care in 
Cardiology and have had a tremendous positive impact on patient outcome. 
 ven 
virtually impossible to identify. Some groups have even begun to question the use of blood 
biomarkers in the study of acute brain injury. Numerous studies over the years have resulted in 
either insignificant findings or could not be replicated. Traditional methods for the identification 
of these biomarkers have fallen short of the rigor and sensitivity necessary to identify the 
troponin or CK-MB for brain injury. I would argue that now, more than ever, with the 
widespread use and dissemination of novel genomic and proteomic methods is the time that 
“brain specific” biomarkers can and ultimately will be identified.  
transformed biomedical research as we know it through advanced knowledge of genetic 
contributions to disease. Through the continued work of deciphering the genome, the 
International HapMap project, comparative genomics, epigenomics, and refinement of 
computational biology techniques personalized medicine is becoming a reality. In the near future 
Most would argue that peripheral blood markers specific for brain injury has pro
The completion of the Human Genome Project in 2003, only six years ago, has already 
it will be inevitable to avoid addressing genetic/genomic contributions to disease or response to 
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tr nt when interpreting the clinical utility of novel therapeutics. Even so, no one would 
argue that there is not going to be a single biomarker for the diagnosis of acute ischemic stroke; 
but rather a more realistic approach is the identification of a collection of biomarkers that may 
not be directly specific for brain injury, but respond differently in concert with one another 
following ischemic stroke. 
The results of this study and the previous studies, suggest a panel of genes can be used to 
diagnosis acute ischemic stroke. No doubt, more work needs to be done and multiple additional 
studies need to be conducted to test this diagnostic panel, but these results are promising. The 9 
genes identified in this study predicted stroke with an accuracy of 95%; whi
eatme
ch is higher than the 
since both compete for L-arginine. (Popovic, Zeh et al. 2007) Trauma is associated with an 
diagnostic capability of both MRI (85%) and CT (54%).  (Chalela, Kidwell et al. 2007)  
 The nine gene panel identified in this study is up-regulated for all genes, except for 
CCR7 and consists of the following: Arginase 1 (ARG1); carbonic anhydrase 4 (CA4); 
chemokine receptor 7 (CCR7); chondroitin sulfate proteoglycan 2 (CSPG2); IQ motif-containing 
GTPase activation protein 1 (IQGAP1); lymphocyte antigen 96 (LY96); matrix metalloproteinase 
9 (MMP9); orosomucoid 1 (ORM1); s100 calcium binding protein A12 (s100A12).  
9.2.1 Arginase-1 
Arginase-1 (ARG1) is an enzyme induced by T-helper 2 cytokines that metabolizes L-arginine to 
ornithine and urea and is a critical regulator of nitric oxide (NO) synthesis.(Durante, Johnson et 
al. 2007) Inflammatory stimuli (T-helper 1 cytokines) result in an increased expression of 
inducible NO synthetase (iNOS) through L-arginine metabolism. It is possible to determine the 
type of inflammatory response to injury depending on the relative amount of ARG1 and iNOS 
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increase activity of ARG1 and a decrease in the level of arginine. (Tsuei, Bernard et al. 2001) In 
addition recent studies suggest activation of the JAK and STAT pathways induces ARG1 in 
smooth muscle. (Wei, Jacobs et al. 2000) Since humoral anti-inflammatory cytokines induce 
ARG1, the up-regulation of ARG1 in this dataset suggests that the response to acute ischemic 
stroke favors an innate humoral immune response. 
olved in 
cellular
e that 
requires an increase in CA4 to convert CO2 to HC03 to maintain pH.  
9.2.3 Chemokine Receptor 7 
9.2.2 Carbonic Anhydrase IV 
Carbonic anhydrase IV (CA4) is a zinc enzyme that catalyzes the conversion between carbon 
dioxide and the bicarbonate ion, thus making it crucial for all physiologic processes inv
 respiration and transport. CA4 is a membrane-bound protein found in tissues throughout 
the body and is found in the brain within the luminal surface of capillary endothelial cells 
suggesting a role for CA4 in the blood brain barrier as a regulator of CO2 and bicarbonate 
homeostasis in the brain. (Ghandour, Langley et al. 1992)  The up-regulation of CA4 in this 
dataset suggests there is an increase in cellular respiration following acute ischemic strok
Chemokines are a family of small proteins that regulate leukocyte trafficking. Aside from their 
role in inflammatory and immune responses there is increasing evidence that they play a 
significant role in glial cell proliferation and migration as part of the neuro-immune response. 
(Columba-Cabezas, Serafini et al. 2003) Several chemokines have been identified in both the 
serum and CSF of stroke patients. CXCL5, CCL2, CCL3, and CXCL8 are significantly increased 
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following stroke and play a modulatory role of inflammation during the acute phase of ischemia. 
(Mines, Ding et al. 2007) In addition CCR8 is expressed in activated microglia on brain sections 
of ischemic stroke patients. (Trebst, Staugaitis et al. 2003) The down regulation of CCR7 in this 
dataset suggests there is decreased glial cell proliferation and migration very early in the acute 
phase of ischemic stroke; which coincides with the literature that these cytokines become 
increasingly more active during recovery and repair.   
9.2.4 Chondroitin sulfate proteoglycan 2  
in the infarct core CSPG2 
expression is dramatically increased, resulting in increased cell death and reactive astrocytosis. 
S cleave CSPG2, including the matrix metalloproteinases. 
(Carmichael, Archibeque et al. 2005) The up-regulation of CSPG2 in this dataset suggests there 
Chondroitin sulfate proteoglycan 2 (CSPG2) also known as versican, was first identified in 
hyaline cartilage where it provides mechanical support. Recent studies have identified CSPG2 as 
a primary component of the extracellular matrix in the CNS. A disaccharide degradation product 
of CSPG2 has been shown to stimulate microglia to possess increase phagocytic activity without 
cytotoxic effects. This suggests a role for CSPG2 in immune-related neurodengenerative 
disorders. (Ebert, Schoeberl et al. 2008) In addition, increased CSPGs exhibit growth inhibiting 
properties and inhibit axonal sprouting within the glial scar. With
everal enzymatic processes 
is inhibited axonal growth in the acute phase of ischemic stroke.  
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9.2.5 IQ Motif-containing GTPase activating protein 1 
IQ Motif-containing GTPase activating protein 1 (IQGAP1) is an evolutionarily conserved 
molecule that serves as a scaffold protein and plays a fundamental role in cell polarity. It 
modulates several cellular activities including cytoskeletal architecture, cell-cell adhesion, 
transcription and signaling (ERK signaling). Rho-family GTPases, including Cdc42 require 
IQGAP1 to regulate actin cytoskeleton and produce a gradient of signaling molecules. Cdc42 and 
IQ roughout the brain. (Fukata, Nakagawa et al. 2003) 
In addition, increased Cdc42 activity has been implicated in the breakdown of the blood brain 
 release of pro-inflammatory 
cytokines (e.g. IL6 and IL8). Interestingly, natural selection has shaped the sequence patterns of 
TLR genes in primate evolution. (Nakajima, Ohtani et al. 2008) However, pathogens and LPS 
are not the only cause of tissue damage; ischemia is another mechanism. There is accumulating 
evidence that ischemic tissue damage is recognized at the cell level via receptor-mediated 
GAP1 it co-localizes with actin filaments th
barrier (BBB). (Wojciak-Stothard and Ridley 2003) An up-regulation of IQGAP1 expression in 
this dataset suggests there is an increase in cellular signaling and transcription in the acute phase 
of ischemic stroke and IQGAP1 may mediate the disruption of the BBB as a means by which 
signals from the brain enter the periphery to augment cellular recruitment.  
9.2.6 Lymphocyte antigen 96 
Lymphocyte antigen 96 (LY96) also known as MD2 protein, is critical for toll-like receptor 4 
(TLR4) activation as an innate response to lipopolysaccharide (LPS) which is the main 
constituent of gram-negative bacteria. (Miyake 2003) TLR4 activation induces transduction 
pathways resulting in NF-kappaB expression and subsequent
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d efore there are exogenous pathogen-
associated molecular patterns (PAMPs; such as LPS) and endogenous alarmins that elicit similar 
and initiation of the 
inflammatory cascade (Kolev, Skopal et al. 2003), further contributing to BBB impairment. Up-
re ute ischemic stroke suggests an increase in proteolytic activity 
early that may contribute to BBB disruption, which would allow cellular migration and signaling 
etection of proteins (alarmins) released by dead cells. Ther
responses of the innate immune system known as damage associated molecular patterns 
(DAMPs). (Bianchi 2007) The upregulation of LY96 in this dataset suggests that the response to 
acute ischemic stroke is mediated by the innate immune system and TLR signaling.  
9.2.7 Matrix Metalloproteinase 9 
Matrix Metalloproteinase 9 (MMP9) is a zinc and calcium dependent endopeptidase responsible 
for regulation of the extracellular matrix (ECM). Ischemia and reperfusion injury results in 
oxidative stress that mediates BBB disruption through metalloproteinase activation. MMP9 
expression is the result of activated leukocytes (particularly neutrophils), (Gidday, Gasche et al. 
2005) and results in IL1beta activation (Russo, Siviglia et al. 2007) 
gultion of MMP9 following ac
to and throughout the CNS.  
9.2.8 Oromucosid 1 
Oromucosid 1 (ORM1) also known as alpha-1 acid glycoprotein is an acute phase protein and 
increases 2-5 times during an acute phase response. It has been shown to suppress lymphocyte 
response to LPS (thereby preventing ongoing tissue damage by neutrophil proteases), decrease 
platelet aggregation (and thus further platelet recruitment), and enhance cytokine secretion (as 
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possibly part of a feedback mechanism). (Hochepied, Berger et al. 2003) It exhibits both pro and 
anit-inflammatory effects and is therefore suggested to play a significant role in 
immunomodulation. An up-regulation of ORM1 in this dataset suggests a neuroimmune response 
in acute ischemic stroke mediated by a balance between pro and anti-inflammatory signaling 
molecules.  
9.2.9 s100 calcium binding protein A12 
AGE interaction in inflammatory and vascular cells results in the 
increased expression of MMPs. (Clynes, Moser et al. 2007) The up-regulation of s100A12 
su t the response to acute ischemic stroke is largely driven by innate 
immunity.  
 s100 calcium binding protein A12 (s100A12) also known as calgranulin C and EN-RAGE 
(extracellular newly identified RAGE binding protein) is specifically related to innate immune 
function. S100A12 is expressed by phagocytes and released at the site of tissue inflammation. It 
is an endogenous DAMP that turns pro-inflammatory after a release into the extracellular space 
following brain injury. (Foell, Wittkowski et al. 2007) The Receptor for Advanced Glycation 
End Products (RAGE) is a member of the immunoglobulin superfamily and is a specific cell 
surface reaction site for advanced glycation endproducts (AGEs) which increase with advancing 
age. Intreaction between AGEs and RAGE has been linked to chronic inflammation (Schmidt and 
Stern 2001) Once engaged R
pports the claim tha
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9.3 GENE LIST COMPARISON TO PREVIOUS STUDIES 
The first whole blood gene expression profiling study for ischemic stroke identified an 18-gene 
panel for ischemic stroke.(Tang, Xu et al. 2006) Five of these genes have been replicated in this 
study, using a different population of patients, a different methodological platform, and a 
different analysis plan. Therefore when used together the following genes have strong evidence 
fo roke: ARG1, CA4, LY96, MMP9, and s100A12.  
 In the study conducted by Tang et al (2006) a group of 15 stroke patients and 8 control 
ition, this study was only conducted with Caucasian 
stroke patients and control subjects, therefore changes in expression cannot be attributed to 
population stratification.  
 The very first gene expression profiling study of stroke conducted by Moore et al (2005) 
recruited patients up to 48 hours following stroke and isolated RNA from one cell type in the 
r diagnostic capability in acute ischemic st
subjects were used to identify a gene expression profile for stroke. The stroke group was 
significantly older (64±14 years) than the control group (49±11) and there were African 
American patients in the stroke group and only Caucasian patients in the control group. 
Population stratification is a major issue for genetic studies and should be avoided; therefore 
even though they did not find large differences in expression based on race, some genes 
identified may have been non-specific changes regulated by race, not by stroke. In this study 
there was a much larger population of stroke patients (n=39) and control subjects (n=24). There 
was a significant difference between stroke patients and control subjects by age (73±14 and 59±9 
respectively); however this group was older than the population of the first study and a separate 
analysis controlling for age was conducted to determine genes regulated by age. S100A12 was 
found to associate with increasing age, and therefore may not be specific for acute stroke, but 
rather a marker of increasing age.  In add
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blood (periphe lo strated that a 
large majority of the early gene expression changes are found within polymorphonuclear 
y in 
 Traditionally the PAMP/TLR activation pathway has only been 
plica
ral b od mononuclear cells; monocytes). Tang et al (2006) demon
leukocytes and neutrophils following ischemic stroke; later changes in gene expression are found 
in monocytes.  For these reasons primarily it is difficult to compare the results of this study to the 
first study conducted by Moore et al (2005), because different cell types were studied. That study 
chose a specific cell type, whereas the Tang et al study and this study isolated RNA from every 
cell present in whole blood. Even so, there was one gene, CSPG2 (Versican), in this stud
common with the Moore et al study.  
 
9.4 INNATE IMMUNITY AND RESPONSE TO ISCHEMIC STROKE 
The innate immune system has been created by mammalian evolution and is a fast and blunt non-
specific endogenous response to cellular stress.(Parham 2003) Adaptive immunity on the other 
hand is much more specific and can take days to weeks to mount a full response. The balance 
between these two forces enables an organism to fight disease and survive. Since the innate 
immune system is not specific, innate immune cells must recognize antigens and stress signals 
through a predetermined set of encoded receptors. Pathogen associated molecular patterns 
(PAMPs) are a diverse set of stress and injury-induced molecules which have highly conserved 
structures that are recognized by pattern recognition receptors (PRRs) such as the Toll like 
receptor (TLR) pathway.
im ted in tolerance to endotoxins (microbes with lipopolysaccharide chains) that alert an 
organism to intruding pathogens. However, it is becoming increasingly clear that microbial 
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invasion is not the only mechanism by which the TLR pathway becomes activated.(Bianchi 
2007; Rubartelli and Lotze 2007.) Products of degradation, damaged DNA, fibrinogen and heat 
shock proteins have emerged as activators of the TLR pathway through a mechanism known as 
damage associated molecular pattern (DAMPs) recognition. This mechanism of endogenous 
alarmin activation shares many commonalities with the response generated by TLR activation 
through exogenous PAMPs.(Kariko, Weissman et al. 2004) This “new” awareness of the 
similarities between trauma and pathogen evoked innate immune responses is receiving a lot of 
recent attention, and has tremendous implications for the response of the human body to acute 
chemic stroke.  
 Alarmins are endogenous molecules released following non-programmed cell death that 
recruit and activate cells of the innate immune system and subsequently promote the restoration 
of dama tis  box 1 
(HMGB1), s100s, annexins, heparan sulfate, and heat shock proteins (HSP) and can engage 
TLRs, IL1 receptors (IL1R) or receptors of advanced glycation end products (RAGE) making the 
alarmins critical regulators of downstream inflammatory and immune responses.(Rubartelli and 
Lotze 2007.; Jordan, Sequra et al. 2008) Engagement of TLRs, IL1Rs, and RAGE receptors all 
result in the translocation of NF-kappaB to the nucleus. NF-kappB is the first step of any 
subsequent release and activation of chemokines and metalloproteinases. In addition, the 
polarized response of the adaptive immune system may be modulated by the presence of DAMPs 
and PAMPs. (Rubartelli and Lotze 2007.) Thus it is becoming increasingly clear why innate 
immunity may play a critical role in understanding the response to human stroke.  
is
ged sue. Putative alarmins include such molecules as high mobility group
inflammatory cascade since it begins transcription of inflammatory cytokines which results in 
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 Inflammation is necessary to recruit immune cells to the site of local injury. It is therefore 
a beneficial part of the response to acute ischemic stroke; however when the inflammatory 
process is prolonged it will exacerbate cell death and negatively impact clinical outcome. Within 
the brain this process of pro and anti-inflammatory signals, known as immunomodulation, is 
mediated primarily by signals from astrocytes and microglia and requires constant 
communication between cytokines and other immune cells to tailor the response as 
necessary.(Jordan, Sequra et al. 2008) There is evidence that peripherally derived cytokines are 
involved in brain inflammation as well and this process is facilitated by blood brain barrier 
(BBB) disruption. When the BBB becomes disrupted (as part of the endogenous response to 
chem
ether to form 
the AP1 early response transcription factor which increases the transcription of neurotrophic 
is ia) the peripheral immune system comes into contact with the central nervous system and 
adds to the local inflammatory process and propagates the changes of gene expression identified 
in this study.  
 TLR4 activation has recently been implicated as a negative effector of the innate immune 
response.(Kilic, Kilic et al. 2008) TLR4 receptors are present on microglia, astrocytes and 
neurons and are activated by alarmins in the brain following acute ischemia.  Both the activation 
of TLR4 and TLR2 result in activation of IRAK1 through interaction with MyD88. This leads to 
engagement of TRAF6, which is a member of the TNF receptor family. Then through the IkappB 
kinase pathway, NF-kappaB translocates from the cytoplasm to the nucleus where it stimulates 
transcription of both pro-inflammatory and anti-inflammatory cytokines and chemokines (e.g. 
pro-inflammatory IL6 and IL8; anti-inflammatory IL10 and TNFα). Simultaneous with NF-
kappaB activation, engagement of TRAF6 also results in: 1) the stimulation of the JNK pathway 
and activation of immediate early response genes cJun and cFos which come tog
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factors, such as brain derived neurotrophic factor (BDNF); and 2) the activation of the MAPK 
signaling cascade with subsequent ELK1 activation with binding to the serum response factor 
(SRF) in the promoter of the cFos proto-oncogene. Therefore, within the TLR4 pathway there are 
both pro-inflammatory mechanisms of engagement (NF-kappaB) and anti-inflammatory and 
neurotrophic pathways of regeneration (BDNF and SRF).(Bianchi 2007; Rubartelli and Lotze 
2007.; Jordan, Sequra et al. 2008)  
 There are only a few studies that have studied TLR4 activation in regard to ischemic 
stroke and all have found that a down regulation of TLR4 results in a decrease in final infarct 
volume and better outcome in mice MCAO models. TLR4 deficient mice seem to be protected by 
ischemic injury through a down-regulation of iNOS production.(Ziegler, Harhausen et al. 2007; 
Caso, Pradillo et al. 2007.) In addition, mice who are TLR4 deficient also have better behavior 
following MCAO that is preceded by significant psychological stress.(Caso, Pradillo et al. 2008) 
umanH  studies have added to this theory of TLR4 mediated negative outcome and have identified 
that increased activation of TLR4 following ischemic stroke corresponds to worse clinical 
outcome.(Yang, Li et al. 2008; Urra, Cervera et al. 2009)  
Given the data some have postulated that deactivation of the innate immune response 
targeting TLR4 is a novel therapeutic approach for treatment of acute ischemic stroke and 
mediation of the acute inflammatory/immune response.(Kilic, Kilic et al. 2008) However, given 
that the TLR4 pathway is highly conserved across species and has survived natural selection this 
raises a completely different perspective. Is it possible that the strongest effect of TLR4 
activation is not neurodegeneration; but rather mediation of the immune response through its role 
as a neurotropic generator? The positive effects of TLR4 activation could be the explanation as to 
why older patients have worse clinical outcomes following stroke when compared to their 
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younger counterparts. To understand this line of thought it is first essential to address the idea of 
ischemic tolerance.  
Ischemic tolerance (IT) or ischemic preconditioning (IP) was first characterized by Janoff 
in 1964 as the protective response of an organism to potentially recurring challenges.(Janoff 
1964.) Thus the notion of IT/IP has become increasingly prominent in the stroke literature over 
time and resides in the fact that the severity of post-ischemic injury can be manipulated through 
all a
s a hyporesponsive state to subsequent 
ischem
sm nd short bursts of ischemia prior to the severe ischemic event. This sub-lethal stress 
primes cells for subsequent ischemic events through exposure to IL1β and TNFα.(Kariko, 
Weissman et al. 2004) Several noxious events can serve as stimuli capable of inducing IT/IP: 
global and focal cerebral ischemia; cortical spreading depression; and even epilepsy.(Dirnagl, 
Iadecola et al. 1999) Preconditioning shifts subsequent responses to ischemia from TLR4 
activation to increased natural killer (NK) cell activity (TNFα. and IFNβ). Therefore immune 
tolerance may be through a protective mechanism of NK cell activity.(Marsh, Stevens et al. 
2009)  
Given the argument that ischemic tolerance induce
ic insults, then it can be assumed that the human body becomes able to tolerate such 
insults over time (in the presence of mild ischemia through hypertension, possibly carotid artery 
blockage, and even small vessel disease secondary to diabetic complications) and that this results 
in a dampened activation of the TLR4 pathway upon significant insults, such as ischemic stroke. 
A down-regulation of TLR4 leads to a less profound inflammatory and immune response, but 
also results in the production of less neurotrophic factors and subsequently less opportunity for 
regeneration and regrowth within the brain. In this study it was found that increased expression 
of NF-kappaB 24 hours following acute ischemic stroke correlated with better clinical outcome 
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on the 30 day MRS; however this relationship was mediated by age. Younger patients had higher 
levels of NF-kappaB and better outcome. Aging provides a brain environment that is already 
“prime
In addition to finding that older patients had lower expression of NF-kappaB, we found 
the exp
d” to a peripheral immune challenge and is one of the biggest predictors of clinical 
outcome following acute ischemic stroke. Is this because of a dampened response of the TLR4 
pathway? Evidence to support this theory lies in the fact that patients who have experienced a 
transient ischemic attack (TIA) very soon before their stroke have better clinical outcomes than 
patients with first ever ischemic stroke.(Weih, Kallenberg et al. 1999; Moncayo, de Freitas et al. 
2000.; Sitzer, Foerch et al. 2004) It is plausible that this pathway of repair was activated with the 
first insult (TIA) and is continuing while the second more severe insult (ischemic stroke) occurs. 
The previous human studies postulating that TLR4 activation correlates with worse clinical 
outcome did not address what made the patients with worse clinical outcome so different; was it 
because they had a previous stroke; or had  a history of hypertension complicated by diabetes; or 
were they just older?  
ression of s100A12 was significantly increased with age. S100 is an endogenous alarmin 
and the increased expression of s100A12 with age implies an environment of increased stress. 
Therefore the downregulation of NF-kappaB with the simultaneous upregulation of s100A12 
with age implies the response of the TLR4 pathway is dampended with age.  
To add to this argument, recent experience with anti-inflammtory approaches in the 
clinical setting has been largely unsuccessful. Enlimomab (a murine monoclonal anti–human 
ICAM-1 antibody)(2001), monoclonal antibody to CD18 (antibody Hu23F2G or 
leukarrest)(Becker 2002), and even arguably Minocycline(Lampl, Boaz et al. 2007; Schabitz, 
Schneider et al. 2008) have either been detrimental or shown to have no clinical benefit when 
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used in a human ischemic stroke population. This is proof that the mechanisms of neuro-
immunomodulation are still poorly understood. It is possible that the identified positive effects of 
ischemic preconditioning are not just in its ability to harness the inflammatory process; but rather 
through a different mechanism of action. If preconditioning afforded protection from 
inflammation at only the level of NF-kappaB translocation, discrimination between detrimental 
and neuroprotective mechanisms would be impossible. There is data suggesting that gene 
expression changes of IT/IP only affect transcription of genes for which trans-activation depends 
on p300 interaction with NF-kappaB. (Ginis, Jaiswal et al. 2002) Therefore it is possible there is 
an effector of NF-kappaB that regulates NF-kappaB and therefore the transcription of 
inflammatory mediators once activated following preconditioning.  
A plausible case for innate immunity through the activation of TLR4 as a mediator of 
response to ischemic stroke has been made from the results of this study. There is some evidence 
present in this dataset for a strong relationship between innate immunity and age, as increased 24 
hour N
e with aging results 
in a dam
F-kappaB expression in younger patients was correlated with better functional outcome at 
30 days post-stroke. Younger patients had a stronger TLR4 receptor activation response than 
older patients (>60years); s100A12 expression increased with age as NF-kappaB expression 
decreased with age. A further look at the relationship between age and TLR4 activation is 
required to assess the possibility that ischemic tolerance developed over tim
pened neurotrophic response of TLR4 activation.  
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9.5 AKAP7 AND BLOOD BRAIN BARRIER DISRUPTION 
Messages from the extracellular space influence intracellular processes via activation of signal 
transduction pathways that involve protein kinase A (PKA) and protein kinase C (PKC).(Fraser, 
Tavalin et al. 1998) Fluctuations in intracellular Ca+2 and cAMP influence a series of cellular 
processes: ion channel regulation; cellular metabolis; growth and differentiation; and cell 
trafficking.(Trotter, Fraser et al. 1999) These signals are propagated via PKA phosphorylation. 
PKA localizes close to L-type Ca+2 channels in order to facilitate rapid and efficient channel 
phosphorylation. There are about 2,000 kinases present in the human genome and up to 25 
different A-kinase anchor proteins (AKAPs).(Edwards and Scott 2000) AKAPs are functionally 
related 
ysiologic partner of the Ca+2 channel 
and fundamental to specific hormone mediated responses that utilize cyclic adenosine 
monophosphate (cAMP).(Fraser, Tavalin et al. 1998) The gene for AKAP7 is alternatively 
spliced resulting in four splice variants all with common functions.(Trotter, Fraser et al. 1999)  
AKAP15, the rat homolog of AKAP7/18, also interacts with neuronal sodium (Na+) 
channels.(Tibbs, Gray et al. 1998; Few, Scheuer et al. 2007) Protein phosphorylation of Na+ 
and characterized by their interaction with either type 1 or type 2 regulatory subunits (RI 
and RII) of PKA.(Edwards and Scott 2000) Specificity of this process is mediated at the 
molecular level by a second motif unique to each AKAP allowing it to sequester PKA or PKC to 
specific intracellular regions.(Fraser, Tavalin et al. 1998)  
A-kinase anchor protein-7 (AKAP7) also known as AKAP18 and AKAP15 (in rat)(Fraser, 
Tavalin et al. 1998) directs the activity of protein kinase A (PKA) and protein kinase C (PKC) to 
calcium and sodium channels in the brain, skeletal muscle, heart, and other organs. AKAP7 
targets PKA to the cytoplasmic face of the plasma membrane, where it enhances cAMP 
responsive calcium (Ca+2) currents and is therefore the ph
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channels in th ain for neuronal 
plasticity which decreases overall excitability within the hippocampus.(Few, Scheuer et al. 2007) 
uring anoxic brain injury. (Grammas, 
Moore 
d 
macrom
e br  serves as a process of neuromodulation and is important 
Dopamine signaling modulates this Na+ current through PKA and requires AKAP15 to anchor 
PKA to the Na+ channel via a leucine zipper-like motif.(Few, Scheuer et al. 2007) Normal 
dopamine signaling is only achieved when PKA is anchored directly to the channel via AKAP15. 
Recent evidence suggests that AKAP15 can regulate Na+ channels via a novel PKA-independent 
pathway as well which suggests AKAP7/18 may be generally distributed throughout the plasma 
membrane and could participate in a wide variety of transmembrane signaling 
pathways.(Bengrine, Li et al. 2007) PKC also decreases Na+ current within the brain and 
enhances the PKA response. The maximum modulation of this effect requires phosphorylation of 
four distinct sites within the Na+ channel. This suggests that signals from multiple pathways can 
converge and become integrated at the cellular level within the brain and makes the process of 
deciphering these signals extremely complex.(Cantrell, Tibbs et al. 2002)  
Alterations of the PKA and PKC pathways occur d
et al. 1998) Engagement of ICAM1 as part of the inflammatory process following 
ischemic stroke induces signals across the BBB via TNFalpha secretion and activation of 
PKA.(Etienne-Manneville, Chaverot et al. 1999) TNFalpha  has been implicated in BBB 
opening in multiple sclerosis(Sharief, Noori et al. 1993), and therefore ICAM1 binding on 
astrocytes may be a stimulus for BBB opening following ischemic stroke as well.  
Brain endothelial cells exposed to oxygen deprivation show an increase in PKC signaling 
with a simultaneous decreased in PKA signaling.(Grammas, Moore et al. 1998) Over activation 
of PKC increases the influx of fluid (via Na+ entry into the intracellular space) an
olecules across the microvascular wall. PKC inhibitors subsequently decrease this 
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permeability(Qi, Inagaki et al. 2008); therefore PKC has been suggested as a mediator of 
microvascular permeability. Neuroprotection via PKC inhibition prevents BBB opening even in 
the presence of sustained high blood pressure. In addition, brain samples of patients with 
hypertension have increased staining of PKC in arteriolar endothelial cells and astrocytes.(Qi, 
Inagaki et al. 2008) PKC signaling also regulates the morphology of tight junction proteins 
within the BBB.(Krizbai and Deli 2003) PKC is involved in both the activation of ERK and PKA 
signaling, and ERK signaling has been shown to increase matrix metalloproteinases.(Tyagi, 
Gillespie et al. 2009)  
In addition to its connection with ERK signaling, the PKC pathway also seems to be 
mediated by the RhoA/RhoKinase pathway. Following ischemia there are two canonical Wnt 
signaling pathways: 1. Wnt/Ca+2 (PKC driven) and 2. Wnt/PCP (RhoA/RhoKinase) driven.(Li, 
Chong et al. 2005) Pro-inflammatory stimuli cause an increase in BBB permeability by inducing 
endothelial cell retraction, dependent upon the phosphorylation state of myosin light chains 
(MLCs
activation of 
RhoA.(
). RhoA and its downstream target RhoKinase increases phosphorylation of MLCs and 
therefore enhance contractility of brain endothelial cells.(Stamatovic, Dimitrijevic et al. 2006) 
PKC also affects phosphorylation of BEC, specifically the tight junctions (TJs). The chemokine 
monocyte chemoattractant protein-1 (CCL2) mediates this process by redistributing the TJ 
proteins dependent on RhoA/RhoKinase activation.(Stamatovic, Keep et al. 2003) A recent study 
found that PKC activation via CCL2 is highly dependent on the co-
Stamatovic, Dimitrijevic et al. 2006) The interaction between RhoA and PKC activates 
the transcription factor AP1(Chang, Pratt et al. 1998) and has been shown to increases stress 
fiber formation.(Coghlan, Chou et al. 2000) In addition there is high affinity binding between 
PKC and RhoA and RhoA can specifically regulate PKC activation.(Slater, Seiz et al. 2001; 
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Schmitz, Lorberg et al. 2002) Strong evidence exists that these two pathways interact to 
contribute blood brain barrier disruption following acute ischemic stroke.  
The finding that AKAP7 expression was higher in Severe HARM (severe blood brain 
barrier (BBB) disruption patients suggests that there is increased PKA and PKC signaling 
following acute ischemic stroke that is associated with BBB disruption. In support of this finding 
is the association of IQGAP1 with Cdc42, a small Rho GTPase. IQGAP1 was identified as one of 
the significant genes for stroke in this study. IQGAP1 colocalizes with Cdc42 in the brain and 
contributes to BBB disruption. Further work should be conducted to determine the relationship 
betwee
There are several limitations to address with this dissertation. The original goal of this study was 
bias age may have on identifying a gene expression profile for stroke. This study however ended 
up with a significantly older stroke population. Therefore age had to be used as a covariate in a 
subsequent analysis, where s100A12 was identified as being associated with old age. This 
secondary analysis results in decreased power to make the assumption that s100A12 was solely 
associated with age. Future studies should aim to have groups with similar ages. In addition, the 
generalizability of the results is limited given the group studied. All of the patients in this study 
 this gene expression profile in other racial and 
ethnic groups to determine its utility in the clinical setting.  
n PKC (mediated by AKAP7/18) and RhoA/RhoKinase signaling in the contribution of 
BBB disruption in acute ischemic stroke.  
9.6 LIMITATIONS  
to compare stroke patients to healthy control subjects matched on age, to eliminate any potential 
were Caucasian, so the next step would be to test
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Another important consideration is the time of the baseline blood draw for the RNA 
profile. For these genes to be used as acute diagnostic markers the baseline blood draw needs to 
conduc
mon with the first whole blood expression profiling 
study of stroke, the results need to be validated and replicated in a larger cohort and tested in the 
acute clinical setting for their diagnostic capability. It will be essential to determine a gene 
profile that can rule out stroke fro  studies need to add a 
“TIA” group for comparison to stroke and control to determine the specificity of the gene profile 
identified in this study for stroke.  
taining GTPase activation protein 1 
ted within 3 hours from onset of injury. The mean time from onset to baseline blood draw 
in this study was 10 hours. Tang et al (2006) determined that gene expression profiles don’t 
change significantly during the first 24 hours from onset of symptoms; in fact, most of the genes 
that were differentially expressed at 3 hours from onset, were also expressed at 5 and 24 hours 
from onset. Even so, this does not rule out the possibility that some genes identified in this study 
may not have been differentially expressed at an earlier time point. 
The final consideration of the study is the diagnostics capability of the findings. Even 
though this study identified 5 genes in com
m stroke mimic; therefore following
9.7 CONCLUSIONS 
The findings of this study support the claim that gene expression profiling of peripheral whole 
blood can be used to identify diagnostic markers of acute ischemic stroke. Nine genes were 
identified in this study as being differentially expressed between stroke patients and control 
subjects: Arginase 1 (ARG1); carbonic anhydrase 4 (CA4); chemokine receptor 7 (CCR7); 
chondroitin sulfate proteoglycan 2 (CSPG2); IG motif-con
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(IQGAP
patients
there is increased PKA and PKC signaling following acute 
ischemic stroke that is associated with BBB disruption. Further work should be conducted to 
determine the relationship between PKC (mediated by AKAP7/18) and RhoA/RhoKinase 
lin n of BBB disruption in acute ischemic stroke.  
It is believed that delayed secondary pathologic responses and neuroprotective changes 
lie in the genomic response of the neuron to the initial insult.(Marciano, Eberwine et al. 2002) 
Given the broad based and at times non-specific response of genes and pathways following brain 
injury and neurological disease it may be futile to search for specific pathways to target 
1); lymphocyte antigen 96 (LY96); matrix metalloproteinase 9 (MMP9); orosomucoid 1 
(ORM1); s100 calcium binding protein A12 (s100A12). 
This is the first whole blood expression profiling of human stroke to analyze the data 
through pathway analysis. A plausible case for innate immunity through the activation of TLR4 
as a mediator of response to ischemic stroke has been made from the results of this study. It was 
found that increased expression of NF-kappaB 24 hours following acute ischemic stroke 
correlated with better clinical outcome on the 30 day MRS; however this relationship was 
mediated by age. Younger patients had higher levels of NF-kappaB and better outcome. Younger 
 had a stronger TLR4 receptor activation response than older patients (>60years); 
s100A12 expression increased with age as NF-kappaB expression decreased with age. A further 
look at the relationship between age and TLR4 activation is required to assess the possibility that 
ischemic tolerance developed over time with aging results in a dampened neurotrophic response 
of TLR4 activation.  
The finding that AKAP7 expression was higher in Severe HARM (severe BBB 
disruption) patients suggests that 
signa g in the contributio
therapeutic strategies (von Gertten, Flores Morales et al. 2005). The ability to assess multiple 
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genes and pathways simultaneously using microarray has led to a paradigm shift regarding the 
acknowledgement of the complexity of the genomic response following brain. Expression 
profilin
profiling in human acute ischemic stroke. Five of the 9 genes identified were replicated from the 
first whole blood profiling study. In addition, this study is one of the first to raise the question as 
to whether mediators of the innate immune response may have a positive influence on clinical 
outcome and therefore should not be deactivated but augmented to target neurotrophic 
following areas of interest: 
1. The capability of the diagnostic gene panel identified in this study for its ability to 
differentiate stroke from stroke mimic. 
2. The generalizability of the diagnostic gene panel to other races and ethnic categories. 
3.  The relationship between age and innate immunity, specifically toll like receptor 
signaling and neurotrophic response.  
4. The relationship between NF-kappaB, LY96, and IL8 mediated by age, on clinical 
outcome following acute ischemic stroke. 
g is essential to understanding these processes and formulating rationale approaches to 
treatment. This study and those conducted by Moore et al (2005) and Tang et al (2006) provide 
the foundation of data that support the use of peripheral whole blood for future blood profiling 
studies of neurological disease; which significantly opens the door of opportunity.  
9.8 FUTURE DIRECTIONS 
This study was important in identifying the utility of peripheral whole blood gene expression 
properties. Future directions in original research or secondary analyses should address the 
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5. The relationship between AKAP7, PKC and RhoA/RhoKinase in the development of 
blood brain barrier disruption in acute ischemic stroke.  
6. The proteomic profiles of the 9 genes identified in this study following acute 
ischemic stroke.  
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APPENDIX A 
CLASSIFICATION OF ACUTE ISCHEMIC CEREBROVASCULAR SYNDROME 
(AICS) 
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Kidwell, CS., Warach, S. Acute Ischemic Cerebrovascular Syndrome: Diagnostic Criteria 
Stroke2003;34;2995-2998; 
1. Sudden onset of left hemiparesis and 
hemineglect. MRI showed right 
frontoparietal intracerebral hemorrhage.
2. Thirty-year-old man with known 
seizure disorder found with altered mental 
status and right hemiplegia. Normal 
diffusion, perfusion-weighted MRI, and 
MR angiography (MRA) were acquired 
while symptoms were still present. EEG 
showed left  temporal spikes.
Acute onset of neurologic dysfunction 
with imaging/laboratory
CONFIRMATION of NONISCHEMIC 
pathology (including normal . 
imaging/laboratory studies that are 
highly sensitive for ischemic
pathology of the given duration, 
severity, and location) as the cause of
the neurologic syndrome
Not AI S
1. Two-hour episode of isolated vertigo 
and headache in a
50-year-old man with a history of 
hypertension; symptoms resolved at time 
of imaging. MRI including DWI was 
negative.
2. Twenty-minute episode of isolated 
word finding difficulty in 85-year-old 
woman with a history of dementia and 
coronary artery disease. Head CT was 
negative, and MRI was not performed.
Acute neurologic dysfunction of any 
duration or severity possibly
consistent with focal brain ischemia 
WITHOUT imaging/laboratory
CONFIRMATION of acute ischemic 
pathology* (diagnostic studies were
not performed or were negative and 
SENSITIVE for ischemic pathology
of the given duration, severity and 
location). Possible alternative etiologies 
are NOT ruled out. Symptoms may be 
nonfocal or difficult to localize.
Possible AICS
1. Sudden onset of pure motor hemiplegia
that persists with normal CT at 12 hours 
after onset. MRI was not performed.
fibrillation and subtherapeutic INR. MRI, 
including DWI, was negative.
Acute onset of neurologic dysfunction 
of any severity suggestive of focal brain 
ischemic syndrome but WITHOUT 
(diagnostic studies were negative but 
INSENSITIVE for isch logy 
of the given duration, severity and 
location). Imaging, laboratory, and 
clinical data studies do not suggest 
nonischemic etiology: possible 
alternative etiologies ARE ruled out.
Probable AICS
1. Sudden onset of right hemiparesis and 
aphasia persisting for 3 hours with DWI 
showing acute ischemic changes.
2. Twenty-minute episode of left 
hemisensory loss, which resolved, with 
acute right thalamic ischemic lesion 
confirmed on DWI.
Acute onset of neurologic dysfunction 
of any severity consistent with focal 
brain ischemia AND imaging/ 
laboratory CONFIRMATION of an 
acute vascular ischemic pathology. 
Definite AICS
ExamplesDefinitionCategory
 2. Ten-minute episode of aphasia and 
right hemiparesis in a patient with atrial
imaging/laboratory CONFIRMATION 
of acute ischemic pathology* 
emic patho
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APPENDIX B 
NINDS STROKE TEAM-HARM RATING SCALE 
       SULCAL HARM
 
 
 
 
 
 
 
 
 
 
 
 
 
Developed by investigators in the Section on Stroke Diagnostics and Therapeutics, NINDS/NIH 
-black CSF in sulci
OR             
-one or two point-like regions                                     
not contiguous across slices
NONE
MILD to MODERATE
-numerous point-like regions 
OR
- linear regions confined to 10 or 
fewer contiguous slices 
SEVERE 
- linear regions
-contiguous across greater                     
than 10 slices 
NONE
SEVERE 
MILD to MODERATE
-black CSF in sulci
-uniform and bilateral
- bright CSF in sulci
-white sulcal space 
--hyper-intense compared to cortex              
-uniform and bilateral
- dirty CSF in sulci
- dark gray to light grey sulcal space
- less than or iso-intense                  
compared to cortex
- uniform and bilateral
BACKGROUND HARM
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APPENDIX C 
GENE LIST OF FIRS
 
T HUMAN EXPRESSION PROFILING STUDY OF ISCHEMIC 
STROKE 
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Moore, D.F., et al., Using peripheral blood mononuclear cells to determine a gene expr ic stroke: a pilot 
investigation. Circulation, 2005. 111(2):p.212-21. 
HypotheticalKIAA0146 protein
Neuronal apoptosis inhibitory proteinBaculoviral IAP repeat-containing protein 1  
Leukocyte differentiation antigenCD36 antigen (thrombospondin receptor)
Involved in cell senescence and deathv-ets Erythroblastosis virus E26 oncogene
homolog 2 (avian)
Inflammatory response mediatorLeukotriene A4 hydrolase
chronic granulomatous diseaseCytochrome b-245, ß polypeptide
Inactivates mitogen-activated protein Dual-specificity phosphatase-1
Hypotensive peptideAdrenomedullin
Tumor progressionFc fragment of IgG, high-affinity Ia,
receptor for CD64
Leukocyte immunoglobulin recpetorPaired immunoglobulin-like type 2 receptor a
Complement receptorComplement component 1, 
q subcomponent, receptor 1
B lymphocyte developmentBone marrow stromal cell antigen 1/CD157
Monocyte differentiation antigenCD14 antigen
Secreted by T cells Interleukin 13 receptor, a1
Interact with hyaluronan and form large supramolecu mplexesChondroitin sulfate proteoglycan 2
Present on endothelial cells and inhibits platelet aggr nEctonucleoside
triphosphate diphosphohydrolase 1 
Innate non-specific immune responseToll-like receptor 2
Human oncogene c-fosv-fos FBJ murine osteosarcoma
Converts sialic acid to acylmannosamines and pyruvan-acetylneuraminate pyruvate lysase
Beta-amyloid proteinAmyloid ß(A4) precursor-like protein 2
Laminin A motif (probably adhesion)Hypothetical protein FLJ22662 
Hemoglobin scavenger receptorCD163
DescriptionGene
ession profile of acute ischem
lar co
egatio
te
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APPENDIX D 
GENE LIST OF SECOND HUMAN EXPRESSION PROFILING STUDY OF ISCHEMIC 
STROKE 
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Tang, Y., et al., Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray 
study. J Cereb Blood Flow Metab, 2006. 26(8):p.1089-102. 
N-acetylneuraminate pyruvate lyase (dihydrodipicolinate synthase)NPL
Glycogen phosphorylationPYGL
B-cell CLL/lymphoma 6BCL6
v-ets erythroblastosis virus E26 oncogene homolog 2 (avian)Ets-2
Histone 2, H2aaHIST2H2AA
Solute carrier family 16 (monocarboxylic acid transporters), 6SLC16A6
Lymphocyte antigen 96LY96
Carbonic anhydrase 4CA4
Arginase IARG1
Ribonuclease, RNase A family 2 
(liver eosinophil-derived neurotoxin)
RNASE2
S100 calcium binding protein A12 (calgranulin C)S100A12
Human N-formylpeptide receptor (fMLP-R98) mRNA, complete cdsFPR1
Coagulation factor V (proaccelerin, labile factor)F5
S100 calcium binding protein PS100P
Matrix metalloproteinase 9 (gelatinase B, 92 kDa gelatinase, 92kDa 
type IV collagenase)
MMP9
S100 calcium binding protein A9 (calgranulin B)S100A9
Cytoskeleton-associated protein 4CKAP4
Clone IMAGE:5019307, mRNA, homologous to mouse homebox
protein (Hox-1.11) gene
Hox 1.11
DescriptionGene 
APPENDIX E 
SAMPLE SIZE CALCULATIONS 
1. Proposed model for study aims 
=0.05, Error Std Dev = 1.5, difference to detect = 1.5, power = 0.9,  
Per group sample size = 44/2 ≈ 22 
With α
 
2. Additional Models 
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With α=0.05, Error Std Dev = 1.1, difference to detect = 1.5, power = 0.9, 
 Per group sample size = 25/2 ≈ 13 
 
With α=0.05, Error Std Dev = 1.1, difference to detect = 2.0, power = 0.9, 
Per group sample size = 15/2 ≈ 8 
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APPENDIX F 
CASE REPORT FORMS 
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Natural History Form 01 – Baseline Blood Tracking 
 
Medical Record #______________________     Blood Draw ID 
 
SPOTRIAS Barcode  
      (if applicable) 
 
 
Natural History Blood Tracking 
Baseline/Acute Blood Draw 
 
 
Collectors Initials ______________ 
 
Date/Time of Blood Draw __ __ / __ __ / __ __ __ __  (mm/dd/yyyy)   __ __:__ __ (24hr) 
 
Centrifuge Date/Time __ __ / __ __ / __ __ __ __   (mm/dd/yyyy)  __ __:__ __ (24hr) 
 
Date and Time of Freeze __ __ / __ __ / __ __ __ __   (mm/dd/yyyy)  __ __:__ __ (24hr) 
 
 
 
Was the Blood:  □ Lipemic            □ Hemolyzed  □ Neither 
     (milky white or viscous plasma)                 (pink/red plasma) 
 
From where was the blood obtained?   
 
□ Venipuncture   □ Peripheral line □ Central line   □ Mediport   
 
□ PICC Line  □ Other (specify)________________ 
 
If the blood was drawn from an IV line (peripheral, central, etc.) was there anything 
running through the line? 
 
□ No              □ Yes (please explain) _________________  
*Was it a  □ Heparin    or   □ Saline Lock?      *Was the IV fluid stopped during the blood draw?    □ Yes     □ No 
 
Were the blood tubes placed on ice? 
 
□ No  □ Immediately  □ Within One Hour      □ Other (specify)________ 
 
Blood Pressure at Time of Blood Draw __ __ __/__ __ __  
 
Data Collected By: □ Neurologist   □ Physician\Not-Neurologist    □ Research Coordinator\RN  
 
□ Self Report\Subject 
 
Comments:______________________________________________________________________________
________________________________________________________________________________________
________________________________________________________________________________________ 
________________________________________________________________________________________ 
Number of 4ml 
citrate cryovials 
  
Number of 4ml 
EDTA cryovials  
Number of 
1.8ml citrate 
cryovials  
Number of 
1.8ml EDTA 
cryovials 
Number of 
1.8ml Serum 
cryovials 
Number of 
Paxgene 
RNA tubes 
Number of 
10ml yellow 
top tubes 
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Natural History Form 02 – Demographic & Clinical variables 
 
Medical Record #______________________      SPOTRIAS Barcode  
                                                        On plasma/DNA sample 
                               (if applicable) 
        
   
 
Natural History Demographic and Clinical Variables 
 
 
 
Collectors Initials ______________ 
 
Date/Time Last Known Normal __ __ / __ __ / __ __ __ __  (mm/dd/yyyy)   __ __:__ __ (24hr) 
 
Date/Time Baseline MRI/CT __ __ / __ __ / __ __ __ __   (mm/dd/yyyy)  __ __:__ __ (24hr) 
 
Patient received IV TPA      □ Yes  □ No 
 
Date/Time of IV TPA Start__ __ / __ __ / __ __ __ __   (mm/dd/yyyy)  __ __:__ __ (24hr) 
 
NIHSS on Admission_____________ 
 
Patient’s Zip Code (1st 3 digits) __ __ __     Country of Origin_______________ 
   
Other Family Members in Coriell Repository?       □ Unknown           □ Yes  □ No  
  
Smoking History       □ Never        □ Previous    □ Current Years Smoking__________ 
  
Family History of Stroke (blood relatives only)   
 □ Yes    □ No      □ Unknown (adopted)  
 
If yes, then list all affected including type (e.g. brother-ischemic stroke) _____________________ 
_______________________________________________________________________________ 
 
Family History of Cerebral Aneurysm (blood relatives only) 
□ Yes    □ No      □ Unknown (adopted)  
 
If yes, then list all affected _________________________________________________________ 
_______________________________________________________________________________ 
 
Primary Clinical Diagnosis     Present       Absent               Present      Absent           
Silent cerebral infarction  □   □   Intracerebral hemorrhage        □   □ 
Transient ischemic attack  □   □   Aneurysmal SAH   □   □ 
Unruptured intracranial aneurysm □   □   Vascular cognitive impairment      □   □    
Symptomatic ischemic stroke □   □   AVM                                               □   □ 
Other (specify) ______________________ 
 
Medical History          Present         Absent  Medication History: List medications and dosages 
Hypertension                       □     □         ___________________________________________ 
Diabetes mellitus                 □     □               __________________________________________ 
Atrial fibrillation                 □     □                      __________________________________________ 
Myocardial infarction         □     □                      __________________________________________ 
Dyslipidemia                 □     □                      __________________________________________ 
Other (specify) _____________________ 
 
Other Diagnoses           Present   Absent          Present    Absent 
Parkinson’s Disease            □     □   Epilepsy         □         □  
Alzheimer’s Disease  □     □   ALS               □         □ 
Dementia   □     □   Other (specify) _____________________  
 
Was a Plasma specimen collected from the patient for SPOTRIAS?             □ Yes  □ No 
 
Was a DNA specimen collected from the patient for SPOTRIAS?     □ Yes  □ No  
 Date of DNA sample collection __ __ / __ __ / __ __ __ __  (mm/dd/yyyy)     
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Natural History Form 03 – Follow up Blood Tracking 
 
Medical Record #______________________     Blood Draw ID 
 
SPOTRIAS Barcode  
      (if applicable) 
 
 
Natural History Blood Tracking 
Follow-up/24hr Blood Draw 
 
 
Collectors Initials ______________ 
 
Date/Time of Blood Draw __ __ / __ __ / __ __ __ __ (mm/dd/yyyy)   __ __:__ __ (24hr) 
 
Centrifuge Date/Time __ __ / __ __ / __ __ __ __ (mm/dd/yyyy)  __ __:__ __ (24hr) 
 
Date and Time of Freeze __ __ / __ __ / __ __ __ __ (mm/dd/yyyy)  __ __:__ __ (24hr) 
 
Was the Blood?  □ Lipemic            □ Hemolyzed  □ Neither 
       (milky white and viscous)            (pink/red color to plasma) 
 
From where was the blood obtained?   
 
□ Venipuncture    □ Peripheral line      □ Central line  □ Mediport □ PICC Line  
 
□ Other________________ 
 
If the blood was drawn from an IV line (peripheral, central, etc.) was there anything 
running through the line? 
 
□ No              □ Yes (please explain) _________________  
*Was it a □ Heparin or □ Saline Lock?            *Was the IV fluid stopped during the blood draw? □ Yes   □ No 
 
Were the blood tubes placed on ice? 
 
□ No  □ Immediately  □ Within One Hour     □ Other (specify)________ 
 
Blood Pressure at Time of Blood Draw __ __ __/__ __ __ 
 
Data Collected By: □ Neurologist   □ Physician\Not-Neurologist    □ Research Coordinator\RN  
 
□ Self Report\Subject 
 
Medications during admission: List medications and dosages____________________________ 
______________________________________________________________________________
______________________________________________________________________________ 
Comments:______________________________________________________________________________
________________________________________________________________________________________
________________________________________________________________________________________ 
Number of 4ml 
citrate cryovials 
  
Number of 4ml 
EDTA cryovials  
Number of 
1.8ml citrate 
cryovials  
Number of 
1.8ml EDTA 
cryovials 
Number of 
1.8ml Serum 
cryovials 
Number of 
Paxgene 
RNA tubes 
Number of 
10ml yellow 
top tubes 
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APPENDIX G 
RNA EXTRACTION 
Paxgene Blood RNA Kit Handbook Procedure 
1. Centrifuge the PAXgene Blood RNA Tube for 10 minutes at 3000–5000 x g using a swing-out 
rotor. 
2. Remove the supernatant by decanting or pipetting. Add 4 ml RNase-free water to the pellet, 
and close the tube using a fresh secondary Hemogard closure. If the supernatant is decanted, take 
care not to disturb the pellet, and dry the rim of the tube with a clean paper towel. 
3. Vortex until the pellet is visibly dissolved, and centrifuge for 10 minutes at 3000–5000 x g 
using a swing-out rotor. Remove and discard the entire supernatant. 
4. Add 350 μl Buffer BR1 and vortex until the pellet is visibly dissolved. 
5. Pipet the sample into a 1.5 ml microcentrifuge tube. Add 300 μl Buffer BR2 and 40 μl 
proteinase K. Mix by vortexing for 5 seconds, and incubate for 10 minutes at 55°C using a 
shaker–incubator at 400–1400 rpm.  
6. Pipet the lysate directly into a PAXgene Shredder spin column (lilac) placed in a 2 ml 
processing tube, and centrifuge for 3 minutes at maximum speed (but not to exceed 20,000 x g). 
7. Carefully transfer the entire supernatant of the flow-through fraction to a fresh 1.5 ml 
microcentrifuge tube without disturbing the pellet in the processing tube. 
8. Add 350 μl ethanol (96–100%, purity grade p.a.). Mix by vortexing, and centrifuge briefly (1–
2 seconds at 500–1000 x g) to remove drops from the inside of the tube lid. 
9. Pipet 700 μl sample into the PAXgene RNA spin column (red) placed in a 2 ml processing 
tube, and centrifuge for 1 minute at 8000–20,000 x g. Place the spin column in a new 2 ml 
processing tube, and discard the old processing tube containing flow-through. 
10. Pipet the remaining sample into the PAXgene RNA spin column, and centrifuge for 1 minute 
at 8000–20,000 x g. Place the spin column in a new 2 ml processing tube, and discard the old 
processing tube containing flow-through. 
11. Pipet 350 μl Buffer BR3 into the PAXgene RNA spin column. Centrifuge for 1 minute at 
8000–20,000 x g. Place the spin column in a new 2 ml processing tube, and discard the old 
processing tube containing flow-through. 
12. Add 10 μl DNase I stock solution to 70 μl Buffer RDD in a 1.5 ml microcentrifuge 
tube. Mix by gently flicking the tube, and centrifuge briefly to collect residual liquid from the 
sides of the tube. 
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13. Pipet the DNase I incubation mix (80 μl) directly onto the PAXgene RNA spin column 
membrane, and place on the benchtop (20–30°C) for 15 minutes. 
14. Pipet 350 μl Buffer BR3 into the PAXgene RNA spin column, and centrifuge for 1 minute at 
8000–20,000 x g. Place the spin column in a new 2 ml processing tube, and discard the old 
processing tube containing flow-through. 
15. Pipet 500 μl Buffer BR4 to the PAXgene RNA spin lumn, and centrifuge for 1 minute at 
8000–20,000 x g. Place the spin column in a new 2 ml processing tube, and discard the old 
processing tube containing flow-through. 
16. Add another 500 μl Buffer BR4 to the PAXgene RNA spin column. Centrifuge for 3 minutes 
at 8000–20,000 x g. 
17. Discard the tube containing the flow-through, e PAXgene RNA spin column in a 
new 2 ml processing tube. Centrifuge ,000 x g. 
18. Discard the tube containing the flow-through. Place the PAXgene RNA spin column in a 1.5 
ml microcentrifuge tube, and pipet 40 μl Buffer BR5 directly onto the PAXgene RNA spin 
column membrane. Centrifuge for 1 minute at 8000–20,000x g to elute the RNA. 
19. Repeat the elution step (step 18) as described, using 40 μl Buffer BR5 and the same 
microcentrifuge tube. 
g. After incubation, chill immediately on ice. 
ructions 
co
 and place th
 for 1 minute at 8000–20
20. Incubate the eluate for 5 minutes at 65°C in the shaker–incubator (from step 5) without 
shakin
21. If the RNA samples will not be used immediately, store at –20°C or –70°C. Since the RNA 
remains denatured after repeated freezing and thawing, it is not necessary to repeat the 
incubation at 65°C. If using the RNA samples in a diagnostic assay, follow the inst
supplied by the manufacturer. 
 
 
PreAnalytix Paxgene Blood RNA Kit Handbook (cat#762164)  
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APPENDIX H 
RNA AMPLIFICATION 
200 
 Illumina Total Prep RNA amplification kit (cat# IL1791) 
201 
APPENDIX I 
ARRAY HYBRIDIZATION 
 
 
Preparation 
1. Preheat the oven (with rocking platform) to 58°C. 
2. Prepare cRNA samples dried down, if necessary to achieve required concentration. 
3. Add RNase-free water to cRNA and mix: 
•For the 6-Sample chip, bring 1.5 μg of cRNA up to a total volume of 10 μl using RNase-free 
water and mix. 
•For the 8-Sample or 12-Sample chip, bring 750 ng up to a total volume of 5 μl using RNase-free 
water and mix. 
4. Leave at room temperature (~22°C) for 10 minutes to resuspend cRNA. 
5. Place the HYB and HCB tubes in the 58°C oven for 10 minutes to dissolve any salts that may 
have precipitated in storage. Inspect the solution; if any salts remain undissolved, incubate at 
58°C for another 10 minutes. After cooling to room temperature, mix thoroughly before using. 
6. Add HYB to each cRNA sample: 
•For the 6-Sample chip, add 20 μl HYB to each cRNA sample. 
•For the 8-Sample or 12-Sample chip, add 10 μl HYB to each cRNA sample. 
7. Place the Illumina Hyb Chamber gaskets into the BeadChip Hyb Chamber. 
8. Dispense 200 μl HCB into the humidifying buffer reservoirs. Only add buffer to reservoirs 
next to
9. Seal the Hyb Chamber with lid and keep on bench at room temperature until ready to load 
BeadChips into the Hyb Chamber. 
10. Remove all BeadChips from their packages. 
 loaded BeadChips. 
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11. Holding the BeadChip by the coverseal tab with tweezers or with powder-free gloved hands, 
slide the BeadChip into the Hyb Chamber insert so that the barcode lines up with barcode 
symbol on the insert. 
12. Preheat the assay sample at 65°C for 5 minutes. 
13. Briefly vortex, then briefly centrifuge to collect the liquid in the bottom of the tube. Allow 
sample to cool to room temperature before using. Pipette sample immediately after cooling to 
room temp. 
14. Load the Hyb Chamber inserts containing BeadChips into the Hyb Chamber. 
15. Dispense assay sample onto the large sample port of each array: 
•For the 6-Sample chip, add 30 μl. 
•For the 8-Sample or 12-Sample chip, add 15 
16. Seal lid onto the Hyb Chamb he Hyb Chamber insert(s). 
17. Incubate for 16-20 hours at 58°C with rocker speed at 5. 
 
Wash and Stain 
Prepare for High-Temp Wash & Overnight Incubation 
1. Prepare 1X High-Temp Wash buffer (add 50 ml 10X stock to 450 ml RNase-free water). 
2. Place waterbath insert into heat block, and add 500 ml prepared 1X High-Temp Wash buffer. 
3. Set heat block temp to 55°C and pre-warm High-Temp Wash buffer to that temperature. 
4. Close heat block lid and leave overnight. 
 
Next Day 
1. Make the Wash E1BC solution (add 6 ml E1BC buffer to 2 L RNase-free water). 
Pre-warm Block E1 buffer (4 ml/chip) to room temperature. 
2. Prepare Block E1 buffer (2 ml/chip) with streptavidin-Cy3 (2 μl of 1 mg/ml stock per chip). 
Use a single conical tube for all BeadChips. Store in dark until detection step. 
. 3140 beaker. 
l Removal 
ssing multiple chambers, remove them from the oven and process the BeadChips 
hamber from the oven, process all of its BeadChips, and so on until all chambers 
at 
ed during removal. 
eled BeadChip into the slide rack 
er using because it 
ll BeadChips from the same Hyb Chamber. 
μl. 
er carefully to avoid dislodging t
Place 1 L of diluted Wash E1BC buffer in a Pyrex No
 
Sea
1. Remove the Hyb Chamber from the oven and disassemble. 
If you are proce
one at a time. Process all BeadChips in the first chamber as described in steps 2–5 below, then 
remove second c
are processed. 
2. Using powder-free gloved hands, remove all BeadChips from the Hyb Chamber and submerge 
them face up at the bottom of the beaker. 
3. Using powder-free gloved hands, remove the coverseal from the first BeadChip. Ensure th
the entire BeadChip remains submerg
4. Using tweezers or powder-free gloved hands, transfer the pe
submerged in the staining dish containing 250 ml Wash E1BC solution. 
Do not empty the staining dish containing the 250 ml Wash E1BC solution aft
will be used again in the 1st Room-Temp Wash below. 
5. Repeat steps 3 and 4 for a
6. Use the slide rack handle to transfer the rack into the Hybex Waterbath insert containing High-
Temp Wash buffer. 
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High-Temp Wash 
Incubate static for 10 minutes with the Hybex lid closed. 
 
1st Room-Temp Wash 
s. 
 highest speed 
 Wash 
anol 
. Briefly agitate using rack handle, then shake on orbital shaker for 10 minutes. 
 
ash 
Block 
. Pipette 4 ml Block E1 buffer into the wash tray(s). 
2. Transfer the BeadChip, face up, into BeadChip wash tray(s) on rocker. 
. Place cover on tray and rock at medium speed for 10 minutes. 
 
per towels, and balance rack. Set speed to 275 relative 
 for 4 minutes. If processing only one 
alance. 
1. After the 10-minute High-Temp Wash buffer incubation is complete, immediately transfer the 
slide rack back into the staining dish containing the Wash E1BC used in step 4 of the Seal 
Removal step
2. Briefly agitate using rack, then shake on orbital shaker for 5 minutes at the
possible without allowing solution to splash out of dish. 
 
Ethanol
1. Transfer rack to a clean staining dish containing 250 ml 100% Ethanol (use fresh from Eth
source bottle). 
2
2nd Room-Temp W
1. Transfer rack to a clean staining dish containing fresh 250 ml Wash E1BC solution. 
2. Briefly agitate using rack handle, then shake on orbital shaker for 2 minutes. 
 
1
3. Rock at medium speed for 10 minutes. 
 
Detect 
1. Pipette 2 ml Block E1 buffer + streptavidin-Cy3 into fresh wash tray(s). 
2. Transfer the BeadChip, face up, into wash tray(s) on rocker. 
3
3rd Room-Temp Wash 
1. Add 250 ml of Wash E1BC solution to a clean staining dish. 
2. Transfer the BeadChip to the slide rack submerged in the staining dish. 
3. Briefly agitate using rack, and then shake at room temperature on orbital shaker for 5 minutes. 
 
Dry 
1. Prepare centrifuge with plateholders, pa
centrifugal force. 
2. Centrifuge the rack of BeadChips at room temperature
slide rack, redistribute the BeadChips between two racks, or counterbalance it with another rack 
loaded with an equal number of used BeadChips to maintain centrifuge b
3. Store dry chips in slide box until scanned. 
 
 
Illumina Whole-Genome Gene Expression Direct Hybridization Assay Experienced User Card 
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APPENDIX J 
CDNA SYNTHESIS 
cDNA synthesis Protocol 
 
• A total of 1ug of total RNA was the input for all samples, therefore the specific ul 
d on the starting ng/ul of each specific 
ined: 
imer and placed on ice 
2ul 
INAL VOLUME 10ul 
f 
entrfiguation. Incubate at 50°C for 50 minutes. 
 
of RNA added to the following reaction depende
sample. 
 
1. In a 0.5ml tube the following were comb
 
50 um Oligo DT 1ul 
RNA   xul 
10mMdNTP mix 1ul 
Rnase-free water xul 
 
FINAL VOLUME 10ul 
 
2. The samples were heated at 65°C for 5 minutes to denature RNA and pr
for at least 1 minute.  
 
3. Prepare cDNA synthesis Master Mix: vortex the 10x RT Buffer for 5 seconds. 
 
10x RT Buffer  
25mM MgCl2  4ul 
0.1 M DTT  2ul 
RNase OUT  1ul 
SuperScript III RT 1ul 
F
 
4. Add 10ul of master mix to each RNA/primer mixture; mix gently and collect by brie
c
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5. Terminate the reaction at 85°C for 5 minutes. Chill on ice. 
 
6. Store cDNA at -20°C or use immediately for PCR.  
 
TaqMan Gene Expression PCR Protocol 
 
1. In a 384 well PCR plate the following were combined for each target gene and housekeeping 
gene separately (to be run in triplicate): 
 
20X TaqMan Gene expression assay   1ul 
cDNA template + RNase-free water  
2x TaqMan Gene expression master m
FINAL VOLUME    20ul 
 
2. Centrifuge the plate briefly and load into the ABI 7900 HT.  
 
der the following conditions for a standard 384 well plate: 
Stage 
Hold  
Hold  
ycle  95  15 sec 
 
esis Systems for RT-PCR systems; Invitrogen (SKU 18080-051) 
9ul 
ix 10ul 
3. The reaction was run un
 
 Temp °C Time 
 50  2 min 
 95  10 min 
C
(40 cycles) 60  1 min 
Superscript III First Strand Synth
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APPENDIX K 
L C CAL DATA ELEMENTS CORIELL CONTRO LINI
207 
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APPENDIX L 
ILLUMINA CUSTOM ALGORITHM  
This model assumes that target signal intensity (l) is normally distributed among 
replicates of a biological condition (stroke patient or control subject). Variation stems from three 
components: sequence specific biological variation (σbio); nonspecific biological variation (σneg); 
and technical error (σtech).  
 
Equation 1. Variance 
 
I = N(μ,)σ 
σ = √ (σ2tech + σ2neg  + σ2bio) 
σtech = a + b < I >, 
 
Variation of nonspecific signal (σneg) is estimated from the signal intensity of negative 
control sequences using the median absolute deviation. For σtech, two sets of parameters (aref and 
bref) and (acond and bcond) are estimated for reference and condition groups respectively. σtech is 
then estimated using iterative robust least squares fit, which reduces the influence of highly 
variable genes, assuming the majority of genes do not have high biological variation amongst 
replicates. When this assumption does not hold, technical error is over-estimated by some 
averaged biological variation. 
 
 
 
When groups contain biological replicates, p-values are produced based on the following 
approach: 
 
Equation 2. P-value determination 
 
Sref  = (max(sref, aref + brefIref)) 
Scond = (max(scond, acond + bcondIcond))  
 
P= z { ⎢Icond - Iref  ⎢÷(√(S2ref + S2neg(ref)/Nref) + (S2cond + S2neg(cond)/Ncond)), 
 
*where Sref and Scond are standard deviations of probe signals from the reference and 
control group respectively; and Nref and Ncond denote the number of samples in each group.  
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It is considered that standard deviations exceeding σtech reflect biological variation. 
However it is assumed that estimates smaller than σtec  error. There the 
larger of the two estimates is used to regulate low abundance transcripts. Z is the two sided tail 
probability of the standard normal distribution.  
 
A diff score for all probes is then computed based on the p-value of significance: 
 
Equation 3. Diff Sc
 
  DiffScore = (10sgn(Icond-Iref)log10(p)) 
 
For each gene, diff scores of corresponding probes are averaged and concordance 
between the probes is reported.  
 p-value of 0.001, Diff Score = ±30  
h are caused by random
ore determination 
 
  For a p-value of 0.05, Diff Score = ±13 
  For a p-value of 0.01, Diff Score = ± 20 
  For a
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APPENDIX M 
T-TEST ANALYSIS IN GENESPRING 
T roach in GeneSpring is a traditional one-he t-test app way test to compare conditions 
defined by a single parameter on the Null Hypothesis of equal mean expression between two 
groups.  
 
  t = X1-X2 ÷ √(s21 +s22)/n) 
211 
APPENDI
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X N 
− 
PATHWAY LEGEND 
, red color – up-regulated 
− , green color – down-regulated   
  
          Edges in Pathway Nodes in Pathway 
 
 
APPENDIX O
BEAD STUDIO 1.5 FOLD, P<0.05 GENE LIST, 344 GENES 
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 TargetID Signal_Control Signal_Stroke DetectionPval_Control DetectionPval_Stroke Diff_Score
       
1 ABCA1 1596.4 2840 0 0 53.7854
2 ABHD5 983.9 1686.6 0 0 77.4183
3 ACOX1 339.3 515.3 0 0 119.5554
4 ACSL1 3986.8 7866.2 0 0 38.8788
5 ADA 1351.1 898.9 0 0 -37.4839
6 ADM 4615.7 7266.2 0 0 44.2196
7 AES 2909.1 1817.1 0 0 -37.3061
8 AGTPBP1 377.4 713.5 0 0 16.7387
9 ALDH1A1 466.6 849.3 0 0 36.2014
10 ANKRD22 365 634.2 0 0 17.5708
11 ANKRD33 836.1 1347.9 0 0 41.5799
12 ANTXR2 1661 2755.9 0 
393 748 0 
0 108.5084
13 ANXA3 0 26.1211
14 APOBEC3A 1506.9 2942.8 0 0 16.461
15 APRT 2497.4 1478.3 0 0 -105.035
16 AQP9 17286.2 25991.6 0 0 52.855
17 ARG1 370.7 1584.3 0 0 44.1284
18 ATP6V0E2L 3244.5 1894.4 0 0 -107.946
19 AXIN2 583.1 360.9 0 0 -50.6605
20 B3GNT5 259.2 402.1 0 0 23.6942
21 B4GALT5 2403.5 3922 0 0 64.3467
22 BANF1 3516.5 2176.9 0 0 -60.3227
23 BASP1 15501.3 23858.7 0 0 41.2831
24 BAZ2B 1714.6 3018.9 0 0 107.9458
25 BCL6 4435.5 7321.1 0 0 33.7781
26 BIN1 3591.6 2136.9 0 0 -94.3404
27 BIRC2 1934.3 3054.3 0 0 71.6924
28 BNIP3L 722.9 1465.2 0 0 25.6773
29 BPI 333.7 600.9 0 0 13.9413
30 C11ORF2 5923.1 3721.6 0 0 -49.4056
31 C12ORF57 5734.4 3578.7 0 0 -44.2676
32 C15ORF29 420 642.7 0 0 17.748
33 C16ORF30 852.4 496 0 0 -63.587
34 C17ORF49 2779.7 1791.9 0 0 -46.9947
35 C20ORF3 1573.8 2380.5 0 0 59.9599
36 C5AR1 2903.5 5151.8 0 0 97.4469
37 C6ORF48 4769.5 3169.3 0.0006 0 -16.0556
38 C9ORF142 2770.9 1728.5 0 0 -60.7955
39 C9ORF45 700.2 453.2 0 0 -59.0956
40 CA4 1214.9 2651.5 0 0 40.4265
41 CAMP 3760.2 7458.7 0 0 13.2241
42 CARD12 428.6 658.4 0 0 96.1255
43 CCPG1 883.1 1390.5 0 0 74.4016
44 CCR7 6923.4 3331.2 0 0 -71.3653
45 CD163 394 775.9 0 0 62.0098
46 CD19 927.8 583 0 0 -26.1922
47 CD2 6981.5 4071.7 0 0 -79.2269
48 CD247 15897.2 9923.7 0 0 -66.3071
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49 CD3D 11348.7 6155.6 0 0 -96.9847
50 CD55 2640.2 4253.1 0 0 55.3114
51 CD58 1398.3 2132.7 0 0 49.8504
52 CD6 4663.7 2440.1 0 0 -114.163
53 CD79A 1692.4 1054.6 0 0 -16.985
54 CD79B 3006.5 1677 0 0 -56.3897
55 CD81 13594.1 8818.9 0 0 -68.2672
56 CD8A 3247.8 1984.6 0 0 -20.2773
57 CD8B 491.6 306.5 0 0 -48.7896
58 CD96 2075.2 1278.2 0 0 -79.2264
59 CDC25B 3421.1 2201.2 0 0 -65.8457
60 CEACAM6 264 538.8 0 0 16.8023
61 CEACAM8 451.8 1080.7 0 0 15.9986
62 CKAP4 2220.2 4121.4 0 0 76.707
63 CLC 14875.7 8835.3 0 0 -20.739
64 CLEC4D 317.1 588.2 0 0 59.614
65 CLEC4E 373 635.7 0 0 30.896
66 CORO1C 909.5 1589.5 0 0 110.8775
67 CPD 1201.9 2264.6 0 0 85.3606
68 CREBBP 939 1501.1 0 0 69.0741
69 CRISPLD2 1962.2 3916.5 0 0 52.855
70 CSPG2 3272.3 6559.7 0 0 53.2479
71 CTNNA1 739.6 1126.1 0 0 74.061
72 CTNNAL1 251.9 380.8 0 0 25.758
73 CTSS 2698.2 4501.4 0 0 106.6598
74 CTSZ 1133.6 1929.1 0 0 96.6401
75 CUTA 2709.4 1724.7 0 0 -57.0073
76 CXCL16 2513.6 3934.4 0 0 51.761
77 CYBRD1 1078.6 1814.4 0 0 73.225
78 CYP1B1 762 1476.5 0 0 62.4409
79 D4S234E 1131.9 713.2 0 0 -24.4686
80 DAAM2 238 380.3 0 0 24.276
81 DEXI 1768.3 1152.3 0 0 -85.2882
82 DNAJA3 1998.9 1309.7 0 0 -82.8754
83 DOCK8 2120.2 3559.7 0 0 106.98
84 DPYD 737.9 1318.4 0 0 88.1617
85 DSC2 479.5 807.9 0 0 29.4951
86 DUSP1 9655.2 14748.7 0 0 38.111
87 DUSP6 1238.9 1870.9 0 0 13.3443
88 DYRK2 2626.8 1651.5 0 0 -42.4577
89 DYSF 2506.9 4556.9 0 0 39.1409
90 EBI2 1601.8 1052.7 0 0 -39.5908
91 ECHDC2 3016.5 1689.6 0 0 -115.751
92 ECHDC3 445.7 965 0 0 17.8497
93 EEF1G 23718.3 14296.5 0 0 -88.8905
94 EGFL5 364.8 578.9 0 0 57.6906
95 EIF2AK2 2428 4297.4 0 0 44.0172
96 EIF3S5 10976.3 6764.2 0 0 -90.1658
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97 EMR3 1401.9 2370.7 0 0 67.1934
98 EVL 8039.3 4602.8 0 0 -103.094
99 F13A1 893 1579.3 0 0 28.8585
100 F2RL1 776.3 1221.5 0 0 37.7668
101 F5 518.2 898.3 0 0 56.9211
102 FAIM3 6400.3 3525.7 0 0 -70.7354
103 FAM102A 983.9 642.4 0 0 -53.6603
104 FAM108A2 936.9 595 0 0 -37.9544
105 FAM113B 3898.5 2265.1 0 0 -66.6676
106 FAM63A 1871.5 2929.4 0 0 40.2719
107 FBL 4255.9 2709.3 0 0 -79.395
108 FCGR1A 574.5 1000.9 0 0 31.0612
109 FCGR1B 1023.1 1555.6 0 0 13.1141
110 FCGR3B 5082.3 9627.3 0 0 13.3409
111 FCHO2 398 624.9 0 0 34.6538
112 FCRLM1 1571.4 900.6 0 0 -33.6132
113 FECH 486.9 817.7 0 0 15.4236
114 FKBP5 1634.1 3278.4 0 0 15.106
115 FLJ10357 353.7 630.1 0 0 56.6357
116 FLJ11151 997.3 1699 0 0 17.743
117 FLJ11305 3582.6 2302.7 0 0 -69.0264
118 FLJ20273 1062.1 1998.8 0 0 42.81
119 FLJ42957 415.1 640.6 0 0 44.0067
120 FLT3LG 1048.6 620.8 0 0 -102.123
121 FNBP4 4132 2643.2 0 0 -78.6628
122 FOS 1160 1758 0 0 54.1648
123 FPRL1 2153.9 3368.9 0 0 38.7286
124 FTHL12 14086 23072.9 0 0 18.4383
125 GIMAP5 5407.8 3013.8 0 0 -62.8844
126 GIMAP6 1972.1 1262.4 0 0 -46.3559
127 GLTSCR2 34194.4 21457.6 0 0 -83.6438
128 GNLY 6803 4224.2 0 0 -13.0998
129 GOLGA8B 4199 2505.3 0 0 -48.3234
130 GPR160 485.7 782.7 0 0 50.432
131 GPR177 629.4 1062.6 0 0 38.1491
132 GPR18 1134.3 723 0 0 -81.9171
133 GPR97 490.2 811.1 0 0 49.6932
134 GRAP 2317.5 1264.7 0 0 -76.4163
135 GZMK 4894.3 2741.5 0 0 -28.9085
136 GZMM 1251 800.2 0 0 -43.7455
137 HAL 969.6 1709 0 0 85.2882
138 HDAC4 772.4 1213.1 0 0 33.8785
139 HECW2 309.8 532.5 0 0 60.3227
140 HIF1A 612.6 1064.5 0 0 33.2376
141 HIGD2A 5710.4 3583.5 0 0 -88.8903
142 HIP1 362.9 549.6 0 0 42.9591
143 HIST1H4C 23769.7 15121.7 0 0 -63.3885
144 HIST1H4H 546 954.5 0 0 30.4851
145 HIST2H2AA3 3583.8 5858.4 0 0 48.1938
146 HIST2H2AC 1969.6 2957.9 0 0 38.0212
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147 HIST2H2BE 818.2 1406.3 0 0 96.3813
148 HK2 637.2 1210.6 0 0 38.7445
149 HLA-DQB1 1017.2 575.3 0 0 -31.1697
150 HLX1 603.3 905.3 0 0 66.6871
151 HMFN0839 1024.7 1900.3 0 0 96.8593
152 HMGB2 2890.7 4898 0 0 17.1087
153 HMGCR 1040 1622.3 0 0 94.661
154 HP 294.8 517.8 0 0 28.5996
155 HPSE 419.6 629.5 0 0 41.7312
156 HSDL2 701.2 1173.9 0 0 97.8487
157 HSPA1A 4384.2 7383.1 0 0 35.0406
158 HSPA8 13024.6 8638.2 0 0 -68.4789
159 IBRDC2 1044.5 1585.9 0 0 39.1861
160 ICAM2 6620.8 4002.8 0 0 -98.447
161 ID3 1116.6 616.7 0 0 -114.411
162 IFIT2 6820.1 10666.7 0 0 17.2781
163 IGF2BP2 1302.6 2214.1 0 0 14.851
164 IGF2R 5478.4 9220 0 0 57.6982
165 IL17R 1160.3 1756.3 0 0 52.4376
166 IL18R1 724.9 1164.9 0 0 15.6523
167 IL18RAP 4561.4 7327.5 0 0 22.0562
168 IL2RB 3202.4 1996.3 0 0 -50.8265
169 IL32 2560.4 1507.4 0 0 -66.8553
170 IL7R 10745.1 5630.9 0 0 -61.53
171 IQGAP1 1467.3 2953.3 0 0 70.9521
172 IRAK3 920.9 1673.7 0 0 57.871
173 IRS2 785.8 1450.7 0 0 39.1066
174 ITGA2B 312.8 484.9 0 0 16.9578
175 ITGAM 1710.4 2741.5 0 0 83.6438
176 ITK 4025.1 2220.3 0 0 -107.35
177 ITPK1 895.9 1397.7 0 0 52.2192
178 ITPR3 2360.7 1377.1 0 0 -107.946
179 JMJD1C 1283.5 1949.3 0 0 61.7315
180 KBTBD7 840.7 1399.2 0 0 32.3664
181 KCNJ15 479.6 846.4 0 0 55.9495
182 KCTD12 302 626.3 0 0 14.9858
183 KIAA1147 1956 1293.7 0 0 -74.3197
184 KIAA1434 821.2 1265.6 0 0 70.4031
185 KIAA1600 1434.5 2213.3 0 0 85.3606
186 KIAA1754 2148.6 3229.7 0 0 72.6622
187 KIF1B 429.2 719.4 0 0 134.8221
188 KLF4 623.8 969.1 0 0 48.5948
189 KLHL2 625.2 1142.7 0 0 35.1923
190 KLHL3 773.8 506 0 0 -93.2913
191 KLRB1 10335.7 6144.6 0 0 -58.3631
192 KRT10 2130.6 1335.5 0 0 -92.2052
193 KRTCAP2 6660.4 4402.5 0 0 -58.6918
194 LAMP2 2857.5 4772.9 0 0 100.8472
195 LDHB 5693.6 3714.8 0 0 -21.177
196 LEF1 3410.8 1942.9 0 0 -49.9729
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197 LGALS2 523.4 810.4 0 0 35.1958
198 LHFPL2 480.3 791.4 0 0 78.5833
199 LIME1 7971 4688.5 0 0 -96.1255
200 LMNB1 672.5 1069.8 0 0 41.2334
201 LOC441268 702.7 1068.3 0 0 27.8489
202 LOC646200 21328.6 13931.3 0 0 -72.3671
203 LRRFIP1 5341.1 8046.9 0 0 42.0347
204 LRRK2 620.5 1040.7 0 0 55.6544
205 LTB 13867.7 8913.3 0 0 -79.4956
206 LY96 4606.7 9419.7 0 0 49.6941
207 MAFB 1225.7 1906.8 0 0 35.9358
208 MAL 5565.6 2795.5 0 0 -76.463
209 MANSC1 493.3 900.5 0 0 68.4597
210 MAP3K2 941.8 1538.1 0 0 46.1578
211 MARCKS 4264 7287 0 0 95.3097
212 MATK 1421.2 941.3 0 0 -28.8905
213 MCEMP1 2121.8 4143.4 0 0 37.0225
214 MEGF9 645.2 1119.2 0 0 26.0697
215 MFGE8 1284.4 782.3 0 0 -55.6268
216 MGC13057 826.5 1369.4 0 0 14.5403
217 MGC17330 5563.2 3353.6 0 0 -46.5673
218 MGC2463 1866.1 1124.1 0 0 -68.8701
219 MIR16 789.4 1186.7 0 0 45.9295
220 MLSTD1 698.6 1225.4 0 0 74.5372
221 MME 1063.9 1846.9 0.0029 0.0003 17.4911
222 MMP9 2334.7 7022.2 0 0 30.009
223 MOSC1 1165.7 2031.3 0 0 36.2001
224 MOSPD2 391.9 617 0 0 31.3968
225 MPO 310.1 553.7 0 0 13.9675
226 MT1X 2299.4 1408.7 0 0 -73.3436
227 MTMR6 891.6 1403 0 0 40.8722
228 NCR3 813 500.1 0 0 -79.2269
229 NDST1 360.2 574.2 0 0 43.7633
230 NDUFA12 3768.3 2469.1 0 0 -71.2322
231 NDUFB11 5369.7 3529.1 0 0 -73.6551
232 NDUFS8 3612.7 2357.5 0 0 -78.3684
233 NEDD9 510.8 799.3 0 0 16.7301
234 NELL2 1416.3 849.8 0 0 -32.1822
235 NFIL3 766.9 1320.7 0 0 73.6669
236 NKG7 19294 12128.1 0 0 -30.822
237 NOSIP 6710.5 4314.4 0 0 -67.0961
238 NOV 491.2 768.6 0 0 63.1656
239 NPL 2441 3666.3 0 0 71.4921
240 NT5C2 2768.2 4208.3 0 0 64.3988
241 OCIAD2 1885.7 1251.8 0 0 -38.0765
242 OLFM4 425.6 1127.1 0 0 18.9712
243 OLR1 271.6 497.2 0 0 15.0239
244 ORF1-FL49 1206.3 1878.3 0 0 34.8729
245 ORM1 812.1 2438.8 0 0 17.0037
246 OSBPL8 1013.1 1630.9 0 0 35.9259
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247 PADI4 6462.1 12128.8 0 0 49.8453
248 PARP9 545.9 890 0 0 28.6994
249 PASK 910.5 538.4 0 0 -38.3819
250 PDK4 470.8 990.6 0 0 102.7114
251 PGLYRP1 1745.5 3171 0 0 16.983
252 PIK3AP1 940.3 1540.1 0 0 15.0014
253 PLEK2 578.6 944.3 0 0 15.4851
254 PLEKHA1 2099.6 1335.4 0 0 -61.1927
255 PLXDC2 629.6 1086.2 0 0 338.2282
256 PLXNC1 586.6 936.1 0 0 60.3227
257 PPBP 1902.7 3165.6 0 0 17.4116
258 PPP3CA 455.4 734.8 0 0 19.0882
259 PPP4R1 1641.2 2608.9 0 0 72.7681
260 PRAM1 916.6 1375.2 0 0 62.1266
261 PREX1 707.8 1107.1 0 0 85.3606
262 PROS1 313.2 515.1 0 0 41.4417
263 PTGS2 1851.7 2780.3 0 0 35.9257
264 PTPRCAP 2542.9 1450 0 0 -69.1964
265 PYGL 2307.9 4096.7 0 0 52.1436
266 RAB33B 902.2 1577 0 0 17.8916
267 RBP7 916 1531.9 0 0 68.4154
268 REPS2 507.4 830.6 0.0001 0.0001 51.0499
269 RETN 369.6 574.4 0 0 19.4434
270 RGC32 5891.7 3739.1 0 0 -39.5908
271 RGS2 22350.1 39626.8 0 0 98.3674
272 RIS1 967.8 1799.6 0 0 14.4304
273 RNF13 821.9 1289 0 0 66.7021
274 RNF149 1579.5 2400.8 0 0 24.9521
275 ROCK1 340.6 518.7 0 0 43.1
276 RPAIN 3322.5 2203.9 0 0 -67.0894
277 RPL13A 10151.4 6327.3 0 0 -60.3227
278 RPL4 19401.7 12366.5 0 0 -55.5316
279 RPS15 31980.7 21230.3 0 0 -64.9007
280 RPS23 3607.2 2386.4 0 0 -24.5268
281 RPS4X 20532.1 11904.4 0 0 -74.1174
282 RRAGD 1150.7 1897.3 0 0 68.1093
283 RTN3 1351.9 2139 0.0005 0.0003 30.1272
284 S100A12 6684.7 14239.4 0 0 39.5291
285 SAP30 653.6 1212 0 0 45.9964
286 SCAP1 3748.7 2394 0 0 -65.8538
287 SDCBP 4662.2 7471.4 0 0 86.0235
288 SDPR 1465.8 3018.9 0 0 41.3317
289 SESN3 1633.8 2864.3 0 0 25.8016
290 SH3BGRL2 594.2 995 0 0 23.4456
291 SIGLEC5 702.7 1147.2 0 0 35.7806
292 SIPA1L2 681.4 1176.3 0 0 31.4506
293 SIRPB1 567.5 925.5 0 0 80.1607
294 SKAP2 957.6 1810.5 0 0 38.628
295 SLAMF1 798 528 0 0 -82.1932
296 SLAMF6 4813.4 3158 0 0 -61.0676
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297 SLC11A1 3749 6175.2 0 0 34.1734
298 SLC22A15 505.1 763.1 0 0 78.1126
299 SLC22A4 1038.7 1728.8 0 0 72.8324
300 SLC25A42 1936.6 1222.5 0 0 -96.1255
301 SLC2A14 354 596.4 0 0 47.5236
302 SLC40A1 1865.9 2809.2 0 0 54.6594
303 SNRPF 4816.2 2934.1 0 0 -91.2539
304 SNURF 1327 836.4 0 0 -50.3731
305 SNX10 1356.2 2439.3 0 0 39.1366
306 SORL1 5187.2 7819.4 0 0 42.7491
307 SPOCK2 8735.7 5218.6 0 0 -58.6718
308 SRP14 11153.5 7407.8 0 0 -68.3183
309 SRPK1 1652.4 2781.8 0 0 84.4405
310 STK3 404.8 666.5 0 0 338.2282
311 STX2 956.9 627.4 0 0 -58.259
312 SUSD3 1768.2 1089.3 0 0 -107.876
313 SVIL 847.1 1369.9 0.0003 0 116.0819
314 TAOK1 379.6 732.2 0 0 65.0848
315 TCEA3 741.2 479 0 0 -41.4719
316 TCN1 688.1 1321 0 0 24.71
317 TGM3 445.2 698.2 0 0 31.9939
318 THBS1 301.6 546 0 0 43.5021
319 TIMM22 1818.8 1201.9 0 0 -80.9857
320 TLN1 1151.5 1947.2 0 0 57.6894
321 TLR2 397.7 661.5 0 0 44.963
322 TLR4 921.7 1395.6 0 0 49.8996
323 TMEM55A 709 1193 0 0 93.9985
324 TNFRSF25 1118 677 0 0 -72.8108
325 TNFRSF4 873 569.8 0 0 -22.832
326 TNFRSF7 1157.9 752.2 0 0 -80.1097
327 TNFSF10 4761.3 7880 0 0 77.2802
328 TNFSF13B 4280.7 6759.5 0 0 66.6517
329 TPST1 390.6 793.6 0 0 26.8336
330 TRIB2 1175.3 779.9 0 0 -69.5436
331 TSC22D3 3196.7 4919.5 0.0004 0.0001 29.7609
332 TSPAN2 303.2 471.7 0 0 16.0218
333 VASP 507.9 832.3 0 0 42.3093
334 VMD2 844.5 1281.2 0 0 57.1551
335 VNN3 706.2 1251.9 0 0 81.1909
336 VPREB3 984.7 561.6 0 0 -30.3742
337 WBSCR18 1260.4 784.4 0 0 -85.3606
338 WSB1 1764.1 2739.6 0 0 43.397
339 XK 414.8 725 0 0 14.3033
340 YY1 1602.6 2565.9 0 0 14.3766
341 ZCCHC6 503.4 806.2 0 0 65.822
342 ZFP36L1 4514.4 7373.3 0 0 19.4089
343 ZNF337 1263.1 785.5 0 0 -103.544
344 ZNF537 493.3 743 0 0 74.3928
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APPENDIX P 
BEAD STUDIO 2 FOLD, P<0.05 GENE LIST, 19 GENES 
TargetID Signal_Control Signal_Stroke DetectionPval_Control DetectionPval_Stroke Diff_Score 
      
1 ARG1 370.7 1584.3 0 0 44.1284
2 BNIP3L 722.9 1465.2 0 0 25.6773
3 CA4 1214.9 2651.5 0 0 40.4265
4 CCR7 6923.4 3331.2 0 0 -71.3653
5 CEACAM6 264 538.8 0 0 16.8023
6 CEACAM8 451.8 1080.7 0 0 15.9986
7 CSPG2 3272.3 6559.7 0 0 53.2479
8 ECHDC3 445.7 965 0 0 17.8497
9 FKBP5 1634.1 3278.4 0 0 15.106
10 IQGAP1 1467.3 2953.3 0 0 70.9521
11 KCTD12 302 626.3 0 0 14.9858
12 LY96 4606.7 9419.7 0 0 49.6941
13 MMP9 2334.7 7022.2 0 0 30.009
14 OLFM4 425.6 1127.1 0 0 18.9712
15 ORM1 812.1 2438.8 0 0 17.0037
16 PDK4 470.8 990.6 0 0 102.7114
17 S100A12 6684.7 14239.4 0 0 39.5291
18 SDPR 1465.8 3018.9 0 0 41.3317
19 TPST1 390.6 793.6 0 0 26.8336
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APPENDIX Q 
GENE SPRING 1.5 FOLD, P<0.05, GENE LIST 355 GENES 
223 
Symbol 
Corrected p-
value 
Fold 
change in 
Stroke 
Regulation 
in Stroke Control_Norm_Intensity Stroke_Norm_intensity
      
1 ABCA1 8.96E-04 1.8123047 up -0.45283636 0.4049892
2 ABHD5 2.51E-05 1.7271396 up -0.4730409 0.31534383
3 ABTB1 0.001192165 1.5105206 up -0.43969214 0.15535371
4 ACOX1 1.72E-08 1.7499906 up -0.39899746 0.40834972
5 ACSL1 0.010596965 2.1238022 up -0.7834313 0.30321807
6 ACSL4 0.002242988 1.5745142 up -0.31663528 0.33827147
7 ACTN1 0.042329837 1.6357639 up -0.3341905 0.37577406
8 ADM 1.19E-04 1.7796249 up -0.5932397 0.23833346
9 AES 8.82E-04 1.618435 down 0.33804038 -0.35655907
10 AES 0.012148798 1.5252695 down 0.28743228 
0.027960693 2.1777713 up -0.44277832 
-0.32163197
11 AKAP7 0.68007416
12 ALOX5 0.005035329 1.5656404 up -0.35596168 0.2907913
13 ALPK1 0.004968409 1.5049171 up -0.32445824 0.26522574
14 ANKRD13 9.21E-07 1.538632 up -0.34640583 0.27524242
15 ANKRD22 0.024183083 1.6826864 up -0.36122015 0.38954622
16 ANKRD33 0.0343414 1.5372375 up -0.29694462 0.32339543
17 ANTXR2 1.41E-11 1.7635393 up -0.49011627 0.32835746
18 APAF1 8.24E-05 1.5452136 up -0.33461007 0.2931962
19 APRT 9.48E-07 1.6393174 down 0.48864126 -0.224454
20 APRT 1.46E-06 1.5625386 down 0.38686624 -0.25702557
21 AQP9 1.76E-04 1.6632756 up -0.49637404 0.23765317
22 ARG1 7.46E-06 3.1748993 up -0.62863874 1.0380721
23 ARHGAP9 5.86E-07 1.5350637 up -0.41039085 0.20790768
24 ARID3A 0.008217917 1.5044478 up -0.25097618 0.33825788
25 ARPC5 0.031313017 1.5089691 up -0.4154583 0.17810494
26 ATP6V0E2L 2.03E-04 1.6451572 down 0.28906953 -0.42915595
27 ATP6V1A 1.17E-06 1.5905582 up -0.4467425 0.22279061
28 ATP6V1B2 7.05E-05 1.503222 up -0.32041124 0.26764688
29 ATP8B2 1.40E-06 1.5161607 down 0.32480156 -0.27562112
30 AXIN2 2.35E-04 1.5935856 down 0.41863 -0.25364652
31 B4GALT5 5.62E-05 1.7408099 up -0.3609185 0.43884018
32 BANF1 0.001854022 1.5270411 down 0.35846767 -0.25227118
33 BASP1 0.001656124 1.692908 up -0.40485874 0.35464483
34 BAZ1A 3.32E-06 1.624906 up -0.3937578 0.3065984
35 BAZ2B 1.04E-07 1.8645284 up -0.49394333 0.40486747
36 BCAS4 3.53E-04 1.522654 down 0.31792894 -0.2886593
37 BCAS4 0.002069403 1.625156 down 0.34984484 -0.35073334
38 BCL11B 6.72E-04 1.6628457 down 0.44529155 -0.28836277
39 BCL6 2.38E-04 1.8440986 up -0.48973742 0.39317834
40 BIN1 1.62E-04 1.5449402 down 0.37067512 -0.25687593
41 BIN1 6.68E-06 1.6605223 down 0.37887493 -0.35276216
42 BIRC2 3.82E-06 1.6563947 up -0.38282505 0.3452215
43 BLR1 0.022906728 1.6622154 down 0.40923765 -0.3238697
44 C16orf30 3.22E-05 1.6956762 down 0.51157886 -0.25028187
45 C20orf3 9.49E-05 1.586716 up -0.31725883 0.3487852
46 C5AR1 2.64E-08 1.9257851 up -0.48803505 0.45741165
47 C9orf142 0.002057869 1.5200473 down 0.37669584 -0.22742042
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48 C9orf45 6.71E-04 1.5882019 down 0.39246467 -0.27492967
49 CA4 0.005262172 2.1216044 up -0.54479116 0.5403645
50 CARD12 2.59E-06 1.5208824 up -0.4216908 0.18321778
51 CCPG1 1.05E-06 1.6663233 up -0.4289535 0.30771482
52 CCR7 0.001150122 2.0941548 down 0.40388396 -0.66248417
53 CD163 1.94E-06 1.977347 up -0.44644794 0.5371181
54 CD163 2.83E-04 1.5054584 up -0.260286 0.32991675
55 CD19 0.025516115 1.6571147 down 0.47358933 -0.25508416
56 CD2 5.24E-04 1.6109037 down 0.39074025 -0.29713
57 CD247 0.01357406 1.5364294 down 0.14497347 -0.47460806
58 CD3D 8.57E-05 1.7770516 down 0.3560257 -0.47345987
59 CD3D 0.001207411 1.6545517 down 0.40761673 -0.3188237
60 CD55 2.31E-04 1.7383883 up -0.42369995 0.3740504
61 CD58 6.86E-04 1.5795712 up -0.38774312 0.27178988
62 CD6 8.63E-06 1.8855989 down 0.4859031 -0.4291197
63 CD79A 0.03709512 1.6709588 down 0.57601184 -0.16466431
64 CD79B 0.003114411 1.7321764 down 0.49508777 -0.2974981
65 CD79B 8.90E-04 1.6874268 down 0.5566309 -0.198194
66 CD79B 9.41E-06 1.9654621 down 0.6683068 -0.30656168
67 CD8B 0.001805257 1.5227647 down 0.43020198 -0.176491
68 CD96 3.64E-06 1.6501937 down 0.45680213 -0.26583323
69 CD96 0.015361225 1.5224718 down 0.24109836 -0.36531714
70 CD97 7.91E-04 1.5206416 up -0.2835666 0.32111362
71 CDC25B 0.002287968 1.5018301 down 0.37478307 -0.21193856
72 CDC42 0.01226788 1.6299903 up -0.43720877 0.26765466
73 CEACAM1 0.008439163 1.5251158 up -0.24410792 0.3648109
74 CEBPD 3.88E-04 1.642421 up -0.45097446 0.2648495
75 CENTD3 0.010357025 1.5383601 up -0.31860456 0.30278873
76 CKAP4 9.24E-07 1.9349477 up -0.457984 0.49431062
77 CLEC2D 3.21E-04 1.5738429 down 0.40625414 -0.24803734
78 CLEC4D 1.77E-04 1.6824795 up -0.33771107 0.4128778
79 CLEC4E 0.008569909 1.5838113 up -0.39539754 0.26800284
80 CORO1C 2.92E-07 1.7304131 up -0.47520924 0.31590727
81 CPD 1.12E-06 1.8952067 up -0.48466924 0.43768594
82 CREB5 0.006681411 1.5786003 up -0.46433613 0.19430982
83 CREBBP 1.55E-09 1.7318016 up -0.4753668 0.31690684
84 CRISPLD2 1.25E-04 2.0627022 up -0.562452 0.48208353
85 CSPG2 9.08E-04 2.0874317 up -0.52938193 0.53234696
86 CTBS 1.10E-04 1.5915315 up -0.37712824 0.29328746
87 CTNNA1 4.94E-05 1.5275059 up -0.4146488 0.1965292
88 CTSS 8.76E-11 1.8215016 up -0.53922606 0.3259022
89 CTSZ 5.66E-07 1.7908455 up -0.54706603 0.29357484
90 CUTA 1.66E-06 1.5084157 down 0.4256169 -0.16741714
91 CXCL16 6.42E-04 1.6656028 up -0.36483136 0.37121302
92 CYBRD1 6.43E-06 1.698955 up -0.454548 0.31009966
93 CYP1B1 3.36E-04 1.8498029 up -0.47369754 0.41367403
94 DOCK8 4.54E-09 1.8103185 up -0.5535638 0.3026797
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95 DPYD 9.35E-06 1.7590023 up -0.40481353 0.40994382
96 DSC2 0.013481921 1.7159183 up -0.36346447 0.41551638
97 DUSP1 3.80E-04 1.682358 up -0.3743663 0.37611845
98 DYRK2 0.002165404 1.5440761 down 0.27149758 -0.3552462
99 DYSF 0.001368416 1.8924569 up -0.35435605 0.5659044
100 E2F3 4.42E-04 1.5338274 up -0.36689016 0.25024593
101 EBI2 0.02487179 1.5259324 down 0.3679166 -0.24177445
102 ECHDC2 4.46E-05 1.716245 down 0.33941677 -0.4398388
103 EEF1G 0.001656069 1.5083916 down 0.2436264 -0.34938464
104 EIF2AK2 4.74E-04 1.8460835 up -0.35851967 0.52594817
105 ELOVL5 0.001900409 1.6279141 up -0.39230406 0.31072047
106 EMR3 0.004741052 1.7467172 up -0.533542 0.27110407
107 EMR3 7.42E-04 1.6231146 up -0.4570636 0.24170125
108 ERGIC1 5.13E-05 1.7122784 up -0.41896558 0.35695165
109 ETS2 4.67E-05 1.5149037 up -0.37972677 0.21949929
110 EVL 3.34E-05 1.6366651 down 0.23423262 -0.4765265
111 F13A1 0.009173424 1.6828539 up -0.36125728 0.3896526
112 F5 8.70E-04 1.6404358 up -0.31013 0.4039491
113 FAIM3 2.21E-04 1.753313 down 0.49295402 -0.31712955
114 FAM102A 6.35E-05 1.5720942 down 0.39831316 -0.2543745
115 FAM108A2 5.86E-04 1.6873633 down 0.3757974 -0.37897322
116 FAM113B 8.18E-04 1.6465008 down 0.41296184 -0.30644146
117 FAM63A 4.44E-04 1.7099757 up -0.5002774 0.27369848
118 FCGR1A 0.004699358 1.6864612 up -0.3136489 0.44035026
119 FCGR2A 0.02978616 1.5598056 up -0.3418266 0.29953963
120 FCRLM1 0.019254506 1.7570693 down 0.53679 -0.2763811
121 FGL2 6.61E-08 1.6761547 up -0.5055029 0.23965244
122 FLJ10357 0.004686741 1.6282496 up -0.34833077 0.3549911
123 FLJ20273 0.017583247 1.8363116 up -0.57000357 0.30680737
124 FLJ22662 1.40E-04 1.6477797 up -0.45327643 0.2672469
125 FLT3LG 6.61E-07 1.6907467 down 0.4784862 -0.27917433
126 FOLR3 0.024284562 2.118018 up -0.6204037 0.46231112
127 FOS 6.16E-04 1.5530001 up -0.3837123 0.25134563
128 FPRL1 4.32E-04 1.7971767 up -0.58970034 0.25603193
129 G6PD 2.31E-05 1.6428543 up -0.40454507 0.31165946
130 
GALNAC4S-
6ST 0.01168357 1.5734186 up -0.39839706 0.25550553
131 GCA 2.69E-05 1.6104963 up -0.4180822 0.26942316
132 GIMAP5 6.17E-05 1.6169097 down 0.42828014 -0.264959
133 GIMAP6 7.11E-05 1.5072603 down 0.3661282 -0.22580044
134 GLTSCR2 2.93E-06 1.5102428 down 0.35104704 -0.24373353
135 GNS 0.001315591 1.5672792 up -0.29288337 0.3553789
136 GOLGA8B 0.019092575 1.5502025 down 0.3525721 -0.27988455
137 GPR160 0.007821544 1.5169402 up -0.28531924 0.31584504
138 GPR18 7.06E-05 1.5627205 down 0.4083766 -0.23568314
139 GPR30 0.028008992 1.5636444 up -0.3322477 0.3126648
140 GPR97 0.001374495 1.5649818 up -0.3129496 0.3331963
141 GRAP 5.82E-06 1.8223768 down 0.42434028 -0.44148108
142 GRN 3.09E-04 1.664943 up -0.44770584 0.28776696
143 GZMM 0.00463308 1.5544308 down 0.44149742 -0.19488896
144 HAL 2.61E-06 1.7816619 up -0.6127035 0.22052002
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145 HECW2 8.44E-04 1.5826768 up -0.27963033 0.38273627
146 HIST1H4H 0.025849922 1.6558021 up -0.3873155 0.3402147
147 HIST2H2AA3 0.001009389 1.7219576 up -0.35815826 0.4258914
148 HIST2H2AC 0.008723038 1.5482497 up -0.25483742 0.37580085
149 HIST2H2BE 1.52E-06 1.7038007 up -0.43292883 0.33582774
150 HK2 0.03578569 1.811657 up -0.37718323 0.48012656
151 HK3 0.03889349 1.5000247 up -0.35806254 0.22692375
152 HMFN0839 7.93E-07 1.8398898 up -0.4553827 0.42423669
153 HMGCR 1.74E-08 1.5929891 up -0.43603715 0.23569927
154 HSDL2 1.26E-06 1.6443654 up -0.457348 0.260183
155 HSPA1A 0.019009802 1.8337098 up -0.49020323 0.38456213
156 IBRDC2 0.006122901 1.5297966 up -0.3149556 0.2983843
157 ICOS 3.24E-04 1.5032278 down 0.32166818 -0.26639554
158 ID3 1.62E-07 1.8190107 down 0.46612728 -0.3970268
159 IFRD1 0.027392516 1.5545528 up -0.4628234 0.17367627
160 IGF2R 1.66E-04 1.8231611 up -0.39209458 0.47434753
161 IL17R 2.01E-04 1.5576218 up -0.25372782 0.3856172
162 IL1R2 0.024156215 1.9028513 up -0.49603036 0.43213242
163 IL2RB 0.0216144 1.5622303 down 0.28538325 -0.35822386
164 IL32 2.87E-04 1.6781938 down 0.523773 -0.22313634
165 IL32 0.003380901 1.5434707 down 0.29242566 -0.33375248
166 IL7R 6.93E-04 1.79816 down 0.39379862 -0.45272276
167 IQGAP1 2.10E-05 2.0312161 up -0.6165189 0.4058248
168 IRAK3 5.62E-04 1.7741777 up -0.4731234 0.35402712
169 IRS2 0.001384218 1.7316405 up -0.33676544 0.455374
170 ITGAM 1.18E-05 1.6832777 up -0.376963 0.37431028
171 ITK 1.57E-05 1.744029 down 0.51855147 -0.2838726
172 ITPK1 4.00E-04 1.5347396 up -0.28709295 0.33090094
173 ITPR3 1.54E-04 1.6576486 down 0.37658942 -0.35254872
174 JMJD1C 1.55E-05 1.670232 up -0.47736505 0.26268348
175 KCNJ15 7.00E-06 1.9459618 up -0.4480821 0.51240134
176 KCNJ15 3.74E-04 1.5781107 up -0.39775145 0.26044694
177 KIAA0319L 0.001731742 1.5387497 up -0.3019117 0.3198469
178 KIAA1434 9.65E-05 1.5216612 up -0.3586335 0.24701358
179 KIAA1600 4.60E-07 1.6111467 up -0.4475591 0.24052879
180 KIAA1754 8.76E-06 1.6043354 up -0.4228462 0.25912964
181 KIF1B 2.43E-09 1.8922873 up -0.5140801 0.40605095
182 KLHL3 2.75E-06 1.5122335 down 0.31773272 -0.27894816
183 KYNU 0.003430352 1.5191779 up -0.3092837 0.29400706
184 LAMP2 1.12E-12 1.9813491 up -0.6557247 0.33075836
185 LAMP2 9.83E-08 1.7617275 up -0.55963165 0.25735906
186 LAMP2 3.04E-05 1.6477886 up -0.5334689 0.18706226
187 LEF1 0.005539591 1.6863836 down 0.3746798 -0.37925288
188 LENG4 2.56E-04 1.5949947 up -0.38667235 0.2868792
189 LHFPL2 1.55E-06 1.6218902 up -0.40214118 0.29553494
190 LILRB2 6.76E-05 1.5454783 up -0.42800203 0.20005141
191 LILRB3 0.004217023 1.5993952 up -0.3658454 0.311681
192 LIME1 3.67E-04 1.5787994 down 0.22906034 -0.42976752
193 LMNB1 0.011581204 1.5341495 up -0.29421118 0.3232279
194 LOC90925 0.04949146 1.5222939 down 0.5025979 -0.10364902
227 
195 LRP10 0.015376614 1.5328355 up -0.32945156 0.28675127
196 LRRFIP1 3.33E-05 1.6990031 up -0.46420875 0.30047974
197 LRRK2 5.82E-05 1.7916175 up -0.42061105 0.42065164
198 LTB 4.17E-05 1.6349725 down 0.44332907 -0.2659372
199 LY9 1.70E-05 1.640391 down 0.4601098 -0.25392994
200 LY96 0.033536546 2.15995 up -0.7933622 0.3176357
201 MAFB 0.003815692 1.5573182 up -0.31047216 0.3285916
202 MAL 9.73E-04 1.9025011 down 0.45145655 -0.47644073
203 MAL 1.49E-05 1.816752 down 0.45890352 -0.402458
204 MANSC1 0.001718018 1.6770176 up -0.42764106 0.31825674
205 MAP3K2 0.001394401 1.6754934 up -0.4422439 0.3023421
206 MARCKS 1.42E-08 1.886556 up -0.53175384 0.38400105
207 MAX 0.004743695 1.5399661 up -0.28441906 0.33847952
208 MCEMP1 0.029402638 1.9077737 up -0.219588 0.7123021
209 MCL1 7.70E-04 1.539178 up -0.44949344 0.17266665
210 MFGE8 0.00110316 1.6206914 down 0.412401 -0.28420842
211 MFSD1 4.50E-07 1.5461406 up -0.39453056 0.23414093
212 MGAM 0.001307882 1.6493242 up -0.2990539 0.42282104
213 MGC17330 0.018769413 1.5535309 down 0.29595855 -0.3395924
214 MGC2463 2.35E-04 1.6216009 down 0.5048474 -0.1925714
215 MLSTD1 9.44E-06 1.6862478 up -0.3698455 0.38397112
216 MME 5.07E-04 1.9353366 up -0.47561494 0.4769696
217 MMP9 2.93E-04 2.6441047 up -0.63609403 0.7666853
218 MOSC1 0.00227161 1.7277516 up -0.49102435 0.2978715
219 MSL3L1 0.025648326 1.5070935 up -0.31500092 0.2767681
220 MT1X 2.38E-04 1.5549619 down 0.41850176 -0.21837743
221 MTMR3 1.77E-06 1.6137481 up -0.35766384 0.33275157
222 MTPN 1.08E-09 1.5344805 up -0.4420948 0.17565541
223 MXD1 7.09E-05 1.6072506 up -0.4908303 0.19376458
224 MYADM 0.002521299 1.6312991 up -0.36531603 0.34070525
225 MYH9 2.17E-05 1.6730189 up -0.4239423 0.31851146
226 NALP12 1.79E-05 1.6381502 up -0.47598743 0.23608024
227 NCF2 0.020657025 1.614869 up -0.4883368 0.20308037
228 NCOA1 1.51E-05 1.5352702 up -0.31525442 0.30323818
229 NCR3 3.25E-06 1.5855395 down 0.48847985 -0.17649396
230 NDEL1 2.51E-05 1.5662156 up -0.4093908 0.23789208
231 NDST1 0.009242461 1.5071554 up -0.37224576 0.21958244
232 NEDD9 0.037254654 1.8163608 up -0.72076803 0.14028278
233 NELL2 0.009759055 1.7378407 down 0.49079415 -0.30650166
234 NFIL3 1.15E-04 1.6974876 up -0.5051343 0.25826675
235 NPL 8.49E-07 1.633246 up -0.46844235 0.23929977
236 NT5C2 3.09E-06 1.6819997 up -0.5887868 0.16139057
237 NT5C3 3.37E-04 1.5968759 up -0.39640757 0.27884462
238 NUMB 1.22E-08 1.6520604 up -0.42498946 0.299277
239 OCIAD2 0.002119827 1.5631819 down 0.29741773 -0.3470679
240 ORF1-FL49 0.019740919 1.5727817 up -0.34972474 0.30359367
241 OSBPL8 0.011188532 1.5013292 up -0.17578995 0.4104503
242 OSCAR 6.12E-06 1.5227277 up -0.33202776 0.27463028
243 PACSIN2 1.08E-04 1.5298753 up -0.3423233 0.27109072
244 PADI4 1.24E-04 2.0203402 up -0.6873165 0.3272818
228 
245 PAK2 1.63E-07 1.5011356 up -0.30425522 0.28179914
246 PARP9 0.04576779 1.6042404 up -0.33633992 0.34555042
247 PASK 0.001573324 1.6221251 down 0.54210055 -0.15578456
248 PBEF1 0.004247805 1.6449306 up -0.4714088 0.24661796
249 PCNX 0.014886572 1.5285668 up -0.3545656 0.25761405
250 PDE5A 0.018205058 1.5289818 up -0.37917784 0.23339343
251 PDK4 2.48E-07 1.9925152 up -0.49069417 0.5038966
252 PDLIM7 0.008335682 1.5847545 up -0.36441982 0.2998395
253 PHC2 0.02985304 1.5579419 up -0.32678905 0.31285232
254 PICALM 4.43E-10 1.6524075 up -0.49607673 0.22849278
255 PJA2 2.07E-06 1.638601 up -0.39961645 0.31284806
256 PLEKHA1 3.65E-04 1.572546 down 0.33863863 -0.31446368
257 PLXDC2 1.17E-10 1.7024015 up -0.44182992 0.32574144
258 PLXNC1 0.003308967 1.5152813 up -0.246924 0.35266173
259 PPP3R1 4.84E-05 1.6244959 up -0.3795699 0.32042217
260 PPP4R1 1.27E-06 1.8080214 up -0.56513435 0.28927743
261 PRAM1 4.55E-05 1.5166794 up -0.3346273 0.2662889
262 PREX1 1.03E-05 1.5301241 up -0.34114835 0.27250025
263 PRIC285 0.038515233 1.5011227 up -0.2618407 0.32420126
264 PTGS2 0.016307665 1.5577009 up -0.2766855 0.36273268
265 PTPRCAP 2.32E-04 1.7066637 down 0.52009594 -0.25108287
266 PYGL 2.32E-04 1.9196414 up -0.6383079 0.30252883
267 RAB11FIP1 7.78E-04 1.5217462 up -0.28387347 0.3218542
268 RAB27A 1.06E-07 1.5071427 up -0.35081485 0.2410011
269 RAB31 8.00E-05 1.5792797 up -0.4238473 0.23541942
270 RAI17 2.32E-06 1.5056869 up -0.33112147 0.2593003
271 RASSF2 2.00E-06 1.6398529 up -0.3305169 0.3830495
272 RASSF2 4.06E-07 1.5429187 up -0.39883316 0.22682887
273 RBP7 2.14E-05 1.6992726 up -0.4763657 0.28855166
274 REPS2 4.50E-04 1.8212063 up -0.493821 0.3710734
275 RGS2 2.87E-10 1.9746453 up -0.66856736 0.3130261
276 RNF13 1.32E-06 1.6937143 up -0.443818 0.3163725
277 ROD1 6.08E-04 1.6012528 up -0.5105467 0.1686544
278 RPL3 1.48E-04 1.5848476 down 0.33151624 -0.3328278
279 RPS4X 0.002112172 1.5540142 down 0.32695517 -0.3090445
280 RRAGD 7.12E-05 1.6515806 up -0.35344505 0.37040228
281 RTN3 6.86E-06 1.6639026 up -0.34274092 0.39183012
282 S100A12 0.010172865 2.3543987 up -0.93866426 0.29669446
283 SAP30 0.008034376 1.6950442 up -0.26140532 0.49991754
284 SART2 2.98E-04 1.5520507 up -0.37208435 0.26209128
285 SDCBP 8.01E-07 1.7689717 up -0.4568527 0.36605826
286 SERPINA1 5.01E-04 1.5274287 up -0.22692633 0.38417876
287 SERPINA1 5.46E-05 1.6768464 up -0.43405333 0.31169724
288 SH3GLB1 0.002829893 1.5190563 up -0.39959073 0.20358467
289 SIRPB1 2.89E-05 1.5733961 up -0.3352778 0.31860414
290 SIRPG 8.19E-05 1.5064514 down 0.35418966 -0.23696446
291 SKAP2 0.007368376 1.8684648 up -0.61319184 0.28866163
292 SLA 0.001085509 1.646025 up -0.44141772 0.2775685
293 SLAMF1 2.09E-05 1.50217 down 0.35049072 -0.23655732
294 SLC16A3 5.51E-04 1.5039946 up -0.30064014 0.28815922
229 
295 SLC22A4 6.54E-06 1.7355455 up -0.5452797 0.25010952
296 SLC25A42 2.35E-06 1.5265827 down 0.41294122 -0.19736457
297 SLC2A14 0.036492433 1.5166202 up -0.23506396 0.3657958
298 SLC2A3 8.77E-06 1.6691002 up -0.33857092 0.40049958
299 SLC40A1 0.001077361 1.5836873 up -0.39218852 0.27109903
300 SNRK 4.17E-05 1.535039 up -0.38939023 0.22888504
301 SNRPF 5.71E-04 1.5414165 down 0.28002155 -0.34423518
302 SNRPN 1.98E-04 1.5017962 down 0.39556482 -0.1911243
303 SNURF 1.01E-05 1.648245 down 0.5175985 -0.20333214
304 SNX10 0.04400697 1.7789679 up -0.5271935 0.30384696
305 SORL1 0.001287614 1.6717653 up -0.37337554 0.36799684
306 SP100 4.03E-05 1.5320935 up -0.32607222 0.2894322
307 SPAG9 3.72E-07 1.5381135 up -0.36690667 0.25425524
308 SPOCK2 0.01628029 1.519338 down 0.30433238 -0.29911047
309 SRPK1 4.29E-06 1.7410624 up -0.45548466 0.34448323
310 ST8SIA4 8.36E-10 1.7178135 up -0.50841254 0.2721608
311 STAG2 2.95E-04 1.516143 up -0.42515066 0.17525512
312 STK3 2.28E-09 1.5741026 up -0.37065306 0.28387648
313 STOM 1.36E-04 1.6047417 up -0.46994388 0.21239723
314 STX11 0.003483108 1.5377244 up -0.3606926 0.26010433
315 STX2 3.72E-06 1.6198126 down 0.43591103 -0.25991583
316 SUSD3 2.54E-07 1.5676636 down 0.42616597 -0.22245002
317 SVIL 2.91E-09 1.8678638 up -0.37932047 0.52206874
318 TAOK1 0.002065993 1.6937113 up -0.27258304 0.48760498
319 TCEA3 4.77E-04 1.511375 down 0.39037618 -0.20548546
320 THOC3 9.19E-04 1.5055869 down 0.4264152 -0.16391076
321 TLE4 8.61E-08 1.5549959 up -0.40907827 0.22783256
322 TLN1 2.48E-05 1.7057545 up -0.29009762 0.4803124
323 TLR2 0.002389603 1.5521672 up -0.27070537 0.36357853
324 TLR4 0.001042742 1.5305343 up -0.28821686 0.32581848
325 TLR8 0.003152421 1.5388085 up -0.35743284 0.26438078
326 TLR8 4.04E-05 1.6914089 up -0.48619732 0.2720281
327 TM9SF2 1.58E-06 1.6009583 up -0.45154515 0.22739068
328 TMEM49 4.25E-04 1.5581822 up -0.4439707 0.19589333
329 TMEM55A 8.74E-06 1.6568463 up -0.48433432 0.24410544
330 TMEM91 0.006200825 1.5575422 up -0.43001485 0.20925644
331 TNFRSF25 1.10E-04 1.7684107 down 0.48251605 -0.33993736
332 TNFRSF7 1.09E-04 1.5374962 down 0.37414774 -0.24643512
333 TNFSF10 2.31E-07 1.8427252 up -0.50972724 0.37211373
334 TNFSF13B 5.04E-08 1.7849591 up -0.6033955 0.2324955
335 TRAF5 4.21E-04 1.5331247 down 0.3040305 -0.31244445
336 TRIB1 0.001714893 1.5124131 up -0.33436236 0.26248994
337 TRIB2 7.96E-04 1.5173746 down 0.3352317 -0.26634556
338 TSC22D3 7.15E-05 1.6924903 up -0.41409767 0.34505
339 TSC22D3 2.15E-09 1.8774674 up -0.5252797 0.38350818
340 TSEN34 1.60E-06 1.6337733 up -0.4572495 0.25095838
341 TXNDC13 0.005317458 1.5814332 up -0.41053784 0.25069478
342 VASP 2.68E-05 1.7724652 up -0.4458139 0.37994343
343 VCL 6.95E-05 1.5214889 up -0.36566982 0.23981395
344 VEGFB 4.56E-06 1.6234121 down 0.40394688 -0.29508245
230 
345 VMD2 0.001219483 1.5103511 up -0.30331692 0.29156697
346 VNN2 1.45E-08 1.7898074 up -0.55726606 0.28253838
347 VNN2 0.04293769 1.5314873 up -0.5372459 0.07768749
348 VNN3 2.23E-06 1.6555603 up -0.44342068 0.28389886
349 VNN3 1.29E-06 1.9406601 up -0.5721719 0.38437554
350 VPREB3 0.004627587 1.9301076 down 0.6043759 -0.34430534
351 WBSCR18 3.12E-05 1.6152911 down 0.3094127 -0.38238144
352 WSB1 3.73E-05 1.622479 up -0.4006877 0.29751208
353 ZAP70 6.08E-05 1.5332873 down 0.36498556 -0.25164247
354 ZCCHC6 6.02E-05 1.5224382 up -0.2387861 0.36759755
355 ZNF337 6.54E-07 1.5926328 down 0.40538433 -0.2660293
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APPENDIX R 
GENE SPRING 2 FOLD, P<0.05, GENE LIST 16 GENES 
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86387 1.0380721
5 CA4 2.00E-04 2.1216044 up -0 95044 0.5403645
6 CCR7 4.37E-05 2.0941548 down 0.4 88396 -0.6624842
7 CRISPLD2 4.74E-06 2.0627022 up - 62452 0.48208353
8 CSPG2 3.45E-05 2.0874317 up -0 93819 0.53234696
9 FCGR3B 0.024003983 2.235583 up -0 27389 0.5179123
10 FOLR3 9.23E-04 2.118018 up -0 04037 0.46231112
11 IQGAP1 7.97E-07 2.0312161 up -0 65189 0.4058248
12 LY96 0.001274389 2.15995 up -0 33622 0.3176357
13 MMP9 1.11E-05 2.6441047 up - 36094 0.7666853
14 ORM1 0.00609218 2.2461765 up -0 04059 0.6170654
15 PADI4 4.70E-06 2.0203402 up -0 73165 0.3272818
16 S100A12 3.87E-04 2.3543987 up -0 86643 0.29669446
Symbol 
Corrected p-
value Fold change Regulation Control Stroke 
1 ACSL1 4.03E-04 2.1238022 up -0.7834313 0.30321807
2 AKAP7 0.001062506 2.1777713 up -0.4427783 0.68007416
3 APOBEC3A 0.03293885 2.2190735 up -0.5995044 0.55045307
4 ARG1 2.84E-07 3.1748993 up -0.62
.59
03
0.5
.52
.64
.62
.61
.79
0.6
.55
.68
.93
234 
APPENDIX S 
GENES REGULATED BY AGE IN STROKE GROUP  
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Gene 
Fold 
change Regulation 
Corrected p-
value Stroke <60y Stroke >60y
1 ACSL1 2.484374 up 0.0446085 -0.74035513 0.5725272
2 ARFGEF1 2.213192 up 0.008257919 -0.7595796 0.38654903
3 ARPP-19 2.1646469 up 0.01195357 -0.90462375 0.209508
4 ATP11B 2.3637316 up 0.03603059 -0.8622775 0.37878868
5 BIN2 2.1958306 up 0.031200677 -0.7576958 0.377071
6 CAST 2.252003 up 0.029694267 -0.98087955 0.19032918
7 DHRS8 2.2953622 up 0.009798116 -0.93625236 0.2624695
8 F11R 3.1309345 up 0.007976374 -1.25972 0.38687336
9 FAM49B 3.2131665 up 0.040724937 -1.1172744 0.5667214
10 FBXO38 2.5393336 up 0.025979264 -0.960459 0.38399088
11 FLJ11151 2.7070642 up 0.014563354 -0.7309369 0.7057922
12 GNA13 2.5798671 up 0.043621372 -0.88985026 0.4774464
13 GPBP1 2.0558481 up 0.04165832 -0.7248635 0.3148702
14 HEBP2 2.1112642 up 0.002986089 -0.65289176 0.4252153
15 HECA 2.5280104 up 0.004940345 -1.0853611 0.25264132
16 HMGB2 3.197031 up 0.008333158 -1.0408751 0.63585764
17 HNRPC 2.4634032 up 0.020800604 -1.0007415 0.2999113
18 MCTS1 2.4712584 up 0.030100342 -1.0774565 0.22778945
19 METTL7A 2.5580256 up 0.04897627 -0.713773 0.64125764
20 MYADM 2.6774745 up 0.04692652 -0.7664151 0.6544577
21 NEDD9 2.1855106 up 0.033739414 -0.75630903 0.3716613
22 PAPSS1 2.4646783 up 0.048576247 -0.8755778 0.4258215
23 PIK3AP1 2.8321755 up 0.035703324 -0.81097174 0.6909389
24 RTN3 2.834121 up 0.004845684 -0.89699674 0.60590464
25 RTN4 2.2975173 up 0.020294828 -0.7311121 0.46896365
26 SF3B14 2.135227 up 0.03467603 -0.7967069 0.29768255
27 SLC2A11 2.752874 up 0.041122623 -0.6690398 0.7918988
28 SULF2 2.012786 up 0.021191685 -0.51547337 0.49372038
29 TUBA1 2.221746 up 0.011949345 -0.79954374 0.3521501
30 USP8 2.414108 up 0.016071992 -0.8737992 0.39769098
31 VHL 2.0118108 up 0.045644812 -0.72845244 0.28004214
236 
APPENDIX T 
LOGISTIC REGRESSION FOR GENES ASSOCIATED WITH HARM 
Model One: HARM categories-None, mild, moderate, or severe with the following covariates: signal intensities for the 16 genes 
specific for stroke, age, gender, rtPA treatment, hypertension, diabetes, hyperlipidemia, and smoking 
 
                       
Parameter Wald χ 2 p-value Odds Ratio 5% CI 
LY96 7.78 0.005 0.244 0.091-0.658 
ORM1 4.05 0.044 2.064 1.019-4.181 
Age 6.58 0.01 0.924 0.870-0.982 
rtPA treatment 6.12 0.013 0.099 
 
Percent Concordant 84.1  Somers' D 0.685 
Percent Discordant 15.6   Gamma 0.687 
Percent Tied 0.3    Tau-a 0.520 
Pairs 308     c 0.843 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9
0.016-0.618 
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Model Two: HARM categories-None, mild, moderate, or severe with the following covariates: signal intensities for the 16 genes 
specific for stroke, age, gender, rtPA treatment, 
 
Paramete χ r Wald 2 p O ds Ra 95% CI 
LY96 5.54 0.17-0.851 
Age 5.59 0.018 0.936 0.887-0.989 
6.14 0.013 0.109 
 
P t Concordant 81.5 Somers' D 
Percent Discordant 18.5   Gamma 0.629 
 0.0   Tau-a 0.47
Pairs 329     c 0.815 
Model 
-value d tio 
0.019 0.381 
rtPA treatment 0.019-0.629 
ercen   0.629 
Percent Tied  6 
 
 
Three: Severe Harm (ye r ith the followins o no) w g covariates: signal intensities for the 16 genes specific for stroke, age, 
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Model Four: Severe Harm (yes or no) with the following covariates: signal intensities for the 16 genes specific for stroke, age, 
gender, rtPA treatment, 
 
Parameter Wal p-value Odds Ratio 95% CI 
AKAP7 4.48 0.034 0.399 0.170-0.93
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Percent Tied 1.6    Tau-a 0.239 
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